kauvery hospital

KMC SPECIALITY HOSPITALS (INDIA) LIMITED

ANNUAL REPORT 2025-26

Building an **Institution** That **Endures**

For centuries, the Kaveri River has sustained the communities along its banks through its constancy, reach and ability to renew. KMC Specialty Hospitals (India) Limited draws quiet inspiration from that enduring presence. Our own journey has been shaped over time, through investments in clinical capability, people, technology and governance and through the trust built with patients, clinicians, employees and communities.

Each addition to our capacity and every improvement in the way we deliver care has contributed to an institution designed not only to meet present needs, but also to remain relevant as those needs evolve.

FY 2025-26 marks another meaningful stage in this journey. Improved financial performance, expanding clinical capabilities, investments across the six capitals and a sustained focus on patient outcomes show how KMC is performing today while preparing for the future. This report brings together the capabilities we are building, the value they create and the foundations that will enable us to remain a trusted healthcare institution for generations to come.

The Journey Ahead



The Source—

Where Every **River Begins.**

Every enduring institution begins with something elemental: a clear purpose, a set of values and the conviction to stay true to both over time. For KMC, these beginnings have shaped the way we lead, grow and care. Like the first waters that determine a river's course, they continue to guide the institution we are becoming.

KMC at a Glance

An Institution **in Numbers**

From financial performance and clinical capabilities to operational scale and institutional progress, these highlights present a concise snapshot of KMC in FY 2025-26.

Performance

Rs. 305.8 Cr
Revenue from Operations

Rs. 93 Cr
EBITDA

Rs. 46.73 Cr
PAT

Scale

450 Beds
Hospital Capacity

170+
Doctors

1695
Employees

Institution

2
Hospitals

Centre of Excellence

Liver & Bone Marrow Transplants

Mother & Child Care

Neurosciences, Gastro Sciences, Orthopedics, Plastic Surgery & Critical Care

Built to Care

KMC Specialty Hospitals (India) Limited has grown into one of Tamil Nadu's trusted multi-specialty healthcare institutions by combining clinical expertise, modern infrastructure and compassionate care. As part of the Kauvery Hospital network, we continue to expand access to advanced medical services while remaining guided by a clear purpose, enduring values and an unwavering focus on patients.

Our Vision

To be the most respected and trusted healthcare provider

Our Mission

To make great healthcare affordable

Our Values

C – Continual Improvement
We never stop learning, evolving and finding better ways to serve our patients.

H – Heartfelt Personal Touch
Every patient is more than a case number, they are someone we care for deeply.

E – Ethical
Honesty, fairness and doing what's right are the backbone of every decision we make.

E – Empathetic Care
We listen, we understand and we stand by our patients every step of the way.

R – Real Accountability
We take full responsibility for the quality and impact of our care.

S – Service Excellence
We hold ourselves to the highest medical standards, ensuring every patient gets world-class treatment.

Care, Delivered Across Campuses

KMC's integrated care network brings together specialized clinical expertise, modern infrastructure and patient-centered services across two complementary campuses. Together, they enable us to serve diverse healthcare needs while maintaining consistent standards of clinical excellence, safety and compassionate care.

Trichy Cantonment

250 Beds

As KMC's flagship tertiary care campus, the Cantonment Hospital serves as a referral destination for advanced and complex medical care. It brings together expertise across neurosciences, gastro sciences, orthopedics, critical care, plastic surgery and several other specialties, supported by advanced diagnostic capabilities, modular operating rooms and comprehensive clinical infrastructure.

The hospital continues to play a central role in delivering multidisciplinary care to patients across the region.



Maa Kauvery

200 Beds

Purpose-built for women and children, Maa Kauvery offers specialized services across obstetrics, gynecology, neonatology, pediatrics, fertility care and pediatric super specialties.

Designed around the unique needs of mothers, infants and children, the hospital combines advanced clinical infrastructure with a compassionate, family-centered approach to deliver coordinated care from pregnancy through childhood.

Management Messages

Message from the **Executive Chairman**

Dear Shareholders,

FY 2026 has been an important year in our journey—not simply because of our financial performance, but because of the continued strengthening of the institution behind those numbers.

Our performance represents the trust that patients and families place in us, the commitment of our clinicians and employees and the discipline with which we continue to build for the long term.

As we grow, one principle must remain unchanged: quality must always come before scale. Clinical excellence, patient safety, ethical practice, good governance and the trust of our patients are non-negotiable. Growth has meaning only when it enables us to deliver better outcomes and make high-quality healthcare accessible to more people.

One important area of opportunity is specialised mother and child healthcare through Maa Kauvery. We believe there is considerable scope to create a differentiated model of care built around clinical excellence, compassion and affordability. This is a natural extension of the philosophy on which Kauvery was founded—bringing high-quality healthcare closer to families without allowing quality to become synonymous with high cost.

> Clinical excellence, patient safety, ethical practice, good governance and the trust of our patients are non-negotiable.

Healthcare itself is changing rapidly. Technology, artificial intelligence, digital health and advances in clinical practice will increasingly influence how care is delivered. Our approach is to adopt these capabilities thoughtfully—where they improve clinical outcomes, patient experience and safety and enhance the effectiveness of our people—while ensuring that technology strengthens rather than replaces the human connection at the heart of healthcare.

However, enduring healthcare institutions are ultimately built by people, culture and purpose. Developing clinical talent, nurturing future leaders, strengthening organisational capabilities and creating opportunities for the next generation of healthcare professionals will therefore remain central to our journey. Over time, our contribution must also extend beyond hospital walls through medical education, research, preventive and community health and responsible institution building.

As we look ahead, our ambition is not merely to become a larger healthcare organisation. We want to build an institution that society can trust for generations. Our endeavour will be to combine excellent clinical outcomes with affordability and compassionate care, while remaining anchored in strong values, sound governance and institutional integrity. If we remain steadfast in these principles, sustainable growth will follow as a consequence.

> We want to build an institution that society can trust for generations.

For us, therefore, growth is an outcome; trust is the foundation; and better healthcare for society is the purpose.

Best Regards

Dr S. Chandrakumar
Executive Chairman

Message from the **Managing Director**

Dear Shareholders

It gives me great pleasure to connect with you once again through our Annual Report.

FY 2025–26 has been an important year of delivery for KMC. As we continue to grow, I believe our progress should not be measured merely by numbers or size. In healthcare, what matters ultimately is whether growth translates into better outcomes, greater access, affordability and, above all, greater trust among our patients.

Bringing Advanced Healthcare Closer to Home

One of our continuing priorities has been to bring sophisticated tertiary and quaternary healthcare closer to the communities we serve.

During the year, we strengthened our capabilities in robotic surgery with the fourth-generation Da Vinci robotic surgical system across multiple specialties, including cardiothoracic surgery, gastrointestinal surgery, surgical oncology, urology, gynaecology and kidney transplantation.

Our oncology capabilities have also continued to evolve, with complex cancer surgeries, robotic interventions, targeted chemotherapy and advanced treatment modalities such as TMLI radiation therapy and CAR-T cell therapy.

For us, acquiring advanced technology is not an achievement by itself. The real achievement is when a patient from Trichy or another Tier-2 town can access sophisticated treatment closer to home, without having to travel to a metropolitan city.

Maa Kauvery — Caring for Generations

Maa Kauvery continues to be an important part of our journey in building comprehensive healthcare for women and children.

The recognition of Maa Kauvery as the Best Mother and Child Hospital by The Economic Times and its Green Hospital recognition from CII-TN MedClave are encouraging milestones.

However, the recognition that matters most is the confidence that mothers and families place in us. Our ambition is to create an ecosystem where women and children receive compassionate, safe and comprehensive care—from routine maternity services to complex neonatal and paediatric care.

Technology with a Purpose

Technology continues to transform the way we deliver healthcare.

EMR adoption has reached 82%, while our Connected Healthcare programme monitored 972 patients during the year. The platform has helped our teams identify deterioration early, safely stabilise patients in wards and, in appropriate situations, avoid ICU transfers.

Connected ICU monitored 956 patients and we are progressively introducing AI-enabled predictive platforms. Connected Ambulance is another important initiative being implemented.

Our philosophy towards technology is simple: technology should solve a healthcare problem.

Whether through AI, automation, EMR or remote monitoring, technology must ultimately make healthcare safer, reduce errors, improve efficiency and allow our doctors and nurses to spend more meaningful time caring for patients.

Our People, Our Culture

Buildings, medical equipment and technology can be purchased. Culture cannot be purchased.

The culture of an institution is built over years through the everyday actions of its doctors, nurses and employees. Their commitment, compassion and willingness to go beyond their defined responsibilities for patients remain among KMC's greatest strengths.

We continue to invest in the well-being of our people. Today, 100% of our employees are covered under health insurance. Our Great Place to Work certification and recognition among India's Best Workplaces in Hospitals are encouraging validations of this journey.

Growth with Responsibility

As healthcare organisations grow, maintaining affordability and operational discipline becomes increasingly important.

LEAN practices, technology, automation and continuous improvement help us eliminate waste and utilise our resources better. But our philosophy remains clear:

> We must eliminate waste, never compromise care.

The efficiencies we create must ultimately translate into better and more affordable healthcare for our patients.

The Road Ahead

As we look towards FY 2027, our priorities remain clear: strengthen clinical excellence, deepen technology adoption, improve patient experience, invest in our people and continue making advanced healthcare accessible and affordable.

But above all these priorities sits one responsibility—the trust our patients place in us.

> Growth is meaningful only when that trust grows with us.

As KMC moves forward, we will continue to combine advanced medicine with compassionate care, technology with a human touch and growth with responsibility.

I thank our doctors, nurses, employees, partners and, most importantly, our patients and their families for their continued faith in us.

Together, we will continue to build healthcare that is advanced, affordable, ethical and trusted.

Best Regards

Dr S. Manivannan
Managing Director

The First Current—

Purpose **Becomes Practice.**

Purpose takes shape in how an institution is governed, led and held accountable. At KMC, responsible leadership, ethical conduct and clear governance practices guide how decisions are made and responsibilities are carried. This is where intent begins to move, giving direction to the institution and meaning to the values we stand for.

Governance

Governance That Keeps **Purpose Accountable**

Our governance framework brings independence, oversight and accountability into the way our institution is directed. With clearly defined Board and Committee responsibilities, structured evaluation and regular engagement, it provides the discipline needed to guide decisions and uphold the interests of our stakeholders.

Governance at a Glance

50% Independent Directors

1 Women Independent Director

Our Governance Structure

Board of Directors

↓

Board Committees

Audit Committee Oversight of financial reporting, internal controls, audit processes and related compliance matters	**Nomination and Remuneration Committee** Oversight of Board composition, senior management appointments, remuneration and succession-related matters	**Risk Management Committee** Oversight of enterprise, ESG, information, cybersecurity, compliance and other risks
Corporate Social Responsibility Committee Oversight of CSR activities and community initiatives	**Stakeholder Relationship Committee** Oversight of shareholder grievances and stakeholder matters	**Borrowing and Banking Committee** Oversight of borrowing, banking and related financing matters

↓

Management

↓

Functions and Business Operations

ESG Philosophy

What Endurance **Asks of Us**

For us, ESG is part of how we build an institution for the long term. It brings together responsible use of resources, the well-being of our people, accountability in decision-making and our responsibilities to the communities around us.

Our ESG Priorities

E — ENVIRONMENT

Towards 100% Renewable Energy
92% renewable energy achieved in FY 2025-26

100% renewable energy transition from April 2026

Green Infrastructure
LEED Silver certification for Maa Kauvery

Water Conservation
STP systems and rainwater harvesting units supporting responsible water management

Healthcare Waste Management
100% safe segregation and eco-friendly disposal of healthcare waste

S — SOCIAL

Supporting Our People and Communities
Great Place to Work certification at Group level

Gender Diversity
More than 75% women in our workplace

Employee Well-being
Free health insurance for our employees and their families

Annual free health checkups for our employees

Employee Training and Upskilling
700+ specialized training programs delivered

Fair Pay and Economic Equity
Verified 1:1 gender pay parity across equivalent roles

Community Health outreach
Free medical camps for communities

G — GOVERNANCE

Accountability in Practice
50% Independent Directors
1 Woman Independent Director

Strategic Integration
Integrating ESG metrics into Board dialogues

Healthcare Data Privacy
Oversight of information security, cybersecurity and patient data protection

Clinical Governance and Patient Safety
Oversight mechanisms supporting clinical standards and patient safety

Operational Assurance
Mandatory and voluntary audits across operations



Business Ethics

The Standards **Behind Trust**

Ethical conduct is fundamental to the way KMC is governed and operated. Our policies and controls establish clear expectations around integrity, responsible behavior, grievance redressal, anti-corruption, workplace dignity, data privacy and information security. Together, these mechanisms provide a consistent framework for accountability across the institution.

Ethics in Practice

Protecting Information
Our information-security practices include server and database encryption, encryption of data in transit, role-based access controls and periodic security audits. The Cantonment Unit is also ISO 27001:2022 certified for information security management.

Speak-Up and Grievance Mechanisms
Our Whistle Blower Policy enable Directors and employees to report unethical behavior, fraud or violations, with safeguards against victimization. Employees can also raise concerns through a dedicated digital grievance redressal system.

Respect at the Workplace
Internal Complaints Committee is constituted in accordance with POSH requirements, supported by policies covering equal opportunity, inclusion and diversity, workplace violence and grievance redressal.

Code of Conduct
Our Code of Conduct sets out expected standards of employee responsibility and conduct, with compliance applicable across the organization.

Anti-Corruption and Anti-Bribery
A formal anti-corruption and anti-bribery policy forms part of our framework for responsible business conduct.

FY 2025-26

NIL	NIL	NIL
POSH Complaints	Whistle Blower Complaints	Material Fines, Penalties, Settlements or Compounding Fees Reported

Leadership

Our **Board of Directors**



Dr S. Chandrakumar
Executive Chairman (Whole-Time)

Dr S. Manivannan
Managing Director

Dr T. Senthilkumar
Director

Dr S. Vijayabaskaran
Director

Mr Sunil Gulati
Independent Director

Mr P. Ravichandran
Independent Director

Mrs N. Jeyanthei
Independent Director

Mr Mohan Srinivasan
Independent Director

Key Managerial Personnel

Dr D. Senguttuvan
Executive Director & Unit Head

Corporate **Information**

Board of Directors

Dr S Chandrakumar
Executive Chairman (Whole-Time)

Dr S Manivannan
Managing Director

Dr T Senthil Kumar
Non-Executive Director

Dr S Vijayabaskaran
Non-Executive Director

Mr Sunil Satyapal Gulati
Independent Director

Mr Ravichandran Purushothaman
Independent Director

Mrs N Jeyanthei
Independent Director

Mr Mohan Srinivasan
Independent Director

Key Managerial Personnel

Dr D Senguttuvan
Executive Director & Unit Head

Mr K Anand Babu
Chief Financial Officer

Ms Indumathi P
Company Secretary &
Compliance Officer
(w.e.f May 28, 2025)

Bankers

State Bank of India

Statutory Auditors

M/s. Deloitte Haskins & Sells,
Chartered Accountants
ASV N Ramana Tower, 52,
Venkatnarayana Road, T. Nagar,
Chennai – 600 017

Internal Auditors

Grant Thornton Bharat LLP
11th floor, A wing, Mylapore
Division,Prestige Polygon,
471, Anna Salai, Rathna Nagar,
Teynampet, Chennai - 600035

Registered Office

No. 6, Royal Road, Cantonment,
Trichy – 620 001
CIN: L85110TN1982PLC009781

Hospital Units

Cantonment – Trichy
No. 6, Royal Road, Cantonment,
Trichy – 620 001

Maa Kauvery, Cantonment – Trichy
No. 27, Alexandria Road, Cantonment
Trichy – 620001

Tributaries—

Every Stream **Adds to the River.**

No institution grows through a single capability. It evolves through many strengths working together, each contributing in its own way while moving towards a shared purpose. For KMC, our capitals represent these enduring sources of value. Together, they expand our ability to deliver better patient outcomes, support our people, advance clinical excellence and build an institution prepared for the future.

Financial Capital

The Source of Our Ability **to Invest and Grow**

Every meaningful advancement in healthcare begins with the capacity to invest. Whether it is expanding clinical capabilities, adopting advanced technology, strengthening infrastructure, or supporting our people, sustained financial performance provides the foundation that enables an institution to grow with purpose. At KMC, financial discipline is not an end in itself—it is the means through which we continue to improve patient care while building an institution prepared for the future.

Investing in What Matters Most

For a hospital, the ability to invest consistently has a direct bearing on the care it can provide. New clinical capabilities require specialist talent and medical technology. Higher patient volumes need adequate infrastructure and support systems. Better experiences depend on people, processes and facilities keeping pace with the institution's growth. Financial discipline gives KMC the room to make these choices while maintaining continuity in the way we serve patients.

FY 2025-26 added meaningfully to that foundation. Revenue from Operations increased by **32.0% to Rs. 305.8 Cr**, EBITDA grew by **55.1% to Rs. 93.0 Cr** and Profit After Tax rose by **118.1% to Rs. 46.7 Cr**. The improvement across revenue and profitability gives KMC greater flexibility to support its clinical ambitions and future requirements.

The value of this progress extends beyond the financial statements. It supports the people, infrastructure, technology, learning and wider care ecosystem on which KMC's future depends. In that sense, Financial Capital is not simply a record of performance; it is one of the foundations that allows the institution to keep building for patients, clinicians and the communities it serves.

A Diversified Clinical Revenue Base in FY 2025-26

27% Mother & Child Care Services	**19%** Neurosciences	**12%** Gastro Sciences	**7%** General Medicine
6% Critical Care	**6%** Plastic Surgery	**6%** Orthopedics	**4%** Renal Sciences
3% Hematology	**10%** Others		

58%
Contribution from Our Three Largest Specialties

Five Years of
Financial Progress

Over the past five years, KMC has expanded its financial base and its capacity to invest in clinical capabilities, infrastructure, technology and people. The trends below capture that progress.

Growth



Profitability



Beyond the Balance Sheet

Financial progress creates the capacity to invest in the capabilities that shape KMC's future.

Financial Capital
The source of our ability to invest and grow

Page 19

Human Capital
People behind care

Page 22

Social & Relationship Capital
Trust beyond hospitals walls

Page 28

Intellectual Capital
Knowledge and innovation that advance care

Page 33

Natural Capital
Responsible growth for a healthier future

Page 40

Manufactured Capital
Infrastructure for advanced and accessible care

Page 42

Human Capital

Caring for Those Who Care

Behind every patient experience is a team of people bringing different skills, responsibilities and perspectives to care. At KMC, we invest in their growth, well-being and sense of belonging, while extending support beyond the workplace. Building an institution that endures also means creating an environment where the people who care for others can build meaningful and fulfilling careers.

The People Behind KMC

Our workforce brings together clinical expertise and the many capabilities required to support it. Doctors, nurses and other clinical professionals work alongside administrative, operational and corporate teams, each contributing to the continuity of the patient experience. During FY 2025-26, our on-roll workforce stood at **1,695 employees**, while **533 people joined KMC during the year**.

For many of our people, KMC is also where their professional journey begins. **62%** of our employees are first-generation employees, while for **47%**, Kauvery represents their first employment experience. This places greater meaning on the opportunities we create for people to learn, take on responsibility and build careers over time.

Our People at a Glance

1,695
On-Roll Employees

533
New Hires During FY 2025-26

78%
Women in Our Workforce

Workforce Composition

451
Nurses

285
Clinical Support

307
Other Clinical Staffs

591
Non-Clinical

61
Corporate



For Many, KMC is Where a Career Begins



62%
First-Generation Employees

47%
Experiencing Their First Employment at Kauvery

Gender Diversity



78%
Female

22%
Male

Learning That Builds Careers

In a hospital, learning has a direct bearing on how confidently people perform their roles and respond to changing clinical and operational needs. At KMC, development therefore extends beyond periodic training. We create opportunities for employees to build role-specific skills, prepare for greater responsibilities and develop the capabilities needed as their careers progress.

Our learning initiatives span clinical, functional, behavioral and leadership development, with programs such as KLIFT, KLIFE, KCOMP and CCDP creating structured opportunities across employee groups. This breadth allows learning to respond to different roles and stages of an employee's career.

Learning at a Glance

726
Training Programs

41,136
Training Hours



Our Learning Ecosystem

CCDP
51 Programs | 15,300 Hours

KCOMP
49 Programs | 1,317 Hours

KLIFT
13 Programs | 158 Hours

KLIFE
10 Programs | 130 Hours

From First Employment to a Career

For many employees, Kauvery is their first workplace. Structured learning gives them opportunities to build capability, assume greater responsibility and progress through their professional journey.

Supporting the Caregiver

Working in a hospital can place considerable demands on the people delivering care. Clinical responsibilities, long hours and emotionally difficult situations make employee well-being an important part of sustaining the people behind patient care. At KMC, support extends across emotional and mental well-being, physical activity and workplace health and safety.

Kushi is centered on a simple mission: helping employees feel happier at work. It creates opportunities for well-being and engagement, giving employees space to connect, participate and step away from the demands of their everyday roles.

For employees who need more personal support, access to a Happiness Coach provides an avenue to discuss mental well-being concerns and seek counseling or therapeutic support. Amber provides another channel for employee well-being, while Walkaholic encourages movement and healthier routines through shared participation among colleagues.



Well-being in Action

76 Sessions
833 Participants
Kushi

683
Employees Attended Amber Sessions

30
Employees Attended Happiness Coach Sessions

Walking Together

1,021
Walkaholic Participants

2,53,571 km
Distance Covered Across Two 100-Day Editions

A Safer Place to Work

Regular risk assessments, safety inspections, health checks and emergency drills help maintain a safe environment for our people and patients. Training in infection control, fire safety, PPE, chemical handling and emergency response reinforces safe practices across clinical and non-clinical teams.

Voice, Recognition and Belonging

A workplace takes shape not only through the work people do, but through how they experience being part of it. At KMC, recognition and engagement create space to acknowledge contribution, celebrate the roles that keep the hospital running and bring colleagues together beyond their day-to-day responsibilities.

Recognition took several forms across the year. Long Service Awards acknowledged enduring association with KMC, while initiatives such as **Flying Angels, Super Pharmacist and Super Typist** recognized individual and functional contributions. **Nurses Day, Housekeeping Day, Pharmacy Day, Fun Friday, Vanakkam Kauvery and QNK** gave teams opportunities to come together beyond their everyday roles.

75%
Employee Satisfaction

Recognizing Contribution

Long Service Awards | Flying Angels | Super Pharmacist | Super Typist | Smart Nurse | Scrub Star Programs

Moments That Bring Us Together

Nurses Day | Housekeeping Day | Pharmacy Day | Fun Friday | Vanakkam Kauvery | QNK | Yoga Day | Sports Day | Marathon

When Support Became a Turning Point

There are moments when support matters beyond the professional role we perform each day. For these two Kauverians, counseling offered a space to be heard, understand difficult emotions and find healthier ways forward.

A Safe Space to Be Heard

"My counseling experience with the happiness coach has been very positive. She creates a safe, non-judgmental space, listens attentively and explains coping strategies in a clear and approachable way. Since starting the sessions, I have experienced a noticeable improvement in my emotional well-being."

A Student - Trichy



From Surviving Each Day to Truly Living It

A Kauverian shares a year-long journey of understanding difficult emotions, building healthier habits and rediscovering a sense of confidence and peace.

Late in 2024, life became difficult in ways I did not understand. I was carrying a heavy emotional burden, often felt lost within myself and struggled to make sense of what I was experiencing. Counseling was support I had neither asked for nor expected, yet it reached me when I needed it most.

With guidance from the happiness coach, I began looking for healthier ways to navigate difficult moments. We identified my pain points, understood the reasons behind my emotions and learned to separate genuine fears from unnecessary worries. I also made mindfulness part of my daily routine, gradually building habits that helped me feel more grounded.

Over time, I began to regain control. Today, I feel more confident, self-reliant and at peace. I enjoy my work, welcome challenges and feel a sense of calm after a difficult period.

Counseling helped me learn, unlearn, heal and grow. It took me from simply surviving each day to living with greater peace, clarity, inner strength and appreciation for myself and others. I remain deeply grateful for the kindness, guidance and support I received throughout this journey.

A Kauverian

Social & Relationship Capital

Trust That Extends **Beyond Care**

For KMC, relationships are built through every experience of care and sustained through trust earned over time. They are shaped by how we support patients and families through their care journeys, listen to their experiences and remain connected with the communities around us.

Building Trust, One Patient at a Time

KMC gathers patient feedback at multiple points across the care journey. Frontline coordinators engage directly with patients on each floor through the Voice of Patient mechanism, allowing concerns to be documented and taken up while care is still underway. Satisfaction surveys and Google Reviews provide additional channels for patients and families to share their experience.

The feedback loop extends to resolution. Concerns are tracked and addressed through defined redressal mechanisms, giving our teams visibility into issues that require attention. In FY 2025-26, all patient feedback received was successfully resolved, with nil pending at year-end

Listening at Every Touchpoint

Voice of Patient
Real-time feedback through frontline coordinators

Patient Satisfaction Surveys
Structured feedback on patients' experience

Google Reviews
Experiences and concerns shared online

→ **Feedback Adressed** → **NIL**
Pending resolution at year-end

Voices of Trust

A Long-Awaited Beginning

After a difficult IVF journey, Mr Ravi and Mrs Amutha Ravi welcomed triplet girls. Born prematurely, all three required intensive neonatal support and were admitted to the NICU at Maa Kauvery. What began as a long-awaited moment for the family soon became an uncertain period of intensive care.

A Difficult Decision

Nearly a month into their NICU stay, the babies continued to require care while the financial burden on the family grew. Unable to sustain treatment in a private hospital, the parents made the difficult decision to move them to a government-aided NICU facility.

Fifteen days later, two of the triplets had not survived. One baby remained, still requiring specialized care.

The Relationship Endured

When a GRO at Maa Kauvery, later saw Mr Ravi near the hospital, she approached him and learned what the family had been through. Unsure whether the surviving child could return to Maa Kauvery, he had come back looking for help.

The GRO brought him into the hospital and connected the family with the management team. Arrangements were made for the surviving baby to return to Maa Kauvery's NICU and resume treatment.

The Family Had Left the Hospital. The Relationship Had Not Ended.

A New Beginning

Back in the NICU, the baby remained under the care of the Maa Kauvery team as her condition gradually improved. She eventually reached a point where she could be discharged and return home with her parents.

For a family that had experienced both profound loss and uncertainty, her return home marked a new beginning. For Maa Kauvery, the journey was also a reminder that care can extend beyond an episode of treatment, through the relationships built with patients and families along the way.

The Trust **We've Earned**

The year brought recognition across several areas that matter to our patients, people and institution, from clinical care and patient safety to workplace practices, green infrastructure and information security.

Honors That Defined the Year

Best Mother and Child Hospital – Maa Kauvery

Maa Kauvery was recognized as Best Mother and Child Brands by The Economic Times, Mumbai, in 2025, acknowledging its focus on specialized care for women and children.

Icons of Healthcare – Trichy & Thanjavur

Maa Kauvery was recognized among the Icons of Healthcare for Trichy & Thanjavur by The Times of India in 2025.

Workplace Recognition at the Group Level

India's Best Workplaces™ in Hospitals 2026

Recognized under the Great Place To Work® workplace recognition program for the hospital sector.

Most Preferred Workplace 2025-26

Recognized among the Most Preferred Workplaces for 2025-26, adding to the Group's workplace recognitions during the year.

Great Place to Work Certification

Certified as a great workplace for the period February 2026 to February 2027.

Sustainable Infrastructure

LEED Silver Rating – Maa Kauvery

Awarded by the U.S. Green Building Council (USGBC), recognizing Maa Kauvery's green building practices.

Green Hospital Recognition – Maa Kauvery

Recognized by CII-TN MedClave in the above-100-beds category.

Clinical Care and Patient Safety

NNF Level III A Accreditation – Maa Kauvery

Special accreditation from the National Neonatology Forum for the NICU at Maa Kauvery.

Manyata Certification – Maa Kauvery

Certification for compliance with FOGSI Quality Standards for Safe Delivery.

Quality and Operational Excellence

Basic 5S Platinum-level Certification – Maa Kauvery

Recognition of structured workplace practices and operational discipline.

5S Model Hospital Certification – Cantonment

Certification recognizing the adoption of 5S practices at the Cantonment unit.

CII Kaizen – Best in Category

Initiatives from Oncology, Nephrology & Urology and Cosmetology received Best in Category recognition at the 39th National Convention for quality-improvement work focused on patient safety.

Information Security

ISO 27001:2022 Certification– Cantonment

Certification against the internationally recognized standard for information security management.

Extending Our Circle of Care

Our relationship with the communities around us extends beyond those who enter our hospitals for treatment. Health camps, screenings and awareness programs take clinical guidance and preventive health information closer to people, while enabling us to engage with different sections of the community in settings that are accessible to them.

Between April and December 2025, KMC conducted 68 health camps and outreach programs, reaching 3,820 beneficiaries. The initiatives ranged from regular Park Camps and CM Scheme Camps to specialty camps and Mammogram Bus programs, with activities conducted across Trichy and locations including Karur, Kulithalai, Viralimalai and Neyveli.

Community Outreach at a Glance

68 Health Camps and Outreach Programs

29 Park Camps

8 CM Scheme Camps

4 Specialty Camps

45 Mammogram Bus Camps

3,820 Beneficiaries Reached

Reaching Different Communities

115 Free Health Check for Police and Journalists

250+ Women Reached Through Mother's Day Program

100+ Participants in Breastfeeding Awareness Rally

75+ Beneficiaries of Stress and Anger Management Program

50+ Beneficiaries of Umbrellas for Roadside Shopkeepers



Intellectual Capital

Knowledge That **Becomes Practice**

At KMC, clinical expertise is supported by defined standards, structured review and continuous learning. Knowledge moves through the institution as teams apply it, examine outcomes, improve processes and share better practices, helping bring greater consistency to both complex care and everyday operations.

Clinical Knowledge in Practice

Specialist Expertise

Depth across Mother & Child Care, Neurosciences, Gastroenterology, Orthopedics, Critical Care and other specialties.

Multidisciplinary Care

Experts come together to address complex cases with integrated clinical judgement.

Advanced Programs

Liver Transplant and Bone Marrow Transplant programs supported by specialist teams and infrastructure.

Clinical Milestones

Significant procedures, complex cases and program milestones during FY 2025-26.

Knowledge in Motion

KNOWLEDGE
- Specialist clinical expertise
- Multidisciplinary care
- Transplant programs
- Clinical milestones

STANDARDIZE
- NABH full accreditation
- 5S practices
- NNF Level III A accreditation
- Manyata certification

APPLY
- Clinical and operational protocols
- Patient-safety practices
- Quality dashboards

SHARE
- Learnings shared across units and functions
- Best practices adopted and scaled

IMPROVE
- Quality circles
- Kaizen
- Process improvement
- Digitization

REVIEW
- Self-zone audits
- Cross-zone audits
- Grand facility & safety rounds
- Cross-unit risk assessments
- HIRA and focused audits
- Fire safety audits
- Facility audits

Technology Capital

Building a Connected **Care Ecosystem**

Technology at KMC connects clinical teams, patient information and care processes across the hospital and beyond. From connected monitoring and digital clinical records to automation and secure information systems, our digital capabilities are helping clinicians access information more readily, maintain continuity with patients and make everyday processes more efficient.



Digital ICU

Connected ICU capabilities enable remote clinical oversight while integrating information from bedside devices including ventilators, syringe and infusion pumps and urometry devices.



Life Signs

Continuous monitoring provides clinical teams with alerts that can support earlier attention when a patient's condition changes.

1 Digital ICU Deployment at Cantonment Unit

555 Patients Managed During the Year

87% Discharge Rate

2.5 Days Average Length of Stay

307 Patients Monitored

2,857 Clinical Alerts Managed

9 ICU Readmissions

46 ICU Readmissions Avoided

Care After Discharge

The care relationship also extends into the days following discharge. Structured post-discharge calls provide a channel to reconnect with patients, understand their recovery and address concerns requiring attention.

	KCN	KMA
Supported Discharges	5,272	4,981
Day-3 Calls Completed	4,221	4,688
Patient Interactions	11,438	5,977



Digitization in Practice

Building a connected digital ecosystem that brings continuity, accuracy and ease to care. Our digital enablers support every step of the patient journey.

IDENTITY	CONSULTATION	DIAGNOSTICS	CLINICIAN ACCESS
Patient enters the digital ecosystem	Clinical information captured and managed digitally	Investigation results integrated into the digital record	Care teams access information and act with greater convenience
ABHA IDs CREATED	**EMR ADOPTION**	**RADIOLOGY REPORTS**	**DOCTORS APP USERS**
Kauvery Hospital Cantonment (KCN) **1,432**	Kauvery Hospital Cantonment (KCN) **98.92%**	Kauvery Hospital Cantonment (KCN) **24,130**	Kauvery Hospital Cantonment (KCN) **20**
Maa Kauvery, Trichy (KMA)* **2,421**	Maa Kauvery, Trichy (KMA) **76.33%**	Maa Kauvery, Trichy (KMA) **19,687**	Maa Kauvery, Trichy (KMA) **6**

Automation That **Improves Efficiency**

Automation is reducing repetitive work across several operational processes at KMC. Across finance, administration, stores and digital functions, it is helping cut manual effort, improve processing consistency and make recurring workflows more efficient.

From Manual to Automate

1,200 mins
Manual processing time

188 mins
Automated processing time

1,012 mins
Saved across the identified automated processes

Automation in Practices

297 mins saved
BMS Reporting
300 mins —> 3 mins
Building Management System reporting automation

160 mins saved
Card Verification
180 mins —> 20 mins
Payment reconciliation automation for card transactions

160 mins saved
UPI Verification
180 mins —> 20 mins
Payment reconciliation automation for UPI transactions

150 mins saved
Lab Stores Reporting
180 mins —> 30 mins
Laboratory purchase store automation

75 mins saved
Sonic Wall Reporting
120 mins —> 45 mins
Firewall logs reporting automation

50 mins saved
Yellow AI / WhatsApp Bot
60 mins —> 10 mins
CRM messaging automation

Across the Institution

Finance
- Card transaction reporting
- Card verification
- UPI verification

Operations
- BMS reporting
- Lab stores reporting
- Open PO and credit note reporting

Administration
- Medical bank statement
- Consultant verification
- Postal tracking

Digital and IT
- Yellow AI
- SonicWall reporting

Built for What Comes Next

Securing Today

Information Security
Defined controls support the protection of information and digital assets.

Cybersecurity
Security measures help protect systems and digital infrastructure from cyber risks.

Data Privacy
Controls around sensitive information support responsible access and use of data.

Access Control
Role-based access helps restrict information and system privileges to authorized users.

ISO 27001:2022
An established information security management framework supports KMC's approach to information security.

Building Tomorrow

Command Centre

5

clinical systems proposed for integration

Digital ICU | ECG | Life Signs / Dozee | Drip Monitoring | Nursing Call Bell

AI-enabled Clinical Support

The Digital ICU roadmap includes AI-enabled discharge summaries, patient-risk classification, automated APACHE II, APACHE IV and GCS scoring and ICU Standardised Mortality Ratio (SMR) tracking to support clinical teams with structured information and risk assessment.

Nursing Resource Management

The proposed Acuity and Duty Allocation Module is intended to support nursing deployment based on patient acuity, skills and clinical privileging.

1,076
Staff Proposed to be Privileged

76
Supervisor Logins

4
Nursing Superintendent Approval Logins

80
Customizable Skill, Competency and Preceptorship Forms

Educational Capital

Knowledge That **Carries Forward**

Clinical knowledge gains greater value when it is taught, tested, discussed and shared. At KMC, postgraduate medical education sits alongside continuing professional learning, research and academic exchange.

Building the Clinical Pipeline

Our academic programs place doctors-in-training in specialist clinical environments, allowing structured education to develop alongside practical exposure. Across two accredited learning hubs, the postgraduate portfolio spans broad-based disciplines as well as advanced specialties including neurosciences, critical care, medical gastroenterology and plastic surgery.

Academic Capacity

16 Accredited PG Medical Education Programs

14 Specialties Covered Through PG Training

76 Doctors / Students Under Training

2 Accredited Learning Hubs

Across the Institution

DNB | 4 Programs

- General Surgery
- Anesthesiology
- Orthopedics
- Pediatrics



DrNB | 4 Programs

- Neuro Surgery
- Plastic Surgery
- Critical Care
- Medical Gastroenterology

Diploma | 6 Programs

- Anesthesiology
- Family Medicine
- ENT
- Radiology
- Pediatrics
- OBG

FNB | 1 Program

- Minimal Access Surgery

CCT | 1 Program

- Emergency Medicine

Advancing and Sharing Knowledge

Learning at KMC extends beyond formal academic programs. CME and CNE sessions, conferences and workshops create regular opportunities for clinicians and nurses to exchange perspectives, discuss evolving practices and learn from peers. Research and publication add another dimension by turning clinical inquiry into knowledge that can be examined and shared.

Learning Without Boundaries

76 CME Sessions

3,400 Participant Engagements

9 CNE Programs

9 Workshops

4 Major In-House Conferences

4 IMA Sessions

3 Doctors Participated in National / International Conferences

Knowledge in Print

107 Journal Publications During FY 2025-26

44 Kauverian Medical / Scientific Journal

63 Nightingale Journal

Research in Progress

Research forms part of the academic environment, allowing doctors to investigate clinical questions, develop evidence and present their work to the wider medical community.

24 Ongoing Postgraduate / Doctor Research Theses

22 Research Papers Presented at Conferences

***Abbreviations:** *PG – Postgraduate | DNB – Diplomate of National Board | DrNB – Doctorate of National Board | FNB – Fellowship of National Board | CCT – Certificate of Completion of Training | CME – Continuing Medical Education | CNE – Continuing Nursing Education | IMA – Indian Medical Association*

Natural Capital

Responsible **by Design**

We are managing energy, water and materials more responsibly across our hospitals, with a focus on renewable energy, efficient infrastructure, water reuse, waste management and green cover.

Building Greener Hospitals

Renewable sources accounted for 92% of KMC's energy consumption in FY 2025-26, with both Trichy hospitals recording shares above 90%. This shift is reducing dependence on conventional energy and lowering the carbon footprint of our operations.

Our Renewable Energy Journey

92%
Energy Consumption from Renewable Sources **FY 2025-26**

100%
Renewable Energy Transition from **April 2026**

Lowering the Carbon Footprint

1,902 Tonnes
Reduction in Carbon Footprint
Kauvery Hospital, Cantonment

1,408 Tonnes
Reduction in Carbon Footprint
Maa Kauvery, Trichy

Resource Efficiency Built into Operations

At our institution resource efficiency measures include optimized chiller settings, pump operations, BMS-based AHU scheduling, timer-controlled external lighting and LED lighting across floors. The reuse of treated water for non-potable applications also helps reduce freshwater requirements.

Managing Resources Responsibly

Giving Water Another Use

6,782.16 kL
Water Recycled

24,222 kL
Water Consumed

~28%
Equivalent to Reported Water Consumption Recycled

The Water Reuse Cycle



Waste Managed During FY 2025-26

Biomedical Waste Disposed | **Waste Under Recycling Initiatives** | **Biodegradable Waste Managed**

From Waste to Alternative Fuel



Growing Green Cover

Our environmental initiatives also extend to land and biodiversity. A 2-acre company-owned site at TV Koil is being developed with native tree species, supported by regular maintenance to help establish green cover and create habitat for local flora and fauna.

2 Acres
Afforestation Site

2,500
Native Trees at the Miyawaki forest, TV Koil

Manufactured Capital

Built to Enable **Better Care**

Our physical infrastructure provides the setting in which clinical expertise can translate into care. During FY 2025-26, additions across surgery, spine care, rehabilitation and other clinical areas expanded the capabilities available to our clinicians and patients.

A 450-Bed Care Platform

Our two hospitals in Trichy bring together **450 beds** across complementary clinical environments. The 250-bed Kauvery Hospital, Cantonment provides the established base of the network, while the 200-bed Maa Kauvery has expanded capacity with a dedicated focus on women and children alongside other specialties.

450 Beds
Across Our Two Hospitals

250 Beds
Kauvery Hospital, Cantonment

200 Beds
Maa Kauvery, Trichy

Preparing for the Next Phase of Capacity

KMC is also preparing to expand its physical capacity beyond the current 450-bed platform, with proposed additions in Trichy and Bengaluru.

100 Beds
Proposed Expansion at Maa Kauvery, Trichy
Proposed addition of four floors to the existing Maa Kauvery unit, adding 100 beds.

91 Beds
Proposed Mother & Child Care Hospital, Bengaluru
Proposed 91-bed hospital focused on mother and childcare.

New Technology at Maa Kauvery

Continuous Video EEG Monitoring
Introduced in the PICU

Near Infrared Spectroscopy (NIRS)
Introduced in the NICU

Blender Oxygen

Transport Incubator
Introduced to support in-house deliveries

Adding Capability Where It Matters

FY 2025-26 saw the addition of technologies and clinical environments designed to support greater precision, expand procedural capability and create dedicated settings for specialized care.

Da Vinci Robotic System

Installed in the Kauvery Hospital, Cantonment OT Complex, the system expands the infrastructure available for robotic-assisted abdominal surgery. Surgeon training is underway to support its clinical adoption.

Robotic-Assisted TKR

Robotic technology was introduced to support greater precision in total knee replacement procedures, adding a new technology-enabled capability to orthopedic surgery.

Advanced Spine Infrastructure

RIWO Spinal Instruments were introduced for advanced spinal procedures, alongside the launch of infrastructure supporting Endoscopic Discectomy from December 2025.

Specialized Care Environments

Kauvery Rehabilitation Centre
A dedicated environment supporting rehabilitation services.

Exclusive Burns Unit
A specialized facility created for the care requirements of patients with burn injuries.

Infrastructure for Complex Care

OPERATING THEATRES
Infrastructure for surgical and advanced procedural care

CRITICAL CARE
Dedicated environments for patients requiring intensive monitoring and intervention

NICU & PICU
Specialized critical care infrastructure for newborns and children

DIAGNOSTICS & IMAGING
Infrastructure supporting clinical assessment, diagnosis and treatment planning

Value Creation Model

Creating Value Through **Connected Capabilities**

Our value creation model shows how the resources and relationships we rely on are translated through our clinical, operational and institutional capabilities into outcomes for patients, employees, communities and other stakeholders.

Inputs → Our Value Creation Engine → Outputs → Outcomes → SDGs aligned

Inputs

Financial
- Net worth: **Rs. 210.43 Cr**
- Total assets: **Rs. 332.12 Cr**
- Capital expenditure: **Rs. 16.64 Cr**

Manufactured
- Hospitals: **2**
- Beds: **450**
- ICU Beds: **135**
- Operating theatres: **10**

Intellectual
- Postgraduate medical education programs: **16**
- Specialties for postgraduate training: **14**
- Students/doctors under training: **76**
- Accredited learning hubs: **2**

Human
- Total workforce: **1695**
- Doctors: **170+**
- Nurses: **450+**

Social & Relationship
- CSR Spend: **Rs. 73 Lakh**
- Institutional/community partnerships: **20**

Natural
- Total water consumed: **2,25,668 kL**
- Total energy consumed: **1,64,61,345.60 MJ**
- Renewable energy consumed: **1,51,46,643.60 MJ**

Our Value Creation Engine

VISION
To be the most respected and trusted healthcare provider

MISSION
To make great healthcare affordable

VALUES



Doctors Engagement Model
Identifying, attracting and retaining the right clinical talent.

Capacity Expansion
Building the infrastructure required to serve more patients.

Cutting-Edge Technology
Relevant technologies supporting patient experience and clinical outcomes.

Centers of Excellence
Focused specialties, clinical programs and academic enablement.

Quality & Digital Enablement
Quality systems, nursing excellence, process discipline and digital integration

Outputs

- Revenue from operations:: **Rs. 305.8 Cr**
- EBITDA: **Rs. 93.0 Cr**
- PAT: **Rs. 46.7 Cr**

Care Delivered
- Patients served: **1,70,145**
- Inpatients admissions: **18737**
- Surgeries/procedures: **7477**
- Deliveries: **826**
- Pediatric bone marrow transplants: **23**
- Interventional radiology procedures: **117**

- EMR adoption: **87.63%**
- Radiology reports: **43817**
- ABHA ID's created: **3853**

- Employee satisfaction: **75%**
- Training hours delivered: **41,136 hours**
- Fully funded employability training: **50 days**

- Students reached through school health camps: **30,000+**
- Community beneficiaries: **3820**
- Health screenings / consultations delivered through outreach: **38**
- Community health and awareness programs conducted: **30**
- Patient satisfaction score: **90%**

- Renewable-energy share: **92%**
- Waste generated: **343 MT**
- Plastic waste recycled / recovered: **148 MT**
- Reduction in carbon footprint: **3,310 tonnes**

Outcomes

- Reinvestment capacity
- Financial resilience
- Long-term shareholder value

- Greater patient capacity
- Access to specialized care
- Capability for complex cases

- Clinical knowledge creation
- Future clinical talent pipeline
- Digitally enabled care
- More consistent clinical processes

- Skilled and engaged workforce
- Multidisciplinary collaboration
- Employee well-being
- Continuity of care
- Gender inclusiveness and equal employment opportunity

- Patient trust
- Preventive-health access
- Community well-being
- Education and livelihood opportunities

- Lower conventional-energy dependence
- Reduced carbon footprint
- Responsible resource use
- Responsible waste management

SDGs aligned

- Financial: SDG 8
- Manufactured: SDG 3, 9
- Intellectual: SDG 3, 4, 9
- Human: SDG 3, 5, 8
- Social & Relationship: SDG 3, 4, 10
- Natural: SDG 6, 7, 12

The Flow—

Where Purpose **Reaches People.**

Across our hospitals, purpose is carried through the way care is delivered: in the expertise brought to complex cases, the discipline behind safe care and the experiences of patients and families who place their trust in us. The Flow brings these dimensions together, showing KMC as it is experienced every day.

Our **Care Network**

Our two hospitals in Trichy bring together distinct yet complementary clinical capabilities. Kauvery Hospital, Cantonment supports a broad spectrum of specialty and complex care, while Maa Kauvery has developed a focused ecosystem for women and children, supported by obstetrics, pediatrics, neonatology and pediatric critical care. Together, they allow patients and families to access a wider continuum of specialist care within KMC.

KAUVERY HOSPITAL, CANTONMENT

Multidisciplinary & complex care

One Network, Complementary Capabilities

MAA KAUVERY, TRICHY

Women, children & specialized pediatric care

Kauvery Hospital, Cantonment

A multidisciplinary clinical hub with capabilities spanning complex medical and surgical care.

Key Clinical Disciplines

Neurosciences | Gastroenterology | Orthopedics | Cardiology | Nephrology & Urology | Critical Care | Plastic & Reconstructive Surgery | Interventional Radiology | Transplant Programs

FY 2025-26 also saw the clinical ecosystem expand through dedicated services, including an **Infectious Diseases Clinic, the Kauvery Rehabilitation Centre and an Exclusive Burns Unit.**

Maa Kauvery, Trichy

A specialist environment centered on women and children, bringing obstetrics, pediatrics and neonatology together with the capabilities required to manage high-risk and complex cases.

Key Clinical Disciplines

Obstetrics & Gynecology | Pediatrics | Neonatology | Pediatric Critical Care | Pediatric Hematology & Bone Marrow Transplantation

During FY 2025-26, the clinical offering expanded further with a Lactation Clinic, Keto-diet Clinic, **Newborn Screening, Pediatric Orthopedics, Oncology Consultation and Uro-gynecology Clinic.**

kauvery hospital

The Depth of Our **Clinical Capability**

Kauvery Hospital, Cantonment

Interventional Radiology: A Growing Clinical Capability

Interventional Radiology recorded a significant increase in activity, with procedures rising from 46 to 117. The program covered 13 procedure types, led by Digital Subtraction Angiography, alongside biliary, vascular, embolization and ablative interventions.

46—>117 Interventional Radiology Procedures	**154.3%** Increase in Procedures
13 Procedures Types	**47** Digital Subtraction Angiography Procedures
15 Percutaneous Transhepatic Biliary Drainage Procedures	**8** Uterine Artery Embolization Procedures

Advancing Neurosurgical Complexity

Our neurosurgery team managed a range of uncommon and technically demanding cranial and spinal cases during the year, including skull-base tumors, rare intracranial disease and complex spinal stabilization.

Huge Tuberculum Sella Meningioma

Complete excision achieved.

C2 Fracture

Occipitocervical fusion performed.

5th Nerve Schwannoma

Complete excision achieved with no neurological deficit.

Cerebellar Hemangioblastoma with VHL Syndrome

Managed surgically.

Maa Kauvery, Trichy

Care Through Critical Moments

During FY 2025-26, teams managed pediatric transplantation, extremely low birth-weight newborns, high-risk obstetric conditions and critically ill children requiring multidisciplinary intervention.

23 Pediatric Bone Marrow Transplant	**1** Liver Transplant
826 Deliveries, Including 88 Twin Deliveries and 2 Triplet Deliveries	

Care Through Complex Pregnancies

120 Post-IVF Pregnancies	**113** Gestational Hypertension Cases
97 Multiple Gestation Cases	**59** Pregnancies Complicated by Cardiac Disease
104 Oligohydramnios / Polyhydramnios Cases	**28** Preeclampsia Cases

Giving the Smallest Patients a Chance

257 Extremely Low Birth-Weight Newborns Admitted to NICU

85% Survival Among Newborns Weighing Below 1.5 kg

Outcomes that Matter

Clinical capability matters most in the outcomes it creates for patients. Across our hospitals, FY 2025-26 brought measurable improvements in neonatal care alongside individual recoveries that show what specialist intervention can mean at critical moments.

Measurable Progress in Neonatal Care

94 —> 22 days
Ventilator days

70 —> 30 days
Average hospital stay for BPD

12.8 —> 7 days
Average umbilical vein cannula duration

226 —> 185 days
Oxygen duration

40% **—> 4.5**%
NNE/feed intolerance

Smallest Patients. Significant Outcomes.

400 Grams
A newborn with a birth weight of 400 grams was successfully supported to full oral feeds.

24 Weeks **+ 3** Days
The lowest gestational-age newborn reported during the year was successfully managed and recovered.

Global Recognition EFSM 2026, Prague

Dr Skanda from the Cantonment unit represented the institution at the European Federation of Societies for Microsurgery meeting in Prague, one of the most prestigious international platforms for microsurgery excellence in June 2026.

Times Leader Healthcare Award 2026

Dr Arivarasan, Consultant Medical Gastroenterologist from cantonment unit, was honored with the prestigious "Excellent Doctor."

Journeys of Hope



A Second Chance at Life

A young girl diagnosed with Acute Myeloid Leukemia underwent a second bone marrow transplant at Maa Kauvery, bringing another opportunity for treatment through the hospital's pediatric transplantation capability.

Living Transfusion-free

A six-year-old girl with thalassemia major underwent an unrelated-donor bone marrow transplant. She is now reported to be living a healthy, transfusion-free life.

A Rare Vascular Emergency

A patient with a post-traumatic high-flow carotid-cavernous fistula presented with symptoms affecting the opposite eye. The condition was managed through endovascular embolization with parent right internal carotid artery occlusion.



Managing a Life-threatening Pulmonary AVM

A 14-year-old boy with hereditary hemorrhagic telangiectasia presented with massive hemothorax caused by a ruptured pulmonary arteriovenous malformation. The condition was treated through endovascular embolization.

Five Years of Pain, Treated Minimally Invasively

A 19-year-old patient had lived with severe thigh pain from osteoid osteoma for five years. CT-guided radiofrequency ablation provided a minimally invasive route to treatment.



When a Routine Check Revealed More

An elderly patient attending a routine health check reported blurred vision. Assessment by the ophthalmologist led to investigation using the newly available Fundus Camera, enabling the clinical team to identify the condition and initiate treatment immediately.

When Recovery Needed Many Hands

An adolescent with severe organophosphorus poisoning developed cardiogenic shock, acute kidney injury and multi-organ dysfunction. Multidisciplinary care included CRRT, SLED, hemodialysis and tracheostomy. The patient later regained independent mobility and was successfully decannulated.





Recovery After Polytrauma

A child with multiple injuries, including Grade III liver injury, intracranial bleed, cervical spine injury, quadriparesis, pneumothorax and fractures, underwent multidisciplinary treatment. Following tracheostomy, decannulation and intensive physiotherapy, the child progressed to sitting without support.



The Land It Touches—

Every Community **Changed by the River.**

Beyond our hospitals are the communities we serve. Our presence extends through preventive health, education, outreach and social initiatives that bring care closer to people, respond to local needs and widen the reach of what KMC can contribute.

Outside Hospital Walls

Care That **Travels Further**

Bringing Health Closer to Communities

Our responsibility to health extends to people who may not always enter our hospitals. Through school health camps and community outreach, we take preventive care and health awareness into settings where people live, study and work, creating opportunities for earlier attention to health needs.

20,000+
School Students Reached

School health camps conducted across various schools brought health screening and awareness directly to more than 20,000 students during FY 2025-26.

Reaching Different Communities

PREVENTIVE HEALTH
Health camps and screenings that bring preventive attention closer to communities.

WOMEN & FAMILIES
Programs addressing areas such as maternal health and breastfeeding awareness.

COMMUNITY GROUPS
Focused health initiatives reaching groups including police personnel, journalists and people working within local communities.

VULNERABLE COMMUNITIES
Health camps extending healthcare benefits to marginalized and vulnerable groups as well as the wider public.

From Awareness to Action

Each outreach creates a point of contact with health outside the hospital setting. For some, that means a preventive check. For others, it can mean greater awareness of a health concern and an opportunity to seek appropriate medical attention.

Knowledge That Reaches the Community

Awareness That Helps People Act

Some of our work in the community begins with information. By sharing practical health knowledge with children, families and the wider public, we help people better understand specific conditions, recognize when medical attention may be needed and engage more meaningfully with their health.

Making Health Easier to Understand

During FY 2025-26, Maa Kauvery extended health education beyond clinical settings through public awareness content on areas relevant to children and their families.

PEDIATRIC EPILEPSY

Helping families better understand epilepsy in children and the importance of appropriate medical attention.

HEADACHE

Building awareness around a common symptom that may sometimes warrant further clinical evaluation.

KETOGENIC DIET

Creating awareness around dietary therapy used in the management of appropriate pediatric neurological conditions.

From Information to Better Choices

AWARENESS

Understanding the health issue

RECOGNITION

Knowing what may require attention

ACTION

Seeking appropriate medical guidance



Opening Up Possibilities Through Education

Kalvi Vazhikatti

Our engagement with young people also reaches beyond health. Through Kalvi Vazhikatti, we created awareness among students from rural and urban communities about opportunities to pursue higher education.

Opportunity Beyond Care

Preparing for the World of Work

Community well-being is also shaped by people's ability to participate in economic life. For participants from financially challenged rural backgrounds, KMC supports a fully funded employability program designed to build practical skills and familiarity with the workplace.

50 DAYS

Fully Funded Employability Training

Learning Beyond the Classroom

The program combines different forms of learning to help participants develop practical workplace readiness.

CLASSROOM TRAINING

Structured learning that builds foundational understanding.

FLOOR OBSERVATION

Exposure to an actual working environment and everyday workplace practices.

ROLE PLAY & WORKSHOPS

Opportunities to learn through interaction, participation and practical situations.

DIGITAL SKILLS

Training in typing and MS Office to build basic workplace proficiency.

WORKPLACE READINESS

Making Participation More Accessible

The program is fully funded by the Company. Selected participants are also provided with uniforms and lunch or refreshments, helping address some of the practical requirements associated with attending the program.

Extending Our Role in the Community

The initiative takes our community engagement into a different space. Alongside helping people access health services and information, it enables participants from rural communities to acquire practical skills and greater exposure to a working environment.

KMC SPECIALITY HOSPITALS (INDIA) LIMITED

CIN: L85110TN1982PLC009781,
Registered Office: No: 6, Royal Road, Cantonment, Trichy– 620001
Website: www.kauveryhospital.com
Email Id: corporatecompliance@kauveryhospital.com | Contact No: 0431-4077777

NOTICE TO SHAREHOLDERS

Notice is hereby given that the **FORTY-THIRD ANNUAL GENERAL MEETING** of the Members of **KMC SPECIALITY HOSPITALS (INDIA) LIMITED** ("the Company") will be held on **Monday, the 28th day of September, 2026 at 10:30 A.M. IST** through Video Conferencing ("VC")/ Other Audio Visual Means ("OAVM") to transact the following businesses:

ORDINARY BUSINESS:

1. **To consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2026 together with the Reports of the Board of Directors and the Auditor thereon.**

2. **To appoint a Director in place of Dr. S Vijayabaskaran (DIN: 05139565), who retires by rotation and being eligible, offers himself for re-appointment.**

SPECIAL BUSINESS:

3. **To approve Material Related Party Transactions under Section 188 of the Companies Act, 2013 and Regulation 23 of the SEBI (LODR) Regulations, 2015 with Sri Kauvery Medical Care (India) Limited, Holding Company**

To consider and if thought fit, to pass, with or without modification(s), the following Resolution as an **Ordinary Resolution:**

"RESOLVED THAT pursuant to Section 188 and other applicable provisions, if any, of the Companies Act 2013 read with the rules made there under and Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any amendment, modification, variation or re-enactment thereof for the time being in force), the prior consent and approval of the shareholders of the Company be and is hereby accorded to grant powers to the Company to enter into the Material Related Party transactions with M/s. Sri Kauvery Medical Care (India) Limited, Holding Company, being related party to the Company, at an arms length price, for an aggregate value not exceeding **Rs. 65,00,00,000/- (Rupees Sixty Five Crores only)** during the FY 2026-27, on such terms and conditions as may be mutually agreed upon, as detailed below;

- Operational Transactions, in the ordinary course of business, including but not limited to availing & rendering of hospital services, purchase of goods, sale of goods, rental expenses, rental income, guarantee expenses, guarantee income, purchase & sale of assets, or any other transaction involving the transfer of resources, services, or obligations not exceeding **Rs. 35,00,00,000/- (Rupees Thirty Five Crores)** only.
- Exchange of Immovable properties, not in the ordinary course of business, for a value not exceeding **Rs. 30,00,00,000/- (Rupees Thirty Crores)** only.

RESOLVED FURTHER THAT the Board of Directors (hereinafter referred to as "the Board", which term shall be deemed to include any Committee constituted / empowered / to be constituted by the Board from time to time to exercise the powers conferred by this Resolution(s) / transaction(s) and / or enter into and / or carry out new contract(s) / arrangement(s) / transaction(s), whether by way of an individual transaction or transactions taken together as a series of transactions or otherwise) of the Company be and is hereby authorized to settle any question, difficulty, or doubt, that may arise in giving effect to this resolution and to do all such acts, deeds and things as may be necessary, expedient and desirable for the purpose of giving effect to this resolution.

4. **Ratification of remuneration to Cost Auditor for the financial year 2026-27**

To consider and if thought fit, to pass, with or without modification(s), the following Resolution as an **Ordinary Resolution:**

"RESOLVED THAT pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the remuneration of **Rs. 80,000/- (Rupees Eighty Thousand only)** plus applicable tax and reimbursement of out of pocket expenses for the financial year 2026-27, as approved by the Board of Directors of the Company, to be paid to M/s G Sugumar & Co, Cost Accountants (Registration No. 102522), Chennai, appointed by the Board as Cost Auditors to conduct the audit of the cost records of the Company for the financial year 2026-27, be and is hereby ratified."

5. **To approve limits of borrowing under section 180 (1) (c) and 180 (1) (a) of the Companies Act, 2013**

To consider and if thought fit, to pass, with or without modification(s), the following Resolution as a **Special Resolution:**

"RESOLVED THAT in supersession of the Resolution passed at the Annual General Meeting of the Company held on September 28, 2020, consent of the members be and is hereby accorded in terms of the provisions of Section 180(1)(c), 180(1)(a) and other applicable provisions, if any, of the Companies Act, 2013 and the Rules made there under (including any statutory modification(s) or re-enactment thereof for the time being in force) to the Board of Directors (hereinafter referred to as "the Board" which shall include any Committee(s) thereof) to borrow from time to time all such sum(s) of money as the Board may deem requisite for the purpose of the Company, notwithstanding that the money(s) to be borrowed together with the money(s) already borrowed by the Company and outstanding (apart from the temporary loans obtained or to be obtained from the Company's bankers in the ordinary course of business) may exceed the aggregate of the paid-up capital, free reserves and securities premium of the Company, provided however that the total amount so borrowed and to be borrowed and remaining outstanding at any one time shall not exceed **Rs. 700,00,00,000/- (Rupees Seven Hundred Crores only)** in the aggregate, with or without creating charges on one or more or all assets of the Company, both present and future."

By the order of the Board
For **KMC Speciality Hospitals (India) Limited**

Place: Chennai
Date: August 14, 2026

Indumathi P
Company Secretary

Notes:

1. An Explanatory Statement setting out the material facts pursuant to Section 102 of the Companies Act, 2013 ("the Act") concerning the special business in the notice in respect of Item No. 3, 4 & 5 is annexed hereto and forms part of this notice.

2. As required under Secretarial Standard on General Meetings (SS 2) issued by The Institute of Company Secretaries of India and Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), brief profile of the Director seeking reappointment in Item No. 2 of this Notice is annexed herewith as Annexure.

3. Pursuant to the General Circular No. 03/2025 dated September 22, 2025, issued by the Ministry of Corporate Affairs (MCA) companies are allowed to hold AGM through Video Conferencing ("VC"), without the physical presence of members at a common venue. Hence, in compliance with the Circulars, the AGM of the Company is being held through VC.

   The forthcoming Annual General Meeting ("AGM") of the Company will thus be held through VC or other audio visual means (OAVM). Hence, Members can attend and participate in the ensuing AGM through VC/OAVM. The deemed venue of the 43rd Annual General Meeting shall be the Registered office of the Company.

4. The Company shall send a physical copy of the Annual Report to those members who have requested the same via mail to the Company and the Registrar and Share Transfer Agent, mentioning their Folio No./ DP ID and Client ID.

5. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI Listing Regulations (as amended), and MCA Circular dated May 05, 2022, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting's agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by CDSL.

   The procedure for participating in the meeting through VC / OAVM is explained below and is also available on the website of the Company at https://www.kauveryhospital.com/investors#.

   The members may contact the RTA at investor@cameoindia.com or the CDSL helpdesk at helpdesk.evoting@cdslindia.com for any query or help with respect to participation in the meeting or e-voting facility.

6. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairperson of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who shall be allowed to attend the AGM without any restriction on account of first come first served basis.

7. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.

8. The members attending the AGM through VC/OAVM can vote during the meeting, provided they have not availed the facility of e-voting and voted prior to the meeting.

9. Pursuant to the provisions of the Companies Act, 2013, a member entitled to attend and vote at the AGM is entitled to appoint a proxy on his/her behalf to attend and vote at the AGM. Since the AGM is held through VC/OAVM pursuant to MCA Circulars, physical attendance of the members has been dispensed with and accordingly, the facility to appoint proxy will not be available for this AGM. Hence the proxy form, attendance slip and Route map are not annexed to this Notice.

   However, in pursuance of Section 113 of the Companies Act, 2013, representatives of a body corporate who is a member, can attend the AGM through VC/OAVM and cast their votes through e-voting. Corporate Members intending to authorize their representatives to attend the meeting are requested to send to the Company a certified copy of the Board Resolution authorizing their representative to attend the AGM through VC / OAVM and cast their votes through e-voting.

10. The cut-off date for the purpose of determining eligibility of members for voting in connection with the 43rd AGM is Monday, September 21, 2026.

11. In case of joint holders, the member whose name appears as the first holder in the Register of members of the Company shall be entitled to vote at the Annual General Meeting.

12. In accordance with the aforesaid MCA Circular mentioned in point: 3, the Notice of the AGM along with the Annual Report 2026 is being sent only through electronic mode to those Members whose email addresses are registered with the Company /RTA/ Depositories. Members may note that the Notice and Annual Report 2026 will also be available on the Company's website at https://www.kauveryhospital.com/investors#, the website of the Stock Exchange i.e. BSE Limited at www.bseindia.com & website of CDSL at www.evotingindia.com

13. In accordance with Regulation 36 (b) of SEBI (LODR) Regulations, a letter providing the web-link, including the exact path, where complete details of the Annual report is available shall be sent to the shareholder(s) who have not registered their email address(es) either with the listed entity or with any depository.

14. The Register of Members and the Share Transfer Books of the Company shall remain closed from September 22, 2026 to September 28, 2026 (both days inclusive).

15. In case of shares held in Electronic form, members are requested to notify any change in address, e-mail id, bank details, etc. to the concerned Depository Participant, quoting their ID No. and in case of shares held in physical form, members are requested to intimate such change to the Registrar and Transfer Agent, Viz. M/s Cameo Corporate Services Limited, Subramanian Building, 1, Club House Road, Chennai - 600002. Further, three reminders in the year 2018 have been sent to the members holding shares in physical form through our Registrar and Transfer Agent, at their registered addresses insisting them to provide PAN and bank a/c details pursuant to directions given by SEBI circular dated April 20, 2018.

16. Further, pursuant to SEBI circular SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023, the members holding securities in physical form shall furnish the details of PAN, KYC & Nomination, which have not been updated in the database of the Registrar and Transfer Agent, Viz. M/s Cameo Corporate Services Limited. The said circular, along with the forms mentioned herein below have also been uploaded on the website of the Company for easy access:

    Form ISR-1: Request for registering PAN, KYC Details or Changes / Updation thereof; to update/ change details of PAN, Bank details, Signature, Mobile number, email id and address registered with the Company/RTA.

    Form ISR-2: Confirmation of Signature of securities holder by the Banker; to update or record the signature of the shareholder with the Company/RTA.

    Form ISR-3: Declaration Form for Opting-out of Nomination by holders of physical securities in Listed Companies; wherein members can declare their intention of opting out of nominating any person for the securities held by them in the Company.

    Form No. SH-13: Nomination Form; to register a nominee for the securities held in the Company.

    Form No. SH-14: Cancellation or Variation of Nomination; to cancel or change the nominees for the securities held in the Company.

    The members holding securities in physical form and intent to register/update any or all of the above details with the Company/RTA are requested to intimate such information/updation to the RTA at the earliest with the above duly filled and signed forms and other relevant documents.

17. The Company's website is www.kauveryhospital.com, Annual Reports of the Company and other shareholder communications are made available on the Company's website.

18. All the members are requested to intimate their e-mail address to the Company's Registrar and Transfer Agents whose e-mail id is investor@cameoindia.com, mentioning the Company's name i.e., KMC Speciality Hospitals (India) Limited so as to enable the Company to send the Annual Report and Accounts, Notices and other documents through Electronic Mode to their e-mail address.

19. Members may please note that as per the SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, listed companies can issue securities only in dematerialized form while processing any request for Issue of duplicate securities certificate; Claim from Unclaimed Suspense Account; Renewal / Exchange of securities certificate; Endorsement; Sub-division / Splitting of securities certificate; Consolidation of securities certificates/folios; Transmission; Transposition. Accordingly, the security holder can avail service requests by submitting duly filled and signed ISR-4 form. A copy of the said form is also available in the website of the company at https://www.kauveryhospital.com/investors#. In view of the above, to process service requests with ease and avail various other benefits not associated with

the physical securities, the members are advised to dematerialize the securities held by them in physical form. The members may contact the Company or the RTA with any clarification or help in this aspect.

Further, Letter of Confirmation ('LOC') will not be issued effective April 2, 2026 and shares will be credited directly to the shareholder's demat account by the Company/RTA, subject to due diligence. Shareholders are requested to provide a Client Master List not older than two months, duly attested by their DPs.

20. Pursuant to SEBI circular No. HO/38/13/11(2)2026MIRSD-POD/ I/3750/2026 dated January 30, 2026 the Company has opened a special window for a period of one year from February 05, 2026 till February 04, 2027 for transfer and dematerialisation of physical securities which were sold/purchased prior to April 01, 2019. The special window shall also be available for such transfer requests which were submitted earlier and were rejected/ returned/not attended to due to deficiency in the documents/process/or otherwise. The Investors are requested to submit their transfer requests accompanied by original security certificates and transfer deeds along with other supporting documents mentioned in the circular with the Company's Registrar and Share Transfer Agent viz., M/s. Cameo Corporate Services Limited latest by February 4, 2027 at the following address:

    M/s. Cameo Corporate Services Limited,

    Address: "Subramanian Building", No.1, Club House Road, Chennai – 600 002

21. The Register of Directors and their shareholding, maintained u/s 170 of the Companies Act, 2013 and Register of Contracts or Arrangements in which Directors are interested, maintained u/s 189 of the Companies Act, 2013 and all other documents referred to in the notice and explanatory statement, will be available for inspection electronically by the members during the Meeting through VC/OAVM. Members seeking to inspect such documents are requested to send an email to the Company at corporatecompliance@kauveryhospital.com.

INSTRUCTIONS FOR SHAREHOLDERS FOR E-VOTING AND JOINING VIRTUAL MEETINGS ARE AS UNDER:

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

Step 2 : Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

(i) The voting period begins on September 25, 2026 at 09:00 a.m. IST and ends on September 27, 2026 at 05:00 p.m. IST. During this period, the shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of September 21, 2026 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.

(ii) Shareholders who have already voted through e-voting process prior to the meeting date would not be entitled to vote during the meeting.

(iii) In terms of **SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020** under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

Step 1: Access through Depositories CDSL/ NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

(iv) In terms of SEBI circular no. **SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020** on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to the above said SEBI Circular, Login method for e-Voting and joining virtual meetings **for individual shareholders holding securities in Demat mode through CDSL/NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with **CDSL**	1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsl website www.cdslindia.com and click on login icon & My Easi New (Token) Tab. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at cdsl website www.cdslindia.com and click on login & My Easi New (Token) Tab and then click on registration option. 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders holding securities in demat mode with **NSDL**	1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Type of shareholders	Login Method
	2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS "Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 4) For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
Individual Shareholders (holding securities in demat mode) login through their **Depository Participants (DP)**	The members can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at above mentioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with **CDSL**	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 18002109911
Individual Shareholders holding securities in Demat mode with **NSDL**	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 022-48867000 and 022-24997000

Step 2: Access through CDSL e-Voting system in case of shareholders holding shares in physical mode and non-individual shareholders in demat mode.

(v) Login method for e-Voting and joining virtual meetings for **Physical shareholders and shareholders other than individuals holding in Demat form.**

1) The shareholders should Log on to the e-voting website www.evotingindia.com.

2) Click on "Shareholders" module.

3) Now enter your User ID

   a. For CDSL: 16 digits beneficiary ID,

   b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,

   c. Shareholders holding shares in Physical Form should enter their Folio Number registered with the Company.

4) Next enter the Image Verification as displayed and Click on Login.

5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.

6) If you are a first-time user follow the steps given below:

	For Physical shareholders and other than individual shareholders holding shares in Demat.
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) • Shareholders who have not updated their PAN with the Company/ Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details **OR** Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. • If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

(vi) After entering these details appropriately, click on "SUBMIT" tab.

(vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

(viii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.

(ix) Click on the EVSN for the relevant Company on which you choose to vote.

(x) On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.

(xi) Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.

(xii) After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else click on "CANCEL" to change your vote and accordingly modify your vote.

(xiii) Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.

(xiv) You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.

(xv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

(xvi) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.

(xvii) **Additional Facility for Non – Individual Shareholders and Custodians –For Remote E-Voting only.**

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the "Corporates" module.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
- It is mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively, Non Individual shareholders are required mandatorily to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; corporatecompliance@kauveryhospital.com, if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for e-voting.

2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for e-voting.

3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.

4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.

5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending a request from their registered email id in advance, atleast **5 days prior to meeting,** mentioning their name, demat account number/folio number, email id, mobile number at corporatecompliance@kauveryhospital.com. The shareholders who do not wish to speak during the AGM but have queries may send their queries **5 days prior to meeting** mentioning their name, demat account number/folio number, email id, mobile number at corporatecompliance@kauveryhospital.com. These queries will be replied to by the company suitably by email or addressed to at the AGM.

   The Company reserves the right to restrict the number of questions and speakers depending on the availability of time for the AGM. Further, the sequence in which the shareholders will be called upon to speak will be solely determined by the Company.

8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.

9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.

10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/ DEPOSITORIES.

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to investor@cameoindia.com /corporatecompliance@kauveryhospital.com.

2. For Demat shareholders - Please update your email id & mobile no. with your respective Depository Participant (DP)

3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

   If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 18002109911

   All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call toll free no. 18002109911.

Explanatory Statement

Pursuant to Section 102(1) of the Companies Act, 2013

The following Explanatory Statement sets out all the material facts relating to the Special Business:

Item No. 3: To approve Material Related Party Transactions under Section 188 of the Companies Act, 2013 and Regulation 23 of the SEBI (LODR) Regulations, 2015 with Sri Kauvery Medical Care (India) Limited, Holding Company

Pursuant to Section 188 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with the Companies (Meetings of Board and its Powers) Rules, 2014 and Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI Listing Regulations') and applicable Industry standards as amended, any transaction(s) with a related party shall be considered material, if the transaction(s) entered into/ to be entered into individually or taken together with the previous transactions during a financial year exceeds 10% of annual turnover of the Company as per the last audited financial statements of the Company and shall require prior approval of shareholders by means of an ordinary resolution. The said limits are applicable, even if the transactions are in the ordinary course of business of the concerned company and at an arm's length basis.

Background, Nature and benefits of the transactions

M/s. Sri Kauvery Medical Care (India) Limited ("SKMC") is the Holding Company of the Company. The Company enters into, or proposes to enter into, the following categories of transactions on an arm's length basis with SKMC:

1) **Operational Transactions:** The Company in the Ordinary course of business and on an arm's length basis, regularly enters into various operational transactions with SKMC for availing & rendering of hospital services, purchase of goods, sale of goods, rental expenses, rental income, guarantee expenses, guarantee income, sale of asset, purchase of asset etc., or any transaction involving transfer of resources, services or obligations of whatever nature. These transactions are continuous in nature.

2) **Exchange of Immovable Properties:**

   In addition to the aforesaid operational transactions, the Company proposes to undertake a specific transaction involving the exchange of immovable properties between the Company and its Holding Company, Sri Kauvery Medical Care (India) Limited ("SKMC").

   Presently, the Company's Cantonment hospital unit at Trichy is being operated on land owned by SKMC, while SKMC's Heart City hospital unit is being operated on land owned by the Company, resulting in cross-ownership of the underlying hospital properties. This arrangement has, inter alia, resulted in the requirement from Bank to provide corporate guarantees and/or security towards the loan availed by the Holding Company.

   With a view to simplifying the existing ownership structure, aligning ownership of the land with the respective hospital operations and mitigating the associated financing and security-related complexities, it is proposed that the Company and SKMC exchange the respective parcels of land which is located in the same campus, such that each entity owns the land on which its respective hospital unit is operated.

   The land situated at Royal Road is proposed to be transferred by SKMC to the Company measures approximately 24,864 sq. ft., whereas the land situated at Alexandria Road is proposed to be transferred by the Company to SKMC measures approximately 14,500 sq. ft. The Company intends to execute the transaction at the prevailing guideline value of the properties. The prevailing guideline value for the SKMC's property is not exceeding Rs. 21.80 Crores, and the guideline value for the Company's property is not exceeding Rs. 8.20 Crores. Accordingly, considering the difference in the extent and value of the properties being exchanged, the Company will pay an additional consideration/ differential value not exceeding Rs. 13.60 Crore (excluding stamp duty and registration fees) to SKMC.

The proposed Material Related Party transactions have been reviewed and approved by the Audit Committee and the Board of Directors at their meetings held on August 13, 2026 and August 14, 2026 respectively. The Board has further recommended to the shareholders, for their final approval, for entering into Material Related Party Transactions with SKMC.

The minimum information to be placed before the shareholders for approval of proposed Material Related Party Transactions with SKMC, holding company as required under the RPT industry standards dated June 26, 2026 is annexed herewith as Annexure and forms part of the explanatory statement of the Notice to shareholders.

The Managing Director and the Chief Financial Officer has issued a management certificate confirming that the terms of the proposed Material RPT with SKMC are in the interest of the Company. This certificate was also reviewed by the Audit Committee in accordance with the applicable RPT Industry standards at their meeting held on August 13, 2026.

The Company seeks approval of the Members for entering into Material Related Party Transactions with SKMC during the Financial Year 2026-27 for an aggregate value not exceeding Rs.65,00,00,000/- (Rupees Sixty-Five Crores only). Pursuant to rule 15(3) of Companies (Meetings of Board and its Powers) Rules, 2014, the nature of transactions with the related parties and the maximum threshold for the Material RPT for the FY 2026-27 are provided below.

Nature of Transaction	Maximum Aggregate Value (Rs.)
Operational transactions in the ordinary course of business including availing & rendering of hospital services, purchase of goods, sale of goods, rental expenses, rental income, guarantee expenses, guarantee income, purchase & sale of assets and other transactions involving transfer of resources, services or obligations	Rs. 35,00,00,000
Exchange of immovable properties (not in the ordinary course of business)	Rs. 30,00,00,000
Total limit for Material RPT for FY 2026-27	**Rs. 65,00,00,000**

The Members are hereby informed that the detailed breakup of the proposed transactions is set out in the Industry Standard Disclosures annexed to this Notice, with the proposed transaction values factoring in potential contingencies and reasonable operational variations. Accordingly, approval of the Members is sought for an aggregate limit of Rs. 65 Crores in respect of the proposed transactions.

The members are further informed that pursuant to Regulation 23 (4) of SEBI Listing Regulations, the related parties as defined thereunder (whether such related party is a party to the aforesaid transactions or not), shall not vote to approve this Ordinary Resolution under Item no. 3.

Memorandum of Interest: None of the Directors, Key Managerial Personnel of the Company or their relatives except Dr S Chandrakumar, Dr S Manivannan, Dr. S Vijayabaskaran and Dr. D Senguttuvan are interested to the extent of their shareholding held in the Holding Company in the aforesaid Ordinary resolution.

The Board of Directors believes these transactions serve the best interests of the Company and its stakeholders and, accordingly recommends the resolution set forth in Item No. 3 for approval of members as an **Ordinary resolution.**

Item No. 4: Ratification of remuneration to Cost Auditor for the financial year 2026-27.

In terms of Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, as amended from time to time, the Company is required to undertake the audit of its cost records by a Cost Accountant in practice.

In compliance with the above and Rule 14 (a) (ii) of the Companies (Audit and Auditors) Rules, 2014, the Audit Committee of the Company at its meeting held on August 13, 2026 considered and recommended to the Board, the appointment of M/s G. Sugumar & co, Cost Accountants (Firm Registration Number: 102522) as the Cost Auditors of the Company for FY 2026-27 at a remuneration of Rs. 80,000/- (Rupees Eighty Thousand only) (plus applicable taxes and reimbursement of out-of-pocket expenses) payable for FY 2026-27.

In making the decision on the appointment and remuneration of the Cost Auditors, the Audit Committee considered, the Cost Auditors' performance during the previous year(s) in examining and verifying the accuracy of the cost accounting records maintained by the Company and the scope of work.

The Board, based on the recommendation of the Audit Committee, approved the appointment of M/s G. Sugumar & co, Cost Accountants (Firm Registration Number: 102522) as the Cost Auditors of the Company for the FY 2026-27. The Board, also on the recommendation of the Audit Committee, approved the remuneration of Rs. 80,000 /- (Rupees Eighty Thousand only) (excluding applicable taxes and reimbursement of out-of-pocket expenses) payable to Cost Auditors for FY 2026-27. In accordance with the provisions of Section 148(3) of the Act read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014, the remuneration payable to the Cost Auditors as recommended by the Audit Committee and approved by the Board must be ratified by the Members of the Company. The consent of the Members is sought for ratification of the remuneration payable to the Cost Auditor of the Company for the Financial Year ending March 31, 2027.

Memorandum of Interest: None of the Directors, Key Managerial Personnel of the Company or their relatives are in any way, concerned or interested financially, or otherwise in this resolution, except to the extent of the Shareholding, if any.

Accordingly, the Board of Directors recommends the resolution set forth in Item No. 4 for approval of members as **Ordinary Resolution.**

Item No. 5: To approve limits of borrowing under section 180 (1) (c) and 180 (1) (a) of the companies Act, 2013.

As per the provisions of Section 180(1) (c) and Section 180(1) (a) of the Companies Act, 2013 the power to borrow moneys, apart from temporary loans obtained from the Company's Bankers in the ordinary course of business, in excess of the aggregate of the paid-up capital, free reserves and securities premium of the Company, can be exercised by the Board with the consent of the Members obtained by way of a Special Resolution.

At the Annual General Meeting of the Company held on September 28, 2020, the Members had accorded consent to the Board of Directors to borrow any sum or sums of money not exceeding at any time the sum of Rs. 200 Crores.

Keeping in view the Company's business requirements and strategic expansion plans, the existing limit is proposed to be increased. Accordingly, it is proposed to seek the approval of the shareholders to enhance the borrowing and security creation limits to a maximum aggregate amount of Rs. 700 Crores (Rupees Seven Hundred Crores only) at any given time.

The Board of Directors considers the proposed enhancement to be in the best operational interests of the Company and its stakeholders. The Board of Directors recommends the resolution set forth in item No. 5 for approval of members as a **Special resolution**.

Memorandum of Interest: None of the Directors, Key Managerial Personnel of the Company or their relatives are in any way, concerned or interested financially, or otherwise in this resolution, except to the extent of their shareholding, if any.

Annexure

Item No: 2

DETAILS OF DIRECTORS SEEKING RE-APPOINTMENT AT THE ANNUAL GENERAL MEETING

(Pursuant to Regulation 36(3) of SEBI (LODR) Regulations & Secretarial Standard 2)

Name of the Director	Re-appointment Dr. S Vijayabaskaran
Director Identification Number	05139565
Type	Non-Executive Director
Age & Date of Birth	57 years, 02/07/1969
Date of Appointment/ Re- appointment	11/08/2023
Qualification	MSc.(AG), PH D, PGDBA, PGDHA
Number of Equity shares held	Nil
Brief Resume	Dr. S. Vijayabaskaran is a doctorate in Agronomy, having diverse experience of over 16 years in managing & administering Multi Specialty Hospitals. He has extensive experience in obtaining NABH accreditation & achieving operational excellence with financial prudence in Hospital administration.
Experience/Expertise in specific functional area	Accounting, Finance, Business Management, Operations, Fund Management, General Administration
List of Public Limited Companies in which outside directorships held	Nil
Chairman/ Member of the committee of Board of Directors of the company	Nil
Membership/ Chairmanships of committees of other public companies (Includes only Audit Committee and Stakeholders Relationship Committee)	Nil
No. of board meetings attended during the year	4
Relationship with Directors inter-se	Brother of Dr S Chandrakumar, Executive Chairman (Whole-Time)

Item No: 3

Information required under Regulation 23 of SEBI LODR read with SEBI Circular dated November 22, 2021, is provided below:

Sl No	Description	Details
1	Summary of the information provided by the management of the listed entity to the Audit committee regarding the type of transaction	**Nature of transactions:** Availing/Rendering of hospital services, purchase of goods, sale of goods, rental expenses, rental income, guarantee expenses, guarantee income, sale of asset, purchase of asset, etc., or any transaction involving transfer of resources, services or obligations of whatever nature **Tenure:** FY 2026-27
2	Name of Related Party and its relationship with listed entity or its subsidiary, including nature of its concern or interest (financial or otherwise)	Sri Kauvery Medical Care (India) Limited – Holding Company
3	Name of the Director or Key Managerial Personnel who is related, if any and nature of relationship	Refer explanatory statement
4	A statement that the valuation or other external report, if any, relied upon by the listed entity in relation to the proposed transaction will be made available through the registered email address of the shareholders	Not Applicable

Sl No	Description	Details
5	If the transaction relates to any loans, inter-corporate deposits, advances or investments made or given by the listed entity or its subsidiary - Applicable terms, including covenants, tenure, interest rate and repayment schedule, whether secured or unsecured, if secured, the nature of security	Not Applicable
6	Value of the transaction and the percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year (FY 25-26) that is represented by the value of the proposed transaction	**Value of Transaction:** Rs. 65,00,00,000/- (Rupees Sixty Five Crores Only) **Percentage of turnover:** 21.26%
7	Justification as to why the related party transaction is in the interest of the listed entity and basis for determination of price	These transactions are undertaken in furtherance of the ordinary course of business (except exchange of immovable properties) to enhance operational efficiency, cost efficiency, leveraging the expertise, complementary strengths and facilities available with the Company and the Holding Company. All transactions are carried out on an arm's length basis.
8	Any other information that may be relevant	All important information forms part of the statement setting out material facts, pursuant to Section 102(1) of the Companies Act, 2013 forming part of this Notice.

Disclosure under Regulation 23 of SEBI (LODR) Regulations, 2015 and Revised Industry Standards.

Proposed Material Related Party Transactions for FY 2026-27.

KMC Speciality Hospitals (India) Limited ('KMC' or 'the Company') will be entering into material related party transactions with Sri Kauvery Medical Care (India) Limited ('SKMC' or 'Related Party') during the FY 2026-27

- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('LODR') requires approval of RPT by the Audit Committee and the material RPT also requires shareholders approval.
- Industry standard on ""Minimum information to be provided to the Audit Committee and Shareholders for approval of Related Party Transactions"" have been prescribed to standardize the information to be provided to the Audit Committee / Shareholders for approval of RPT entered into by the listed entity/its material subsidiaries.
- The effective date of the above industry standard shall be from September 1, 2025 ('effective date') basis the latest SEBI circular on the Revised industry standards issued on June 26, 2025.
- The format of the industry standard is structured as follows:

  Part A: This Part of the Standards captures the minimum information of the proposed RPT and is applicable to all RPTs.

  Part B: This Part is applicable only if a specific type of RPT is proposed to be undertaken and is in addition to Part A. Seven types of RPTs have been specified.

  Part C: This Part is applicable only if a specific type of RPT proposed to be undertaken is a Material RPT as defined under Regulation 23(1) & (1A) of the LODR Regulations ("Material RPTs"); and is in addition to Part A and Part B (with respect to such RPT).

- SEBI via circular dated September 4, 2025 has issued Frequently Asked Questions (FAQS) on the Industry Standards on Minimum information to be provided for Review of the Audit Committee and Shareholders for Approval of RPT
- SEBI via circular dated October 13, 2025 has relaxed the disclosure requirements for RPTs to reduce compliance burden, while retaining safeguards for material transactions. RPT disclosures to Audit Committee and Shareholders will now depend on the value of the transaction:

Individual/Aggregate transaction value during FY (incl. previous & ratified RPTs)	Audit Committee – Information to be provided	Shareholders – Information to be provided
Exceeds 1% of annual consolidated turnover or Rs. 10 Crore (whichever is lower)	Full disclosures as per RPT Industry Standards	Full disclosures as per RPT Industry Standards
Up to 1% of annual consolidated turnover or Rs. 10 Crore (whichever is lower)	Simplified disclosures as per Annexure 13A of SEBI circular dated September 4, 2025	Simplified disclosures as per Annexure 13A of SEBI circular September 4, 2025
Up to Rs. 1 Crore	Exempt from Industry Standard disclosures	Exempt from Industry Standard disclosures

- As KMC is a listed entity, it is required to comply with the SEBI LODR.
- Accordingly, the approval of the shareholder's is being sought for the material RPT proposed to be entered into for the FY 2026-27. The disclosures under the Industry standards are enclosed herewith.

KMC Speciality Hospitals (India) Limited

Proposed Material Related Party Transactions for the FY 2026-27

Applicability of level of disclosure prescribed in the Industry standards

S. No	Transactions	Related party	Value of proposed transactions (Amount in Rs.)	Party-wise subtotal (Amount in Rs.)	Reference	Applicability of Disclosures			
						Part A	Part B	Part C	Minimum Disclosures
1	Revenue from hospital services rendered	SKMC	15,00,00,000	62,61,15,296	SKMC - 1	✓	✓	×	×
2	Hospital services availed	SKMC	5,00,00,000		SKMC - 2	✓	✓	×	×
3	Purchase of goods	SKMC	7,50,000		SKMC - 3	✓	✓	×	×
4	Sale of goods	SKMC	10,00,000		SKMC - 4	✓	✓	×	×
5	Rental expenses	SKMC	28,34,496		SKMC - 5	✓	✓	×	×
6	Rental income	SKMC	36,73,800		SKMC - 6	✓	✓	×	×
7	Reimbursement of expenses received	SKMC	3,50,00,000		SKMC - 7	✓	✓	×	×
8	Reimbursement of expenses paid	SKMC	3,50,00,000		SKMC - 8	✓	✓	×	×
9	Guarantee expenses	SKMC	1,00,00,000		SKMC - 9	✓	×	×	×
10	Guarantee Income	SKMC	98,57,000		SKMC - 10	✓	✓	✓	×
11	Claims made on behalf of holding Company	SKMC	1,00,00,000		SKMC - 11	✓	✓	×	×
12	Sale of asset	SKMC	8,35,00,000		SKMC - 12	✓	✓	×	×
13	Purchase of asset	SKMC	21,95,00,000		SKMC - 13	✓	✓	×	×
14	Reimbursement of claims received	SKMC	1,50,00,000		SKMC - 14	✓	✓	×	×

Name of Related Party : SKMC

Transaction : Revenue from hospital services rendered (SKMC - 1)

Part - A

S. No	Particulars of information	Information to be provided by management
1.	**Basic details of the related party**	
(1)	Name of the related party	Refer Annexure A
(2)	Country of incorporation of the related party	Refer Annexure A
(3)	Nature of business of the related party	Refer Annexure A
2.	**Relationship and ownership of the related party**	
(1)	Relationship between the listed entity/subsidiary and the related party including nature of its concern (financial or otherwise) Explanation: 1. Indirect shareholding shall mean shareholding held through any person, over which the listed entity/Subsidiary/ related party has control 2. While calculating indirect shareholding, shareholding held by relatives shall also be considered.	Refer Annexure A
	Shareholding of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party	Refer Annexure A
	Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity/ subsidiary (in case of transaction involving the subsidiary)	Refer Annexure A
	Shareholding of the related party, whether direct or indirect, in the listed entity/ subsidiary (in case of transaction involving the subsidiary)	Refer Annexure A
3.	**Details of previous transactions with the related party**	
(1)	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the last financial year. Explanation: Details need to be disclosed separately for listed entity and its subsidiary.	Refer Annexure A
(2)	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought.	Refer Annexure A
(3)	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last financial year	Refer Annexure A
4.	**Amount of the proposed transaction(s)**	
(1)	Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ shareholders.	Refer Annexure A
(2)	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Refer Annexure A
(3)	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year	Refer Annexure A
(4)	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary and where the listed entity is not a party to the transaction)	Refer Annexure A
(5)	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available.	Refer Annexure A
(6)	Financial performance of the related party for the immediately preceding financial year: Explanation: The above information is to be given on standalone basis. If standalone is not available, provide on consolidated basis.	Refer Annexure A

S. No	Particulars of information	Information to be provided by management
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Revenue from hospital services rendered
(2)	Details of each type of the proposed transaction	Medical gas, MRI Services, CT Scan, Dialysis services, Neurology, Professional medical services, lab & blood bank services,etc.
(3)	Tenure of the proposed transaction (in years or months)	1 Year
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year	Estimated value of proposed transaction for FY 2026-27
	If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Rs. 15,00,00,000
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	KMC hospital (Cantonment) is located adjacent to SKMC (Heart city) hospital. Since SKMC does not have any inhouse lab, hence it avails lab/Radiology/ Master Health Checkup (MHC) services from KMC hospital for its patients in a revenue sharing model. The proposed transactions facilitate optimal utilization of its existing diagnostic infrastructure, advanced medical equipment, and specialized manpower. By servicing patients originating from SKMC, the Company is able to achieve improved capacity utilization, operational efficiencies, and stable service volumes without incurring additional patient acquisition or marketing costs. The arrangement enables KMC to generate sustainable revenues while leveraging its existing capabilities, making the transactions commercially rational and in the ordinary course of business.
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	Refer Annexure B
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	NA

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding process or other process were undertaken for rendering hospital services, as the transactions arise in the ordinary course of business pursuant to shared healthcare arrangements and operational collaboration within the group.
2	Basis of determination of price.	The commercial terms, including the revenue-sharing and pricing arrangements, have been determined through negotiations, taking into account the respective roles, capital investments, and ongoing maintenance obligations of the parties, and are aligned with the rates charged to third-parties. The revenue sharing arrangements have been arrived at after benchmarking against industry practices and revenue sharing percentages applicable to similar arrangements. Further, the same are also tested for arm's length by an independent firm of Chartered Accountants once in two years to ensure that the same continues to meet the said standard.
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA The transaction does not involve trade advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Name of Related Party : SKMC

Transaction : Hospital services availed (SKMC - 2)

Part - A

S. No.	Particulars of information	Information to be provided by management
Note:	For Sl.No.1 to 4 of Part - A.	Refer SKMC -1
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Hospital services availed
(2)	Details of each type of the proposed transaction	Patient/Staff/Attendant Canteen Services, Testing charges-CT Scan, Professional medical services, etc
(3)	Tenure of the proposed transaction (in years or months)	1 Year
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year	Estimated value of proposed transaction for FY 2026-27
	If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Rs. 5,00,00,000

S. No.	Particulars of information	Information to be provided by management
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	The proposed transactions ensures continuity of essential support services and medical care to the patients by leveraging SKMC's proximity, infrastructure, and manpower. **Canteen services** The canteen services operated by SKMC provide a consistent and reliable food facility for the Company's patients, attendants, and employees at rates comparable to those charged by SKMC to its own patients, thereby avoiding the need for KMC to independently establish and manage such facilities. **Doctor services** The arrangement for sharing of doctors, where services are availed during exigencies or non-availability and reimbursed at actual rates charged to patients, ensures uninterrupted medical services without duplication of manpower and the associated additional costs.
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	NA

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding or other process were undertaken for availing hospital services, as such services require seamless clinical coordination, common protocols, proximity of hospitals and continuous availability, which are critical in the healthcare sector.
2	Basis of determination of price.	The prices were determined based on the commercial factors. Further, the same are also tested for arm's length by an independent firm of Chartered Accountants once in two years to ensure that the same continues to meet the said standard.
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA The transaction does not involve trade advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Name of Related Party : SKMC

Transaction : Purchase of goods (SKMC - 3)

Part - A

S. No.	Particulars of information	Information to be provided by management
Note:	For Sl.No.1 to 4 of Part - A.	Refer **SKMC -1**
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Purchase of goods
(2)	Details of each type of the proposed transaction	Purchase of pharmacy products, consumables
(3)	Tenure of the proposed transaction (in years or months)	1 Year
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Estimated value of proposed transaction for FY 2026-27 Rs. 7,50,000
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	Given the proximity of the hospitals, in case of non-availability of stock or due to exigency, the Company buys pharmacy products and consumables from the SKMC
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	NA

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding or other process were undertaken for such transactions, as these procurements are undertaken on an urgent and ad-hoc basis to address immediate operational requirements, where time-bound availability is critical. Further, the limited quantities involved and the need for immediate fulfilment make a formal bidding process impractical. Pricing for such purchases is based on prevailing standard rates charged to third parties or actual cost, as applicable.
2	Basis of determination of price.	The prices were determined based on the commercial factors. Further, the same are also tested for arm's length by an independent firm of Chartered Accountants once in two years to ensure that the same continues to meet the said standard.
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA The transaction does not involve trade advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Name of Related Party : SKMC

Transaction : Sale of goods (SKMC - 4)

Part - A

S. No.	Particulars of information	Information to be provided by management
Note: For Sl.No.1 to 4 of Part - A.		Refer **SKMC -1**
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Sale of goods
(2)	Details of each type of the proposed transaction	Sale of pharmacy products, consumables
(3)	Tenure of the proposed transaction (in years or months)	1 Year
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Estimated value of proposed transaction for FY 2026-27 Rs. 10,00,000
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	The arrangement facilitates efficient utilization of existing pharmacy operations, ensures uninterrupted availability of medicines through integrated and reciprocal procurement arrangements with SKMC, and aligns with routine operational requirements.

S. No.	Particulars of information	Information to be provided by management
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	NA

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding or other process were undertaken for such transactions, as these procurements are undertaken on an urgent and ad-hoc basis to address immediate operational requirements, where time-bound availability is critical. Further, the limited quantities involved and the need for immediate fulfilment make a formal bidding process impractical. Pricing for such sales is based on prevailing standard rates charged to third parties or actual cost, as applicable.
2	Basis of determination of price.	The prices were determined based on the commercial factors. Further, the same are also tested for arm's length by an independent firm of Chartered Accountants once in two years to ensure that the same continues to meet the said standard.
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA The transaction does not involve trade advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Name of Related Party : SKMC

Transaction : Rental expenses (SKMC - 5)

Part - A

S. No.	Particulars of information	Information to be provided by management
Note: For Sl.No.1 to 4 of Part - A.		Refer SKMC -1
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Rental expenses
(2)	Details of each type of the proposed transaction	Land rental Expenses
(3)	Tenure of the proposed transaction (in years or months)	43 years (November 2010 to March 2053)

S. No.	Particulars of information	Information to be provided by management
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Estimated value of proposed transaction for FY 2026-27 Rs. 28,34,496
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	The lease arrangements were part of a reciprocal commercial understanding between the parties, whereby SKMC and the Company agreed to provide land parcels located in close proximity to each other's hospital facilities at nominal rentals, with a view to ensuring operational convenience and long-term continuity of healthcare services. Further, SKMC is operating its hospital in the premise owned by the Company at Cantonment. The rental rates agreed under the respective lease agreements were aligned with the prevailing market rates at the time of execution of the arrangements.
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	The management has obtained requisite Board approvals for the exchange of land parcels and settlement of differential consideration, upon consummation of the said transaction, these lease arrangements will cease to exist going forward.

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding or other process were undertaken for lease or rental arrangements, as such arrangements are driven by location specificity, proximity to hospital operations, and infrastructure suitability.
2	Basis of determination of price.	The lease rental rates were determined at arm's length and mutually agreed between the parties at the time of execution of the land lease agreements in 2009 and 2013, considering prevailing market rental benchmarks available at that time, as corroborated by third-party data sources. Further, the same are also tested for arm's length by an independent firm of Chartered Accountants once in two years to ensure that the same continues to meet the said standard.

S. No.	Particulars of the information	Information provided by the management
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA The transaction does not involve trade advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Name of Related Party : SKMC

Transaction : Rental income (SKMC - 6)

Part - A

S. No.	Particulars of information	Information to be provided by management
Note: For Sl.No.1 to 4 of Part - A.		Refer SKMC -1
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Rental income
(2)	Details of each type of the proposed transaction	KFC and KHC rental income
(3)	Tenure of the proposed transaction (in years or months)	43 years (November 2010 to March 2053)
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Estimated value of proposed transaction for FY 2026-27 Rs. 36,73,800
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	The lease arrangements were part of a reciprocal commercial understanding between the parties, whereby SKMC and the Company agreed to provide land parcels located in close proximity to each other's hospital facilities at nominal rentals, with a view to ensuring operational convenience and long-term continuity of healthcare services. Further, SKMC is operating its hospital in the premise owned by the Company at Cantonment. The rental rates agreed under the respective lease agreements were aligned with the prevailing market rates at the time of execution of the arrangements.
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA

S. No.	Particulars of information	Information to be provided by management
(9)	Other information relevant for decision making.	The management has obtained requisite Board approvals for the exchange of land parcels and settlement of differential consideration, upon consummation of the said transaction, these lease arrangements will cease to exist going forward.

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding or other process were undertaken for lease or rental arrangements, as such arrangements are driven by location specificity, proximity to hospital operations, and infrastructure suitability.
2	Basis of determination of price.	The lease rental rates were determined at arm's length and mutually agreed between the parties at the time of execution of the land lease agreements in 2009 and 2013, considering prevailing market rental benchmarks available at that time, as corroborated by third-party data sources. Further, the same are also tested for arm's length by an independent firm of Chartered Accountants once in two years to ensure that the same continues to meet the said standard.
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA The transaction does not involve trade advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Name of Related Party : SKMC

Transaction : Reimbursement of expenses received (SKMC - 7)

Part - A

S. No.	Particulars of information	Information to be provided by management
Note: For Sl.No.1 to 4 of Part - A.		Refer SKMC -1
5. Basic details of the proposed transaction		
(1)	Specific type of the proposed transaction	Reimbursement of expenses received
(2)	Details of each type of the proposed transaction	EB & Water charges for KHC & Canteen , Cloud (Microsoft) expenses, regional expenses sharing
(3)	Tenure of the proposed transaction (in years or months)	1 Year
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year	Estimated value of proposed transaction for FY 2026-27
	If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Rs. 3,50,00,000

S. No.	Particulars of information	Information to be provided by management
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	The Group has been able to negotiate better terms, including the pricing, with the vendors in view of the increase in volume of procurement, when procurement is made group wide instead of making purchase individually only for the Company and also brings in efficiency in administrative purpose.
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	NA

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding process was applicable for reimbursement of expenses, as such transactions represent recovery or sharing of actual costs incurred on behalf of group entities in the normal course of business.
2	Basis of determination of price.	The cost is allocated on an appropriate cost allocation basis such as no. of employees, no. of accounts, no. of units, area occupied, etc. depending upon the nature of expense incurred. Further, the same are also tested for arm's length by an independent firm of Chartered Accountants once in two years to ensure that the same continues to meet the said standard.
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA The transaction does not involve trade advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Name of Related Party : SKMC

Transaction : Reimbursement of expenses paid (SKMC - 8)

Part - A

S. No.	Particulars of information	Information to be provided by management
Note: For Sl.No.1 to 4 of Part - A.		Refer SKMC -1
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Reimbursement of expenses paid
(2)	Details of each type of the proposed transaction	Insurance,Travel,SAP, Whatsapps, SMS Charges, Cloud charges, ticket booking charges, regional cost sharing and other common cost
(3)	Tenure of the proposed transaction (in years or months)	1 Year
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year	Estimated value of proposed transaction for FY 2026-27
	If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Rs. 3,50,00,000
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	The Group has been able to negotiate better terms, including the pricing, with the vendors in view of the increase in volume of procurement, when procurement is made group wide instead of making purchase individually only for the Company and also brings in efficiency in administrative purpose.
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	NA

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding process was applicable for reimbursement of expenses, as such transactions represent recovery or sharing of actual costs incurred on behalf of group entities in the normal course of business.
2	Basis of determination of price.	The cost is allocated on an appropriate cost allocation basis such as no. of employees, no. of accounts, no. of units, area occupied, etc. depending upon the nature of expense incurred. Further, the same are also tested for arm's length by an independent firm of Chartered Accountants once in two years to ensure that the same continues to meet the said standard.
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA The transaction does not involve trade advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Name of Related Party : SKMC

Transaction : Guarantee expenses (SKMC - 9)

Part - A

S. No.	Particulars of information	Information to be provided by management
Note: For Sl.No.1 to 4 of Part - A.		Refer SKMC -1
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Guarantee expenses
(2)	Details of each type of the proposed transaction	Cross loan guarantee
(3)	Tenure of the proposed transaction (in years or months)	13 years (April 2022 to March 2035)
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year	Estimated value of proposed transaction for FY 2026-27
	If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Rs. 1,00,00,000
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	The provision of corporate guarantees forms part of the lending pre-requisite prescribed by SBI for availing the respective borrowing facilities. The Company has provided a corporate guarantee to SBI for the borrowings made by SKMC and in turn SKMC has provided corporate guarantee to SBI for the borrowings made by the Company. Both the Company and SKMC charges guarantee commission from each other at the rate of 1% per annum.
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	The percentage of guarantee commission i.e. 1% per annum is aligned with the GST Circular dated October 26, 2023 and judicial precedents in the context of transfer pricing.

Name of Related Party : SKMC

Transaction : Guarantee income (SKMC - 10)

Part - A

S. No.	Particulars of information	Information to be provided by management
Note: For Sl.No.1 to 4 of Part - A.		Refer SKMC -1
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Guarantee income
(2)	Details of each type of the proposed transaction	Cross loan guarantee
(3)	Tenure of the proposed transaction (in years or months)	13 years (April 2022 to March 2035)
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Estimated value of proposed transaction for FY 2026-27 Rs. 98,57,000
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	The provision of corporate guarantees forms part of the lending pre-requisite prescribed by SBI for availing the respective borrowing facilities. The Company has provided a corporate guarantee to SBI for the borrowings made by SKMC and in turn SKMC has provided corporate guarantee to SBI for the borrowings made by the Company. Both the Company and SKMC charges guarantee commission from each other at the rate of 1% per annum.
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	The percentage of guarantee commission i.e. 1% per annum is aligned with the GST Circular dated October 26, 2023 and judicial precedents in the context of transfer pricing.

Part - B (To the extent relevant)

Guarantee (including performance guarantee in nature of security/contractual commitment or which could have an impact in monetary terms on the issuer of such guarantee)), surety, indemnity or comfort letter, by whatever name called, made or given by the listed entity or its subsidiary

S. No.	Particulars of the information	Information provided by the management
1a	Rationale for giving guarantee, surety, indemnity or comfort letter	The provision of corporate guarantees forms part of the lending pre-requisite prescribed by SBI for availing the respective borrowing facilities. The Company has provided a corporate guarantee to SBI for the borrowings made by SKMC and in turn SKMC has provided corporate guarantee to SBI for the borrowings made by the Company.(Cross loan guarantee). Further, it is to be noted that such reciprocal arrangements has been agreed between the company and SKMC.
1b	Whether it will create a legally binding obligation on listed entity?	Yes
2	Material covenants of the proposed transaction including (i) commission, if any to be received by the listed entity or its subsidiary; (ii) contractual provisions on how the listed entity or its subsidiary will recover the monies in case such guarantee, surety, indemnity or comfort letter is invoked.	(i) commission shall be 1% of the outstanding balance at the end of each month (ii) Although the Company has not entered into a separate agreement for provision of the corporate guarantee, Sections 140 and 141 of the Indian Contract Act, 1872 confer statutory rights upon the guarantor upon discharge of the principal debtor's obligation. In terms of these provisions, the guarantor is subrogated to the rights of the creditor and is entitled to step into the shoes of the creditor, thereby acquiring all rights, remedies, and securities available to the creditor against the principal debtor. Accordingly, the guarantor is entitled to recover from the principal debtor the amount paid or obligations performed under the guarantee.
3	The value of obligations undertaken by the listed entity or any of its subsidiary, for which a guarantee, surety, indemnity or comfort letter has been provided by the listed entity or its subsidiary. Additionally, any provisions required to be made in the books of account of the listed entity or any of its subsidiary shall also be specified.	The sanction amount of loan for which guarantee is provided is Rs. 98,57,00,000

Part - C

Guarantee (including performance guarantee in nature of security/contractual commitment or which could have an impact in monetary terms on the issuer of such guarantee), surety, indemnity or comfort letter, by whatever name called, made or given by the listed entity or its subsidiary

S. No.	Particulars of the information	Information provided by the management
1	If guarantee, performance guarantee (in nature of security/contractual commitment or which could have an impact in monetary terms on the issuer of such guarantee), surety, indemnityor comfort letter is given in connection with the borrowing by a related party, provide latest credit rating of the related party Note: a. Standalone rating to be provided while option to provide structured obligation rating (SO rating) and credit enhancement rating (CE rating), if any. b. This information may be provided to the extent it is available in the public domain or as may be provided by the related party upon request.	State Bank of India - IND AA-/Stable (upgraded from IND A+/Positive)
2	Details of solvency status and going concern status of the related party during the last three financial years: FY 2025-2026 FY 2024-2025 FY 2023-2024	The related party has remained solvent and has continued to operate as a going concern during each of the last three financial years. There have been no indications of financial distress, insolvency proceedings, or material uncertainties that may cast significant doubt on its ability to continue its operations. The entity has consistently met its financial obligations as and when due and maintained adequate liquidity and net worth throughout the period under review, as evidenced by the report of the statutory auditors under Companies Auditors Report Order, 2020 ('CARO') of respective years.
S. No.	Particulars of the information	Information provided by the management
3	The value of obligations undertaken by the listed entity or any of its subsidiary, for which a guarantee, performance guarantee (in nature of security/contractual commitment or which could have an impact in monetary terms on the issuer of such guarantee) surety, indemnity or comfort letter has been provided by the listed entity or its subsidiary. Additionally, any provisions required to be made in the books of account of the listed entity or any of its subsidiary shall also be specified.	The sanction amount of loan for which guarantee is provided is Rs. 98,57,00,000

S. No.	Particulars of the information	Information provided by the management
4	Default on borrowings, if any, over the last three financial years, by the related party from the listed entity or any other person. Note: This information may be provided to the extent it is available in the public domain or as may be provided by the related party upon request. In addition, state the following: a) Whether the account of the related party has been classified as a non-performing asset (NPA) by any of its bankers and whether such status is currently subsisting; b) Whether the related party has been declared a "wilful defaulter" by any of its bankers and whether such status is currently subsisting; c) Whether the related party is undergoing or facing any application for commencement of an insolvency resolution process or liquidation; d) Whether the related party, not being an MSME, suffers from any of the disqualifications specified under Section 29A of the Insolvency and Bankruptcy Code, 2016. Note: Past defaults that are no longer subsisting and have been cured or regularized need not be disclosed. FY2025-2026 FY 2024-2025 FY 2023-2024	During the last three financial years, SKMC has not defaulted on repayment of any borrowings or in payment of interest from the listed entity or from any other person. Further, the SKMC's accounts have not been classified as non-performing assets (NPA) by any of its bankers SKMC has not been declared a wilful defaulter by any bank or financial institution or government or any government authority, and no such status is currently subsisting. Reference can also be made to the report of the statutory auditors under CARO of respective years. There are no proceedings initiated/pending against SKMC under the Insolvency and Bankruptcy Code, 2016 which materially impact the business of SKMC. Reference can also be made to the director's report of the Company of respective years. Additionally, SKMC, not being an MSME, does not suffer from any of the disqualifications specified under Section 29A of the Insolvency and Bankruptcy Code, 2016.

Name of Related Party : SKMC

Transaction : Claims made on behalf of holding Companies (SKMC - 11)

Part - A

S. No	Particulars of information	Information to be provided by management
Note: For Sl.No.1 to 4 of Part - A.		Refer SKMC -1
5. Basic details of the proposed transaction		
(1)	Specific type of the proposed transaction	Claims made on behalf of holding companies
(2)	Details of each type of the proposed transaction	Claims of TPA/Corp. pass through KMC on behalf of SKMC
(3)	Tenure of the proposed transaction (in years or months)	1 Year
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Estimated value of proposed transaction for FY 2026-27 Claims made: Rs. 1,00,00,000

S. No	Particulars of information	Information to be provided by management
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	The Company had obtained registration from the MD India TN Health Insurance Scheme . Heart patients under this scheme are treated by the Company in its hospital and wherever the patients require Angioplasty or Heart Surgeries like Bypass Surgery, Valve Replacement, etc., is outsourced to the SKMC (Heartcity) Hospital which is located within the same premises as KMC doesn't have the required facility. The Company makes application to the Government for insurance claims on behalf of the patients under this scheme and the amount so received from this scheme for such cardiac procedures performed by SKMC is being reimbursed on a monthly basis on cost to cost basis
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	NA

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding process was applicable for claims made on behalf of the holding company, as such transactions represent reimbursement of actual claims made on behalf of holding company in the normal course of business.
2	Basis of determination of price.	The amount claimed on behalf of SKMC is reimbursed by KMC upon receipt of claim amount without any charge or mark-up. Further, the same are also tested for arm's length by an independent firm of Chartered Accountants once in two years to ensure that the same continues to meet the said standard.
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA The transaction does not involve trade advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Name of Related Party : SKMC

Transaction : Sale of asset (SKMC - 12)

Part - A

S. No	Particulars of information	Information to be provided by management
	Note: For Sl.No.1 to 4 of Part - A.	Refer SKMC -1
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Sale of asset
(2)	Details of each type of the proposed transaction	(a) Sale of laptop and medical equipment etc. (b) Sale of Land
(3)	Tenure of the proposed transaction (in years or months)	1 Year
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Estimated value of proposed transaction for FY 2026-27 Rs. 8,35,00,000
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	(a) The Group is able to negotiate better terms for laptops, including the pricing, with the vendors in view of the increase in volume of procurement, when procurement is made group wide instead of making purchase individually only for the Company and also brings in efficiency in administrative purpose. Further, certain medical equipments are proposed to be transferred to SKMC at the Written Down Value(WDV) in the books of Company. (b) The proposed transaction of sale of land will lead to simplifying the existing ownership structure, aligning ownership of the land with the respective hospital operations, mitigating the associated financing and security-related complexities. Further, the transaction will also lead to removal of Corporate guarantee given by KMC to SKMC. Hence this is done in the interest of listed entity KMC.
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	NA

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding or other process were undertaken as procurement was undertaken on a group-wide basis to leverage volume-based pricing benefits, standardisation and administrative efficiency. Further, the transfer of medical equipment at written down value (WDV) represents an internal asset realignment within the group for optimal utilisation, for which a bidding process was neither necessary nor appropriate.
2	Basis of determination of price.	(a) The assets (laptops) are proposed to be sold at the rate at which the same has been procured from the vendor, i.e. cost to cost basis. Medical equipments are proposed to be transferred at the WDV in the books of Company. Further, the same are also tested for arm's length by an independent firm of Chartered Accountants once in two years to ensure that the same continues to meet the said standard. (b) The value determined is based on the prevailing guideline value of land.
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA The transaction does not involve trade advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Name of Related Party : SKMC

Transaction : Purchase of asset (SKMC - 13)

Part - A

S. No	Particulars of information	Information to be provided by management
Note: For Sl.No.1 to 4 of Part - A.		Refer SKMC -1
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Purchase of asset
(2)	Details of each type of the proposed transaction	(a) Purchase of laptop and medical equipment etc. (b) Purchase of Land
(3)	Tenure of the proposed transaction (in years or months)	1 Year
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Estimated value of proposed transaction for FY 2026-27 Rs. 21,95,00,000
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	(a) The Group is able to negotiate better terms for laptops, including the pricing, with the vendors in view of the increase in volume of procurement, when procurement is made group wide instead of making purchase individually only for the Company and also brings in efficiency in administrative purpose. Further, certain medical equipments are proposed to be purchased by Company at the Written Down Value(WDV) in the books of SKMC. (b) The proposed transaction of purchase of land will lead to simplifying the existing ownership structure, aligning ownership of the land with the respective hospital operations, mitigating the associated financing and security-related complexities and gaining absolute autonomy over building expansions, and land usage

S. No	Particulars of information	Information to be provided by management
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	NA

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding or other process were undertaken as procurement was undertaken on a group-wide basis to leverage volume-based pricing benefits, standardisation and administrative efficiency. Further, the purchase of medical equipment at written down value (WDV) represents an internal asset realignment within the group for optimal utilisation, for which a bidding process was neither necessary nor appropriate.
2	Basis of determination of price.	(a) The assets (laptops) are proposed to be purchased at the same rate at which the same has been procured from the vendor by SKMC, i.e. cost to cost basis. Medical equipments are proposed to be purchased at the WDV in the books of SKMC. Further, the same are also tested for arm's length by an independent firm of Chartered Accountants once in two years to ensure that the same continues to meet the said standard. (b) The value determined is based on the prevailing guideline value of land.
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA The transaction does not involve trade advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Name of Related Party : SKMC

Transaction : Reimbursement of claims received (SKMC - 14)

Part - A

S. No	Particulars of information	Information to be provided by management
Note: For Sl.No.1 to 4 of Part - A.		Refer SKMC -1
5.	**Basic details of the proposed transaction**	
(1)	Specific type of the proposed transaction	Reimbursement of claims received
(2)	Details of each type of the proposed transaction	Claims of TPA/Corp. pass through KMC on behalf of SKMC
(3)	Tenure of the proposed transaction (in years or months)	1 Year
(4)	Whether omnibus approval is being sought?	Yes
(5)	Value of the proposed transaction during a financial year If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.	Estimated value of proposed transaction for FY 2026-27 Rs. 1,50,00,000
(6)	Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity	KMC had obtained registration from the MD India TN Health Insurance Scheme . Heart patients under this scheme are treated by the KMC in its hospital and wherever the patients require Angioplasty or Heart Surgeries like Bypass Surgery, Valve Replacement, etc., is outsourced to the SKMC (Heartcity) Hospital which is located within the same premises KMC makes application to the Government for insurance claims on behalf of the patients under this scheme and the amount so received from this scheme for such cardiac procedures performed by SKMC is being reimbursed on a monthly basis as per the agreed terms
(7)	Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly. a. Name of the director / KMP b. Shareholding of the director / KMP, whether direct or indirect, in the related party Explanation: Indirect interest shall mean interest held through any person over which an individual has control.	**Refer Annexure B**
(8)	A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.	NA
(9)	Other information relevant for decision making.	NA

Part - B (To the extent relevant)

Sale, purchase or supply of goods or services or any other similar business transaction and trade advances

S. No.	Particulars of the information	Information provided by the management
1	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	No bidding process was applicable for claims made on behalf of the holding company, as such transactions represent reimbursement of actual claims made on behalf of holding company in the normal course of business.
2	Basis of determination of price.	The amount claimed on behalf of SKMC is reimbursed by KMC upon receipt of claim amount without any charge or mark-up.
3	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following:	NA Since, it is sale of service and not a advance
3a	Amount of Trade advance	NA
3b	Tenure	NA
3c	Whether same is self-liquidating?	NA

Annexure - A

Part - A

S. No	Particulars of information	Information to be provided by management
1.	**Basic details of the related party**	
(1)	Name of the related party	Sri Kauvery Medical Care (India) Limited
(2)	Country of incorporation of the related party	India
(3)	Nature of business of the related party	Business of rendering medical and health care services
2.	**Relationship and ownership of the related party**	
(1)	Relationship between the listed entity/subsidiary and the related party including nature of its concern (financial or otherwise) Explanation: 1. Indirect shareholding shall mean shareholding held through any person, over which the listed entity/ Subsidiary/ related party has control 2. While calculating indirect shareholding, shareholding held by relatives shall also be considered.	KMC is subsidiary of SKMC.
	Shareholding of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party	Not Applicable ('NA') Reason: KMC does not have any shareholding in SKMC. Hence, this would not be applicable.
	Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity/ subsidiary (in case of transaction involving the subsidiary)	NA Reason: SKMC is a body corporate having share capital. Hence, this would not be applicable.
	Shareholding of the related party, whether direct or indirect, in the listed entity/ subsidiary (in case of transaction involving the subsidiary)	The related party holds 75% of the total equity shares of KMC
3.	**Details of previous transactions with the related party**	
(1)	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the last financial year. Explanation: Details need to be disclosed separately for listed entity and its subsidiary.	

Particulars	FY 2025-26 (Rs. in Lakhs)
Revenue from hospital services rendered	996.19
Hospital services availed	336.17
Sale of goods	3.32
Purchase of goods	1.37
Rental income	34.31
Rental expenses	28.34
Guarantee expenses	76.36
Guarantee commission income	98.57
Reimbursement of expenses received	179.72
Reimbursement of expenses paid	361.78
Claims made on behalf of the holding company	52.05
Reimbursement of claims received on behalf of the holding company	80.15

S. No	Particulars of information	Information to be provided by management
(2)	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought.	

Particulars	Q1 FY 2026-27 (Rs. in Lakhs)
Revenue from hospital services rendered	257.37
Hospital services availed	88.40
Sale of goods	0.48
Purchase of goods	0.41
Rental income	8.58
Rental expenses	7.09
Guarantee expenses	17.38
Guarantee commission income	24.64
Reimbursement of expenses received	44.03
Reimbursement of expenses paid	70.16
Claims made on behalf of the holding company	14.90
Reimbursement of claims received on behalf of the holding company	28.76

S. No	Particulars of information	Information to be provided by management
(3)	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last financial year	There were no instances of default by SKMC in relation to any obligation arising out of any transaction or arrangement entered into with the listed entity during the last financial year.
4.	**Amount of the proposed transaction(s)**	
(1)	Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ shareholders.	Estimated value of proposed transaction for FY 2026-27 Rs. 65,00,00,000/- (Rupees Sixty Five Crores Only) Note: The total amount of the proposed transactions is Rs. 62,61,15,296. The proposed transaction values factoring in the potential contingencies and reasonable operational variations. Hence, the aggregate limit of Rs. 65 Crores is considered for the proposed transactions.
(2)	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Yes. The proposed transactions with the SKMC during the current financial year, would constitute a material related party transaction.
(3)	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year	21.26% Since KMC has no subsidiaries, associates and joint ventures, consolidation is not applicable and hence standalone turnover is considered.
(4)	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary and where the listed entity is not a party to the transaction)	NA Reason: Since, KMC does not have any subsidiary.
(5)	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available.	2.85
(6)	Financial performance of the related party for the immediately preceding financial year: Explanation: The information is given on standalone basis.	

Particulars	FY 2025-26 (Rs. in Lakhs)
Turnover	1,97,111.27
Profit after Tax	11,634.04
Net worth	1,11,203.85

Annexure - B

Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly or indirectly.

S. No	Name of the director / KMP	Equity Shareholding of the director / KMP, whether direct or indirect, in the related party SKMC	Shareholding of the director / KMP held through relatives, whether direct or indirect, in the related party	
			Nature of relationship	% of shares held
1	S. Manivannan	17.45%	Self	8.77%
			Spouse	2.40%
			Brother	6.28%
2	S Vijayabaskaran	18.42%	Self	1.19%
			Spouse	0.13%
			Brother	17.09%
3	S Chandrakumar	30.09%	Self	17.09%
			Spouse	11.80%
			Brother	1.19%
4	T Senthil Kumar	2.50%	Self	2.50%
5	D Senguttuvan	13.59%	Self	6.25%
			Spouse	7.35%

Notes:

1. The above information has been compiled based on Form MBP-1 in April 2026 provided by the above mentioned Directors and key managerial persons to Board of Directors.

2. Indirect holding i.e. holding through SKMC has not been considered for the purpose of above disclosure.

EVSN 260901031

Other Instructions:

i. M/s. Alagar & Associates LLP, Practicing Company Secretaries (Firm registration No. L2025TN019200), Chennai has been appointed as Scrutinizer to scrutinize the e-voting process (electronically or otherwise) in a fair and transparent manner.

ii. The scrutinizer shall immediately after the conclusion of voting at the general meeting, first count the votes cast at the meeting, thereafter unblock the votes cast through e-voting in the presence of at least two witnesses who are not in the employment of the Company and within a period of 2 working days from the conclusion of the meeting make a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or person authorized by the Chairman in writing for counter signature.

iii. The Results shall be declared either by the Chairman or by an authorized person of the Chairman and the resolution will be deemed to have been passed on the AGM date subject to receipt of the requisite number of votes in favour of the Resolution(s).

iv. Immediately after declaration of results, the same shall be placed along with the Scrutinizer's Report on the Company's website www.kauveryhospital.com/investors# and on the website of CDSL https://www.evotingindia.com, and communicated to BSE Limited, where the shares of the Company are listed, for placing the same in their website.

BOARD'S REPORT

FOR THE FINANCIAL YEAR 2025-2026

To,
The Members

Your Directors have pleasure in presenting their **Forty Third** Annual Report on the business and operations of the Company and the accounts for the Financial Year ended March 31, 2026.

1. Financial highlights for the financial year ended March 31, 2026

Particulars	2025-26 (Rs. In Lakhs)	2024-25 (Rs. In Lakhs)
Revenue from Operations	30576.82	23159.76
Other Income	507.59	308.64
Total Income	**31084.41**	**23468.40**
Operating Expenses	21784.23	17471.23
EBIDTA	**9300.18**	**5997.18**
Finance Cost	830.73	941.59
Depreciation	2167.09	1895.25
Profit before Tax	**6302.36**	**3160.34**
Tax expense	1591.25	730.79
Provision for Deferred Tax	37.67	286.84
Profit for the year	**4673.44**	**2142.70**
Other Comprehensive Income/ (loss), net of tax	(63.66)	(67.59)
Total Comprehensive Income	**4609.78**	**2075.12**

2.Dividend

The Board has not recommended dividend for the financial year 2025-26 keeping in view the long term objectives of the Company.

Your Company has formulated a Dividend Distribution Policy in compliance with Regulation 43A of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. This is also available on the Company's website and can be accessed at: https://www.kauveryhospital.com/investors#.

3.Reserves

The Company has not transferred any amount to General reserve during the financial year.

4.Business and Operations Review

The Company's total Operating income increased by **32%** to **Rs. 30576.82 Lakhs** during the financial year 2025-26 as compared to **Rs. 23159.76 Lakhs** in the previous financial year.

Your Company has earned Profit after tax of **Rs. 4673.44 Lakhs** for the financial year 2025-26 as against **Rs. 2142.70 Lakhs** earned during the previous financial year.

5. Information on state of Company's affairs

Information on operational and financial performance etc., is provided in the Management Discussion and Analysis Report, which is annexed to the Boards' Report and has been prepared inter-alia in compliance with the terms of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from to time ("SEBI Listing Regulations"), 2015.

6. Statement in respect of adequacy of internal financial controls with reference to the Financial Statements

The Company has an Internal Control System commensurate with the size, scale and complexity of its operations. To maintain independence of the Internal Audit function, the Internal Auditor reports to the Chairman of the Audit Committee.

The Internal Audit Team along with the process team monitors and evaluates the efficacy and adequacy of internal control systems in the Company, its compliance with operating systems, accounting procedures and policies of the Company. Based on the report of internal audit, corrective actions in the respective areas are undertaken and controls strengthened. Significant audit observations and corrective actions thereon are reported to the Audit Committee of the Board.

7. Disclosure of particulars of loans/ guarantees/investments outstanding during the financial Year

The Company has not given any loans and advances to any other body corporate and associates as specified under Section 186 of the Companies Act, 2013 ("the Act") during the financial year 2025-26.

The details of the investments made by the Company and the guarantee and security provided by the Company during the financial year are given in the notes to the financial statements.

8. Deposits

The Company has not accepted any public deposits and as such, no amount on account of principal or interest on public deposits is outstanding as on the date of the balance sheet.

9. Statutory Auditors

Section 139 of the Companies Act, 2013 provides for the appointment of Statutory Auditors for a period of five years and hence, M/s Deloitte Haskins & Sells, Chartered Accountants (Registration No.008072S), Chennai were re-appointed as the Statutory Auditors of the Company for a second term in the Annual General Meeting of the Company held on September 27, 2024 for a period of five years till the conclusion of the Forty Sixth Annual General Meeting.

Accordingly, M/s. Deloitte Haskins & Sells will continue as Statutory Auditors of the Company till the financial year 2028-29.

10. The details of significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future

There are no significant and material orders passed by the regulators or courts or tribunals that may have an impact for the company as a going concern and / or company's operations.

Further no application against the Company has been filed or is pending under the Insolvency and Bankruptcy Code 2016. The Company has not done any one-time settlement with any Bank or Financial Institutions.

11. Closure of Register of Members and Share Transfer Books

The Register of Members and Share Transfer Books of the Company will be closed suitably prior to holding Annual General Meeting of the Company for the Financial Year 2025-26.

12. Qualifications or reservations or adverse remarks by the Auditors:

The Board observed that there are no qualifications or reservations or adverse remarks by the Statutory Auditors.

The Board also observed that there are no qualifications or reservations or adverse remarks by the Secretarial Auditors.

13. Share Capital

As at the end of the financial year, the Company's Authorized Equity Share Capital stands at Rs. 2500 Lakhs and paid-up Equity Share Capital stands at Rs. 1630.85 Lakhs consisting of 1630.85 Lakhs fully paid up Equity Shares of Rs. 1 each. During the financial year, the Company has not issued any shares.

The Company has not issued any equity shares with differential rights, sweat equity shares, employee stock options or employee stock purchase scheme. No shares have been transferred to Suspense account in terms of Regulation 39 of the SEBI Listing Regulations.

14. Corporate Governance

Your Company has been complying with the provisions of Corporate Governance as stipulated in the SEBI Listing Regulations.

A separate report on Corporate Governance along with the Practicing Company Secretary's Certificate on compliance of the Corporate Governance norms as stipulated in Schedule V read with Regulation 34(3) of the SEBI Listing Regulations are provided in the Annual Report of the Company.

15. Particulars of Employees

In accordance with the provisions of Section 197 (12) of the Companies Act, 2013, read with Rules 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended, the name and other particulars of employees are to be set out in the **Annexure - 4** forming part of this Boards' Report. However, as per provisions of Sec 136(1) of the Companies Act, 2013 read with relevant proviso of the Act, the Annual Report (including the Boards' Report) is being sent to Members excluding the information relating to 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended. The said information is available for inspection by the members at the Registered Office of the Company. Any member interested in obtaining such particulars may write to the Company and the same will be furnished.

16. Business Responsibility & Sustainability Report

In terms of Regulation 34 of SEBI Listing Regulations, the Business Responsibility & Sustainability Report for the financial year 2025-26 describing the initiatives taken by the Company towards Environment, Social and Governance (ESG) parameters & the performance against the nine principles of the 'National Guidelines on Responsible Business Conduct' (NGRBCs), is as per the format prescribed by SEBI and forms part of the Annual Report.

17. Details of Holding, Subsidiaries, Associate/Joint Venture Companies:

The Company is a subsidiary of Sri Kauvery Medical Care (India) Limited, which holds 75% of shares in the Company. The Company does not have any subsidiary, Associate or Joint Venture Companies.

18. Transfer to Investor Education and Protection Fund

As required under the provisions of Section 124 of the Companies Act, 2013 and other applicable provisions of the Companies Act, 2013, dividends that remain unpaid/unclaimed for a period of seven years, are to be transferred to the account administered by the Central Government viz., Investor Education and Protection Fund ("IEPF"). There are no amounts which remain unpaid/unclaimed for a period of seven years and hence no amount has been transferred to "IEPF".

19. Copy of Annual Return

The duly certified copy of Annual Return for the Financial Year ended March 31, 2026, as prescribed under Section 92 read with Rule 12 of the Companies (Management and Administration) Rules, 2014, as amended shall be placed on the website of the company after the Annual General Meeting and the same can be accessed at http://www.kauveryhospital.com/investors#.

20. Conservation of energy, technology absorption, foreign exchange earnings and outgo:

The particulars required to be given as per Section 134(3) (m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014 are as under:

i. Conservation of energy-

The operations of the Company, being a Healthcare service provider, are not energy-intensive and require normal consumption of electricity. Even so, the Company has been taking significant steps to reduce consumption by using energy-efficient measures, thereby having a positive impact on conservation of energy. Some of which are as follows:

a. Usage of 100% LED lights across hospital units, which are high-energy efficient and long-lasting. Their low heat emission and compatibility with smart controls support energy conservation and operational efficiency.

b. Installation of Brushless DC fans which consumes up to 60% less power than conventional fans and stabilizes performance even during voltage fluctuations.

c. Installation of Star-rated HVAC systems which helps reducing energy consumption by adhering to BEE (Bureau of Energy Efficiency) standards. These systems ensure efficient cooling and heating, leading to lower electricity costs, improved indoor air quality and reduced environmental impact.

d. Variable frequency drives controlled Air Handling Units installed in units enables hospitals to adjust the motor speeds in AHUs, pumps and compressors based on demand.

e. Implementation of Building Management Systems (BMS), in one of its Unit, which enables centralized monitoring and intelligent control of hospital utilities like HVAC and lighting, ensuring optimal energy use.

f. Adoption of group captive renewable energy sources like windmills, solar energy (around 92% of total energy mix) which enables hospitals to source a major portion of their power from clean energy, ensuring cost savings and compliance with sustainability goals. The Company achieved cost savings of over Rs. 139.72 Lakhs through the use of renewable energy sources in the financial year.

The Company remains committed to continuously enhancing its energy efficiency initiatives and is targeting a shift to 100% renewable energy usage from the next financial year among other measures. As energy costs comprise a very small portion of your Company's total expenses, the financial implications of these measures are not material.

ii. Technology absorption

The Company continues to adopt and integrate contemporary technologies across its clinical, operational and enterprise functions with a focus on improving efficiency, enhancing quality of care and strengthening process controls. Key areas on technological improvements include:

- Rolled out new emergency capabilities on Kauvery Kare App, providing patients with a single digital platform for appointments, teleconsultations, health check-ups, reports, prescriptions and family health profiles.
- Supported patients through the Post Discharge Care Program, leveraging structured digital follow-ups and proactive escalation to strengthen continuity of care and ensure early identification of complications.
- Scaling up of the Connected ICU program to enable real-time monitoring of critical patients through advanced sensors and digital platforms, allowing timely-interventions and support.
- Elevated Robotic Process Automation, fully supported by Kauvery's own team, has streamlined routine administrative tasks, enhancing efficiency, accuracy and turnaround times.
- AI and OCR-enabled invoice and GRN automation significantly improved procurement and finance processes, reducing reconciliation time, manual mismatches and the vendor payment cycle.
- Oracle Fusion for Finance and Purchase was implemented as a unified cloud-based ERP, strengthening financial visibility, purchase-to-pay processes and management reporting across the Group.
- A dedicated Procurement ERP for Pharmacy and General Stores was implemented to enhance regional procurement visibility, standardise workflows and improve inventory planning.
- AI capabilities continued to be integrated across clinical and operational functions, including AI-powered medical speech-to-text, Digital ICU risk scoring, AI-assisted discharge documentation, conversational AI for patient engagement and AI-based CRM lead scoring.

The Company's focus on technology-enabled healthcare delivery has also been reinforced through external quality and digital health recognitions including ISO27001:2022 certification, Platinum level in the inaugural NABH Digital Health Assessment. These initiatives reflect the Company's continued focus on leveraging technology to improve patient outcomes, enhance clinical decision-making, reduce manual intervention, strengthen information security and build a more connected and efficient healthcare ecosystem.

iii. Foreign Exchange earnings and outgo

S. No.	Particulars	2025-2026	2024-25
1.	Foreign Exchange earned	Nil	Nil
2.	Foreign Exchange outgo	Nil	Rs. 5.27 Lakhs

21. Corporate Social Responsibility

Corporate Social Responsibility (CSR) is an initiative brought in by the Ministry of Corporate Affairs whereby every company having net worth of rupees 500 Crores or more, or turnover of rupees 1000 Crores or more or a net profit of rupees 5 Crores or more during the immediately preceding financial year is mandated to serve the society by contributing at least 2% of the average net profits of the Company made during the three immediately preceding financial years in various CSR activities as defined in Schedule VII of the Companies Act, 2013.

Further, in terms of the CSR Rules, the CFO has certified to the CSR Committee that the funds disbursed for CSR have been used for the purpose and in the manner approved by the Board for financial year 2025-26.

The Company has duly constituted a Corporate Social Responsibility Committee as required under Section 135 (1) of the Companies Act, 2013 and the relevant rules made thereunder.

The Board has approved and established a policy on Corporate Social Responsibility which is available in the website of the Company at http://www.kauveryhospital.com/investors#. The Salient features of the Policy include the areas of initiatives, guiding principles for selection, implementation and monitoring of activities and the Annual action plan. The policy was last updated in the year 2023 and didn't undergo any changes thereafter.

The Annual Report on your Company's CSR activities along with the Composition of the CSR committee is appended as **Annexure-3** to the Board's Report.

22. Directors and Key Managerial Personnel

Pursuant to the provisions of Section 203 of the Companies Act, 2013, the Board of Directors is duly constituted. The Directors and Key Managerial Personnel as on date of this report are:

S. No.	Name of the Director/KMP	DIN/PAN	Designation
1	Dr. Sundararaj Chandrakumar	01867847	Executive Chairman (Whole-Time)
2	Dr. Selvaraj Manivannan	00910804	Managing Director
3	Dr. Sundararaju Vijayabaskaran	05139565	Non–Executive Non-Independent Director
4	Dr. Thirunavukkarasu Senthil Kumar	01742558	Non–Executive Non-Independent Director
5	Ms. Narayanasami Jeyanthei	07143462	Independent Director
6	Mr. Sunil Satyapal Gulati	00016990	Independent Director
7	Mr. Ravichandran Purushothaman	06584433	Independent Director
8	Mr Mohan Srinivasan	00277477	Independent Director
9	Dr D Senguttuvan	AAWPS2840N	Key Managerial Personnel – Executive Director & Unit Head
10	Mr. Anandababu Kumaraswamy	AETPA9622D	Chief Financial Officer
11	Ms. Indumathi P*	DDXPP3902H	Company Secretary & Compliance Officer

During the financial year under review, following changes occurred in the composition of KMP:

S. No.	Name of the KMP	PAN	Designation	Effective Date	Nature of Change
1	Ms Sushma K	FJMPS6815P	Company Secretary & Compliance Officer	22/05/2025	Resignation
2	Ms. Indumathi P	DDXPP3902H	Company Secretary & Compliance Officer	28/05/2025	Appointment

Details of the composition of the Board and that of various Committees of the Board as at the end of the FY 2025-26 are provided in the Corporate Governance Report annexed to the Annual Report.

23. Declaration given by Independent Directors

All the Independent Directors of the Company have given their declaration under Section 149 (7) of the Companies Act, 2013, confirming that they are in compliance with the criteria as laid down in the said Section for being an Independent Director of the Company. Further, there has been no change in the circumstances which may affect their status as Independent Director during the year.

The Statement of Declaration of Independence from Independent Directors that they meet the criteria of independence as provided in sub-section (6) of Section 149 of the Companies Act, 2013 and the relevant rules and Regulation 16(1)(b) of SEBI Listing Regulations has been obtained from the Independent Directors and the Board has taken on record the same.

All the Independent Directors have registered with the databank of Independent Directors developed by the Indian Institute of Corporate Affairs in accordance with the provisions of Section 150 of the Act and obtained Independent Director registration certificate. Further the Independent Directors have also declared that in the event of expiry of their registration with the Data bank, they shall take the necessary steps to renew their registration in accordance with the applicable provisions of the Companies Act, 2013 read with rules made thereunder.

24. Appointment of Independent Directors during the Financial Year:

There were no Independent Directors appointed in the Company during the financial year.

The integrity, expertise and experience (including the proficiency) of the Independent Directors appointed during the financial year is provided in the Corporate Governance report which forms part of the Annual Report.

25. Policy on Directors' Appointment and Remuneration including criteria for determining qualifications, positive attributes, independence of a director

The Board has, on the recommendation of the Nomination & Remuneration Committee, formulated a policy termed as "Remuneration Policy" for the selection, appointment and remuneration of

Directors, Key Managerial Personnel and Senior Management Personnel as per Section 178(3) of the Companies Act, 2013 which fulfills all the applicable criteria as required under the provisions of the Act. The summary and salient features of the Remuneration Policy is stated in the Corporate Governance Report which forms part of the Annual report.

26. Particulars of contracts or arrangements with related parties

During the financial year 2025-26, the contracts and arrangements entered by the Company with related parties were on an "arm's length" basis and the ordinary course of business. There are no materially significant related party transactions made by the Company with Promoters, Directors, Key Managerial Personnel or other designated persons, which may have a potential conflict with the interests of the Company at large other than the Material Related Party Transaction entered with Sri Kauvery Medical Care (India) Limited, Promoter of the Company for a value not exceeding Rs. 40 Crores during the financial year pursuant to the approval of the Board of Directors on August 13, 2025 and Shareholders' approval at the Annual General Meeting held on September 26, 2025. The details of contracts or arrangements or transactions not at Arm's length basis and the details of material contracts or arrangements or transactions at Arm's length basis entered during the financial year are given in this report as **Annexure 1** in AOC-2.

The policy on dealing with Related Party Transactions as approved by the Board is available on the Company's website and the same can be accessed at http://www.kauveryhospital.com/investors#.

27. Risk Management

The Company has developed and implemented a robust Risk Management Policy to identify, assess, monitor and mitigate various risks that the company may face in its business. The Board and Risk Management committee approaches, identifies and categorizes the major risks relating to Operations, Business, Finance, Legal, Regulatory and other risks periodically that may affect the operations and profitability of the business. The Company's objective is to achieve a balance between acceptable levels of risk and reward in effectively managing its Operational, Financial, Business, Legal, Regulatory and other risks which are carried out through the Risk Management Committee/ Audit committee which meets at periodic intervals.

The composition of the Risk Management Committee and the brief description of terms of reference of such committee is detailed in the Corporate Governance Report which forms part of the Annual Report of the Company.

28. Reporting of Frauds

There was no instance of fraud during the year under review, which required the Statutory Auditors or the Secretarial Auditors to report to the Audit Committee and / or Board under Section 143(12) of Act and Rules framed thereunder.

29. Secretarial Audit Report

Pursuant to Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company has appointed M/s. Alagar & Associates LLP, Practicing Company Secretary, Chennai as the Secretarial Auditors of the Company in the Annual General Meeting held on September 26, 2025 for a period of Five (5) years from FY 2025-26 to FY 2029-30. The Secretarial Audit Report issued by the Company's Secretarial Auditor M/s. Alagar & Associates LLP, Practising Company Secretary is annexed and forms part of this Report in **Annexure-2.**

30. Number of meetings of Board

The details of the number of meetings of the Board of Directors are included as a part of Corporate Governance Report. The intervening gap between the Meetings is within the period prescribed under the Companies Act, 2013 and SEBI Listing Regulations.

31. Composition of Audit Committee

The Audit Committee of the Company has been constituted in accordance with the provisions of Section 177 of the Companies Act, 2013 read with Regulation 18 of the SEBI Listing Regulations. The details of the Audit Committee are included as a part of Corporate Governance Report which forms part of the Annual Report of the Company.

32. Details of establishment of Vigil Mechanism

The Company believes in conducting its affairs in a fair and transparent manner and adopts highest standards of professionalism, integrity and ethical behavior.

Pursuant to Section 177(9) of the Act and Regulation 22 of the SEBI (LODR) Regulations, 2015, the Company has formulated and established a Vigil Mechanism for Directors and employees to report genuine concerns to the Chairman of the Audit Committee. The policy provides opportunities for employees to access in good faith, the Audit Committee, if they observe unethical and improper practices in the Company. The Whistle Blower Policy/ Vigil Mechanism of the Company is available in the website of the Company and the same can be accessed at http://www.kauveryhospital.com/investors#.

33. Prevention of Insider Trading

The Company has adopted a code for prevention of insider trading termed as "Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons" with a view to regulate the trading of securities by the Directors and other designated persons of the Company. The code requires pre-clearance for dealing in the Company's securities and prohibits the purchase or sale of Company's Securities by the Designated Persons and their immediate relatives (who is either dependent financially on such person or consults such person in taking decisions relating to trading in securities) while in possession of unpublished price sensitive information and during the period when the trading window is closed.

The Company maintains a structured digital database through a software called "Vigilant" wherein the details of all the designated persons and their immediate relatives (who is either dependent financially on such person or consults such person in taking decisions relating to trading in securities) are being captured in compliance with Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

34. Board Evaluation

Pursuant to the provisions of the Companies Act, 2013 and Regulation 19 of the SEBI Listing Regulations, the Board of Directors of the Company has completed a formal evaluation of their performance and that of its Committees and individual directors. The evaluation was carried out through a digital platform with an online questionnaire method, consisting of questions with quantitative parameters. The performance of the Individual Directors, including Independent Directors were evaluated through peer evaluation. The performance review of Non-Independent Directors was carried out by the Independent Directors in their separate meeting held during the financial year.

35. Separate Meeting of Independent Directors

The Independent Directors of the Company had met during the financial year to review the performance of the Non-Independent Directors, Chairman (after taking into account the views of Executive and Non-Executive Directors of the Company) and Board as a whole and also assess the quality, quantity and timeliness of the flow of information between the Company's management and the Board.

During the Financial Year under review the Independent Directors met on February 16, 2026 and all the Independent Directors attended the Meeting without the presence of the Non-Independent Directors and the members of the management.

36. Listing fees:

The Company confirms that it has paid the Annual Listing Fees for the financial year 2025-26 to BSE Limited, Stock Exchange where the company's shares are listed.

37. Disclosures under Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013:

The Company has in place a Policy on prevention of Sexual Harassment, in accordance with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. All employees are covered under this policy. The Company has complied with the provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH) to redress the complaints with respect to sexual harassments.

The details of Complaints received by the Company under Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013 during the financial year 2025-26 is as follows:

(a) number of complaints of sexual harassment received in the year: Nil

(b) number of complaints disposed of during the year: Nil

(c) number of cases pending for more than ninety days: Nil

38. Directors' Responsibility Statement as required under Section 134 (5) of the Companies Act, 2013

In terms of provisions of Section 134(5) of the Companies Act, 2013, your Directors confirm that:

(i) in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures.

(ii) the Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the company for that period.

(iii) the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities.

(iv) the Directors had prepared the annual accounts on a going concern basis.

(v) the Directors, had laid down internal financial controls and such internal financial controls are adequate and were operating effectively.

(vi) the Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

39. Material changes and commitments affecting financial position between the end of the financial year and the date of the report

There is no change in the nature of business of the Company during the financial year. There are no material changes and commitments in the business operations of the Company since the close of the financial year on March 31, 2026 till the date of this report.

40. Familiarization Programme for Independent Directors

The Independent Directors are provided with necessary documents, reports and internal policies to enable them to familiarize with the Company's procedures and practices. The Independent Directors are further being continuously provided with ongoing familiarization programs which includes the Company's operations, financial parameters, working capital management, litigations, compliances, fund flows, regulatory updates, etc.

The details of such familiarization programmes for the Independent Directors for the Financial year 2025-2026 are posted on the website of the Company and the same can be accessed at http://www.kauveryhospital.com/investors#.

41. Applicability of maintenance of Cost Records as Specified by the Central Government

As per Section 148(1) of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, Company is maintaining Cost Records as specified by the Central Government.

The Company had appointed M/s G Sugumar & Co, Cost Accountants (Registration No. 102522), Chennai, for auditing the cost records of the Company for the FY 2025-26.

42. Statement with respect to the compliance to the provisions relating to the Maternity Benefits Act, 1961

The Company has complied with the provisions of the Maternity Benefits Act, 1961. The Audit Committee also takes note of the said compliance every quarter as a part of its review of the Quarterly compliance certificates provided by various departments including the Human resources which also contains the above compliance.

43. Secretarial Standards

The Company has complied with the applicable Secretarial Standards, as amended from time to time.

44. Acknowledgments

Your Directors thank the Company's shareholders, Government Agencies, Banks, financial institutions and other stakeholders for their continued support and co-operation to the Company. Your Directors place on record their appreciation for the contribution made by the employees, consultants and officers of the Company during the financial year under report.

For and on behalf of the Board of Directors

Place: Chennai Date: May 29, 2026	**Dr S Manivannan** Managing Director DIN: 00910804	**Dr S Chandrakumar** Executive Chairman (Whole-Time) DIN: 01867847

ANNEXURE - 1

Form No AOC-2

(Pursuant to regulation (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Details of Related Party Transactions

1. Details of contracts or arrangements or transactions not at Arm's length basis: None

There were no contracts or arrangements or transactions entered during the year ended March 31, 2026, which were not at arm's length basis

Sl. No.	Particulars	Details
1	Name (s) of the related party & nature of relationship	-
2	Nature of contracts/arrangements/transactions	-
3	Duration of the contracts/arrangements/transactions	-
4	Salient terms of the contracts or arrangements or transactions including the value, if any	-
5	Justification for entering into such contracts or arrangements or transactions'	-
6	Date of approval by the Board	-
7	Amount paid as advances, if any	-
8	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	-

2. Details of material contracts or arrangements or transactions at Arm's length basis.

Sl No	Particulars	Details
1	Name(s) of the related party & nature of relationship	Sri Kauvery Medical Care (India) Limited – Holding Company
2	Nature of contracts / arrangements / transaction	Availing/ Rendering of hospital services, purchase of goods, sale of goods, rental expenses, rental income, guarantee expenses, guarantee income, sale of asset, purchase of asset, etc., or any transaction involving transfer of resources, services or obligations of whatever nature.
3	Duration of the contracts / arrangements / transaction	FY 2025-26
4	Salient terms of the contracts or arrangements or transaction including the value, if any	The Company in the Ordinary course of business and at arm's length price, enters into various transactions with M/s. Sri Kauvery Medical Care (India) Limited (the Holding Company) for availing & rendering of hospital services, purchase of goods, sale of goods, rental expenses, rental income, guarantee expenses, guarantee income, sale of asset, purchase of asset etc., or any transaction involving transfer of resources, services or obligations of whatever nature on such terms as may be mutually agreed upon for an aggregate value not exceeding Rs. 40 Crores. These transactions are continuous in nature.
5	Date of approval by the Board	Board of Directors approval - August 13, 2025; and Shareholders' approval - September 26, 2025
6	Amount paid as advances, if any	Nil

ANNEXURE - 2

Form No. MR-3

SECRETARIAL AUDIT REPORT

For the Financial Year ended March 31, 2026

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members
KMC Speciality Hospitals (India) Ltd
CIN: L85110TN1982PLC009781
No. 6 Royal Road Cantonment,
Trichy-620001.

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **KMC Speciality Hospitals (India) Ltd** (hereinafter called the **"Company"**). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has during the audit period covering the Financial Year ended March 31, 2026 **("Audit Period")** complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the Financial Year ended March 31, 2026, according to the provisions of:

(i) The Companies Act, 2013 ('Act') and the rules made thereunder, as amended from time to time including Secretarial Standards issued by Institute of Company Secretaries of India ('ICSI') as mandated by the Companies Act, 2013;

(ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;

(iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;

(iv) Foreign Exchange Management Act, 1999 and the rules, regulations, notifications and circulars made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; **(Not applicable for the Audit period)**

(v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'), as amended from time to time:-

- (i) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (ii) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (iii) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **(there were no events requiring compliance during the Audit Period)**
- (iv) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (v) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act, 2013 and dealing with client.
- (vi) The Securities and Exchange Board of India (Depositories and Participants) Regulations,2018;
- (vii) The Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; **(there were no events requiring compliance during the Audit Period)**
- (viii) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; **(there were no events requiring compliance during the Audit Period)**
- (ix) The Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018; **(there were no events requiring compliance during the Audit Period)**
- (x) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; (there were no events requiring compliance during the Audit Period).

(vi) **Other laws applicable specifically to the Company namely:**

1. Atomic Energy Act, 1962
2. Bio-Medical Waste (Management and Handling) Rules, 1998
3. Blood Bank Regulations under Drugs and Cosmetics, Act 1940
4. Drugs and Cosmetic Act 1940
5. Pre-conception and Pre-natal Diagnostic Techniques Act, 1994
6. Pharmacy Act 1948
7. The Tamil Nadu Narcotic Drugs Rules, 1985
8. The Registration of Births and Deaths Act, 1969
9. Transplantation of Human Organ Act 1994
10. Tamil Nadu Tax on Consumption or Sale of Electricity Act, 2003

During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines and Standards, etc., mentioned above.

We further report that the Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors, Independent Directors and Woman Director. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent to them at least seven days in advance or at a shorter notice as the case may be, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

As per the minutes of the meetings duly recorded and signed by the Chairman, the decisions at the Board Meetings were taken unanimously and there was no instance of dissent by any director during the period under review.

We further report that based on the information provided and representation made by the Company, there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that, during the audit period, no events occurred which had major bearing on the Company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, and standards and that the Company has complied with such of those relevant clauses thereto which are applicable.

For **Alagar & Associates LLP**
(Formerly known as M. Alagar & Associates)
Company Secretaries
Firm Registration No: L2025TN019200
Peer Review Certificate No: 6814/2025

D. Saravanan
Partner
FCS No: 13721
CoP No:22608
UDIN: F013721H000431050

Place: Chennai
Date: May 21, 2026

This Report is to be read with our letter of even date which is annexed as **Annexure I** and forms an integral part of this report.

ANNEXURE - I

To,
The Members of
KMC Speciality Hospitals (India) Ltd

Our report is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For **Alagar & Associates LLP**
(Formerly known as M. Alagar & Associates)
Company Secretaries
Firm Registration No: L2025TN019200
Peer Review Certificate No: 6814/2025

D. Saravanan
Partner
FCS No: 13721/CoP No:22608
UDIN: F013721H000431050

Place: Chennai
Date: May 21, 2026

ANNEXURE - 3

1. A Brief outline of the Company's CSR policy, including overview of projects or programs proposed to be undertaken and a reference to the web-link to the CSR policy and project or programs.

As per the Companies Act, 2013, the Company has a policy on Corporate Social Responsibility (hereinafter referred as "CSR") whereby it is mandatory to spend at least 2% of average net profits of the immediately preceding 3 financial years on "CSR" activities. CSR involves incurring costs that do not provide an immediate financial benefit to the Corporates, but instead promote positive social environmental change. In line with the above, the Company's CSR policy is designed keeping in mind the vision, mission, socio-economic environment and capacities of the company.

2. The Composition of the CSR Committee

S. No.	Name	Designation/ Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Dr S Chandrakumar	Chairman – Executive Chairman (Whole-Time)	1	1
2	Dr S Manivannan	Member – Managing Director	1	1
3	Mr Ravichandran Purushothaman	Member – Independent Director	1	1

3. Provide the web-link(s) where Composition of CSR Committee, CSR Policy and CSR Projects approved by the board are disclosed on the website of the Company.: https://www.kauveryhospital.com/investors#

4. Provide the executive summary along with web-link(s) of Impact Assessment of CSR Projects carried out in pursuance of sub-rule (3) of rule 8, if applicable: Not applicable

5. (a) **Average net profit of the Company as per sub section (5) of Section 135:** Rs. 31,98,56,970

(b) **Two percent of average net profit of the company as per section (5) of Section 135:**
Rs. 72,98,964/- rounded off to Rs. 73,00,000/-

(c) **Surplus arising out of the CSR projects or programmes or activities of the previous financial years. –** Nil

(d) **Amount required to be set off for the financial year, if any –** Nil

(e) **Total CSR obligation for the financial year –** Rs. 73,00,000/-

6. (a) **Amount to be spent on CSR Projects: Ongoing Project –** Rs. 73,00,000/-

(b) **Amount spent in Administrative Overheads –** Nil

(c) **Amount spent on Impact Assessment, if applicable –** NA

(d) **Total amount spent for the Financial Year [(a)+(b)+(c)] –** Rs. 73,00,000/-

(e) **CSR amount spent or unspent for the financial year:**

Total Amount Spent for the Financial Year. (in Rs.)	Amount Unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per subsection (6) of section 135.		Amount transferred to any fund specified under Schedule VII as per second proviso to sub-section (5) of section 135.		
	Amount.	Date of transfer.	Name of the Fund	Amount.	Date of transfer.
Rs. 73,00,000/-	Not Applicable				

(f) **Excess amount for set-off, if any:**

S. NO	Particular	Amount (In Rs)
1	2	3
i	Two percent of average net profit of the company as per sub-section (5) of section 135	72,98,964/-
ii	Total amount spent for the Financial Year	73,00,000/-
iii	Excess amount spent for the Financial Year [(ii)-(i)]	1,036
iv	Surplus arising out of the CSR projects or programmes or activities of the previous Financial Years, if any	Nil
v	Amount available for set off in succeeding Financial Years [(iii)-(iv)]	Nil

7. Details of Unspent Corporate Social Responsibility amount for the preceding three financial years: Not Applicable

8. Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the Financial Year: Not applicable

S. No.	Short particulars of the property or asset(s) [including complete address and location of the property]	Pin code of the property or as set(s)	Date of acquisition	Amount of CSR Spent	Details of entity/ Authority/ beneficiary of the registered owner		
1	2	3	4	5	6		
					CSR Registration No. if applicable	Name	Registered Address
			NIL				

9. Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5). – Not Applicable

For and on behalf of the Board of Directors

Place: Chennai

Date: May 29, 2026

Dr S Manivannan
Managing Director
DIN: 00910804

Dr. S Chandrakumar
Executive Chairman (Whole-Time) & Chairman of the CSR Committee
DIN: 01867847

ANNEXURE – 4

Details as per Section 197 of the Companies Act 2013 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

1. The ratio of the remuneration of each director to the median remuneration of the employees of the Company for the financial year

S. No.	Name of the Director	Ratio of the remuneration of director to the median employee remuneration
1.	Dr S Chandrakumar	28.27%
2.	Dr S Manivannan	28.27%

2. Percentage increase in remuneration

S. No.	Name of the Director	Designation	% of increase / decrease in Remuneration
1.	Dr S Chandrakumar	Executive Chairman (Whole-Time)	Nil
2.	Dr S Manivannan	Managing Director	Nil
3.	Dr D Senguttuvan	Key Managerial Personnel	8%
4.	Mr K Anandababu	Chief Financial Officer	31.90%
5.	Ms Indumathi P*	Company Secretary & Compliance officer	*NA

**Ms. Indumathi P appointed as a Company Secretary & Compliance officer of the Company w.e.f. May 28, 2025.*

3. Percentage increase in the median remuneration of employees

The percentage of increase in the Median employee remuneration is 21% as compared to the previous year.

4. Permanent Employees:

The Number of Permanent Employees on the rolls of the Company as on March 31, 2026 is 1695 employees.

5. Average percentile increase made in salaries of employees other than KMP in comparison to the percentile increase in the remuneration of KMP and the justification thereof

The average percentile increase in salaries of employees other than KMP is 12% while that of KMP is 20.41%

Justification for increase in remuneration of Directors and Employees: Compensation revisions take into account performance metrics on sales, operating profits apart from other specific elements attributable to various functions within the organization. The Company's performance against the above metrics was close to or marginally above budgeted levels. The revisions also need to be reviewed in the light of short and medium term forecasts and budgets on profitability apart from qualitative objectives including quality and leadership parameters. Taking into account all the above elements the remuneration levels were increased as disclosed above.

6. Affirmation that the remuneration is as per the remuneration policy of the company

The Company affirms remuneration is as per the remuneration policy of the Company.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

This Management Discussion and Analysis Report is a "forward looking statement" and forms part of the Annual Report of the Company. It Indicates the Company's movement in the external environment vis-à-vis its own strengths and resources detailing the Company's objectives and expectations.

1. INDUSTRY STRUCTURE:

Healthcare has become one of India's largest sectors, both in terms of revenue and employment. Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment. The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services, and increasing expenditure by public as well private players.

India's healthcare delivery system is categorized into two major components - public and private. The government, i.e. public healthcare system, comprises limited secondary and tertiary care institutions in key cities and focuses on providing basic healthcare facilities in the form of primary healthcare centres (PHCs) in rural areas. The private sector provides a majority of secondary, tertiary, and quaternary care institutions with a major concentration in metros, tier-I and tier-II cities.

India's competitive advantage lies in its large pool of well-trained medical professionals. India is also cost-competitive compared to its peers in Asia and western countries. The cost of surgery in India is about one-tenth of that in the US or Western Europe. The low cost of medical services has resulted in a rise in the country's medical tourism, attracting patients from across the world. Moreover, India has emerged as a hub for R&D activities for international players due to its relatively low cost of clinical research.

Government Initiatives

Some of the major initiatives taken by the Government of India to promote Indian healthcare industry are as follows:

i) Healthcare Financing:

- As of July 2025, over 41 Crore Ayushman Cards have been created under Ayushman Bharat - Pradhan Mantri Jan Arogya Yojana.
- The allocation for the Pradhan Mantri Jan Arogya Yojana has been raised to Rs. 9,500 Crore (~$1.05 Billion USD) in Budget Estimates 2026–27, up by Rs. 500 Crore (~$55 Million USD) or 5.56% over the Revised Estimates of Financial Year 2025–26. This increase aims to expand beneficiary coverage, improve service quality, and strengthen hospital networks.
- Under the ICScheme, India has signed 25 country-to-country MoUs, 52 institute-to-institute MoUs, and 15 AYUSH Chair MoUs.
- The government has allocated Rs. 99,858 Crore (US$ 11.50 Billion) to the healthcare sector in the Union Budget 2025-26 for the development, maintenance, and enhancement of the country's healthcare system. This reflects a 9.78% increase from the previous allocation of Rs. 90,958 Crore (US$ 10.47 Billion) in FY25.

ii) Research, Digital & Innovation

- In Union Budget 2025-26, the Department of Health Research is receiving a special enhancement of Rs. 531 Crore (US$ 62 Million) over the next five years to support AI in healthcare, new therapies like gene therapy, cancer and anaemia research, pandemic preparedness, and boosting medical research institutes.
- Union Ministers of State for Health and Family Welfare, Mr. Prataprao Ganpatrao Jadhav and Mrs. Anupriya Singh Patel, recently unveiled three key initiatives at the Ayushman Bharat, Quality Health event. These initiatives aim to enhance healthcare quality and facilitate ease of doing business in India, including a virtual NQAS assessment for Ayushman Arogya Mandirs and an IPHS compliance dashboard for real-time monitoring of public health facilities.
- In 2025, the Ministry of AYUSH has developed the Central Sector scheme for Promotion of International Cooperation for AYUSH (ICScheme) to boost exports, recognition, research, and international collaboration in AYUSH systems.

iii) Trade & Infrastructure Development:

- The India-UK Free Trade Agreement is expected to improve market access opportunities for Indian pharmaceutical and healthcare exporters.
- The Government runs flagship schemes that provide public health insurance, free healthcare and services across all levels and subsidised medicines, along with a widespread and accessible health infrastructure. The guiding principle is to provide universal health coverage, ensuring everyone including the most socio-economically disadvantaged populations, gets access to affordable and quality healthcare so that India can progress towards its goal of being a healthy, productive and prosperous society – a Viksit or developed Bharat by 2047.

Developments in Healthcare:

- Healthcare demand in Tier II and Tier III cities is projected to grow at 16-18% CAGR over the next few years, higher than the CAGR in metros, showing continued momentum beyond 2025.
- Tier II cities are expected to add 40 Million people by FY27, while 70% of hospitals are already empanelled under Ayushman Bharat as of 2025, thereby improving access and accelerating infrastructure expansion by FY27 as targeted.
- India's health-tech sector is projected to reach Rs. 4,43,500 Crore (US$ 50 Billion) by 2033, driven by AI and automation.
- In H1 2025, the Indian health-tech startups received Rs. 7,095 Crore (US$ 828 Million) in funding, a sign of continued investor confidence in the sector.

Significant Industry highlights:

(i) Sector Valuation:

The Indian healthcare sector, valued at Rs. 31,87,668 Crore (US$ 372 Billion) in 2023, is projected to reach Rs. 54,67,022 Crore (US$ 638 Billion) by 2025, growing at a robust 17.5-22.5% CAGR. The sector continues to witness strong long-term growth driven by rising healthcare expenditure, increasing insurance penetration, demographic shifts, and growing demand for quality healthcare services. Healthcare spending is expected to rise to 5% by 2030, reflecting the sector's increasing role in the economy.

(ii) Digital Health and Telemedicine:

Digital health and telemedicine are emerging as key growth drivers. The Indian digital health market is projected to reach Rs. 4,11,275 Crore by 2033.

(iii) Medical Tourism:

Medical tourism continues to strengthen India's global healthcare position. The market value is expected to reach US$ 14.31 Billion by 2029. In 2023, around 634,561 foreign tourists visited India for medical treatment, accounting for 6.87% of total arrivals. With a medical value travel industry of US$ 5-6 Billion and over 500,000 international patients annually, India is among the leading global destinations for advanced treatment, making way for an advanced tertiary care for the society.

(iv) Medical Devices and Innovation:

The Indian medical devices sector has witnessed remarkable growth in recent years and is expected to reach Rs. 4,34,350 Crore by FY31 driven by increasing demand for quality healthcare, advancements in technology, and favourable government policies. Start-ups in this sector have been instrumental in fostering innovation, improving accessibility, and reducing costs.

Road Ahead

- India's healthcare sector is extremely diversified and is full of opportunities in every segment, which includes providers, payers, and medical technology. India is a land full of opportunities for players in the medical devices industry. The country has also become one of the leading destinations for high-end diagnostic services with tremendous capital investment for advanced diagnostic facilities, thus catering to a greater proportion of the population.
- Besides, Indian medical service consumers have become more conscious towards their healthcare upkeep. Rising income levels, an ageing population, growing health awareness and a changing attitude towards preventive healthcare are expected to boost healthcare services demand in the future. Greater penetration of health insurance aided the rise in healthcare spending, a trend likely to intensify in the coming decade.
- India continues to expand its healthcare infrastructure. The Healthcare industry in India is poised for sustained growth, driven by favourable demographics, rising health awareness and continued support from the Government. The sector is undergoing a structural transformation with a clear shift towards the organized, technology driven and patient-centric delivery model.
- Given today's fast paced environment, going forward the industry is expected to witness an increase in the demand for quality healthcare services, particularly in the tertiary and quaternary care segments, supported by increased insurance penetration and government supported health schemes. Besides, Indian medical service consumers have become more conscious towards their healthcare upkeep. Rising income levels, an ageing population, growing health awareness

and a changing attitude towards preventive healthcare is expected to boost healthcare services demand in the future.

Source: IBEF Healthcare update November 2025 and Press information Bureau update March 2026.

2. OPPORTUNITIES AND THREATS:

Opportunities:

- Rising income level
- Greater health awareness
- Increased precedence of lifestyle diseases
- Improved access to health insurance coverage
- Opportunity for horizontal and vertical growth
- Growing elderly population, changing disease patterns
- Encouraging avenues for attracting prospective investments
- Great potential for medical tourism
- Expansion into Quaternary Care
- Growing preferences for organized and accredited healthcare providers

Threats:

- Increased Competition
- Increase in Cost of operation
- Man Power shortages
- Regulatory controls on pricing and treatment costs
- Supply chain vulnerabilities and price risks due to geopolitical war

3. RISKS AND CONCERNS

- Increasing competitive intensity in the healthcare sector
- Increasing cost / scarcity of resources in the Industry
- Constant change in technology and revamping of existing systems.
- Government regulations and restrictions.
- Dependency on key specialities impacting revenue concentration.
- Technology and Cybersecurity Risks
- Regulatory and Legal risks

4. FINANCIAL AND OPERATIONAL PERFORMANCE

The financial statements have been prepared in compliance with the requirements of the Companies Act, 2013, and Indian Accounting Standards (Ind AS) in India. The management accepts responsibility for the integrity and objectivity of these financial statements, as well as for various estimates and judgments used therein. The estimates and judgments relating to the financial statements have been made on a prudent and reasonable basis, in order that the financial statements reflect the state of affairs of the Company in a true and fair manner.

Particulars	2025-26 (Rs In Lakhs)	2024-25 (Rs In Lakhs)
Operating Income	30576.82	23159.76
Other Income	507.59	308.64
Total Income	**31084.41**	**23468.40**
Operating Expenses	21784.23	17471.23
EBIDTA	**9300.18**	**5997.18**
Finance Cost	830.73	941.59
Depreciation	2167.09	1895.25
Profit/(Loss) before Tax	**6302.36**	**3160.34**
Tax expense	**1591.25**	**730.79**
Provision for Deferred Tax	**37.67**	**286.84**
Profit/(Loss) after Tax (PAT)	**4673.44**	**2142.70**
Other Comprehensive Income/ (loss), net of tax	**(63.66)**	(67.59)
Total Comprehensive Income	**4609.78**	**2075.12**

Total Operating income increased by **32%** to **Rs. 30576.82 Lakhs** during the financial year 2025-26 from **Rs. 23,159.76 Lakhs** in the previous financial year.

Your Company has earned Profit after tax of Rs. 4673.44 Lakhs for the financial year 2025-26 as against Rs. 2142.70 Lakhs achieved during the previous financial year.

Improvement in Bed occupancy with better revenue mix coupled with operational efficiency and cost control measures contributed to better profitability.

5. OUTLOOK

The Indian healthcare sector, being one of the fastest growing industries, has always had immense scope for enhancing healthcare services penetration in India, thereby presenting ample opportunities for development of the healthcare industry. India's private healthcare sector in India accounts for approximately 60% - 70% of treatment value in the Indian healthcare system. Most private facilities initiated their plans in response to the COVID-19 pandemic, which involved significant investments to prepare facilities for controlling and preventing the infection, building infrastructure for quarantine and treatment, and equipping the facility with suitable medical supplies and additional workforce.

The biggest health emergencies of our times have not just laid bare the myriad challenges and gaps in our health system but also highlighted the importance of investing in 'well-being' at both personal and system level. Further, digital transformation will remain a key growth enabler. Adoption of telemedicine, electronic health records (EHR), AI in diagnostics and data-driven decision making is expected to enhance clinical outcomes, operational efficiency and patient engagement.

6. INTERNAL CONTROL SYSTEMS AND THEIR ADEQUAY

The Company has a proper and adequate system of internal controls to ensure that all the assets are safeguarded, protected from unauthorized use and the transactions are authorized, recorded and reported correctly. The company conducts audit of various departments with an audit plan through an independent Internal Auditor and reports to the Audit Committee on significant issues with Action Taken Report. Wherever necessary the inputs of the Statutory Auditors are also obtained to ensure efficiency of the operations and accounting.

Further, the internal controls are also being reviewed by the Audit committee at least once in a year.

7. MATERIAL DEVELOPMENTS IN HUMAN RESOURCES/INDUSTRIAL RELATIONS FRONT, INCLUDING NO. OF PEOPLE EMPLOYED

Being in the Healthcare sector, the Company believes that the people are its core strength and recognizes the importance of leadership, technical and behavioral development for employees across the Company. The Company launches continuous improvement & training programs aimed at increasing the knowledge level of employees and senior level personnel and offer rewards to those who perform well in such programs. Staff levels are being maintained adequately as per requirements. As on March 31, 2026, 1695 employees are employed on the rolls of the Company.

8. DETAILS OF SIGNIFICANT CHANGES (I.E. CHANGE OF 25% OR MORE AS COMPARED TO THE IMMEDIATELY PREVIOUS FINANCIAL YEAR) IN KEY FINANCIAL RATIOS, ALONG WITH DETAILED EXPLANATIONS THEREFORE

S. No	Ratios	Basis	Mar 31, 26	Mar 31, 25	Variance (in %)	Reasons
1.	Current ratio	Current Assets/Current Liabilities	1.90	0.88	116.26%	
2.	Debt Equity ratio	Total Liabilities/ shareholder funds	0.34	0.50	(32.49)%	
3.	Debt service coverage ratio	Net Operating revenue / Total Debt	4.07	2.62	55.34%	
4	Return on equity ratio	Net profit after taxes/ Average shareholders' equity	0.25	0.14	78.15%	
5	Inventory Turnover ratio	Sales/ Average Inventory	12.20	12.13	0.58%	
6	Trade receivable turnover ratio/ Debtor Turnover Ratio	Net Credit Sales/ Average Accounts Receivable	12.47	12.73	(2.04)%	
7	Net Profit Margin	Net Profit/ Net Sales	15.28%	9.25%	65.24%	
8	Operating Profit Margin	Operating Income/ Revenue	29.9%	25.6%	17.08%	
9	Interest Coverage Ratio	EBIT/Interest Expense	10.2	5.4	89.88%	

9. DETAILS OF ANY CHANGE IN RETURN ON NET WORTH AS COMPARED TO THE IMMEDIATELY PRECEDING FINANCIAL YEAR ALONG WITH A DETAILED EXPLANATION THEREOF

NIL

10. CAUTIONARY STATEMENT

The information and opinion expressed in this Report may contain certain forward-looking statements, which the management believe are true to the best of its knowledge at the time of its preparation. Actual results may differ materially from those either expressed or implied in this report.

DECLARATION AS TO THE COMPLIANCE OF CODE OF CONDUCT OF THE BOARD MEMBERS AND THE SENIOR MANAGEMENT PERSONNEL

This is to confirm that the Company has adopted the Code of Conduct for its employees including the Directors and Senior Management Personnel. The Code of Conduct is posted on the Company's website.

I confirm that the Company has in respect of the financial year ended March 31, 2026, received from the senior management team of the Company and the Members of the Board a declaration of compliance with the Code of Conduct as applicable to them for the year ended March 31, 2026.

	Dr S Manivannan
Place: Chennai	Managing Director
Date: May 29, 2026	DIN: 00910804

MD & CFO CERTIFICATION AS PER CLAUSE 17(8) READ WITH PART B OF SCHEDULE II OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

We certify to the Board that:

A) We have reviewed financial statements and the cash flow statement for the financial year ended March 31, 2026 and that to the best of our knowledge and belief:

1. these statements do not contain materially untrue statement or omit any material fact or contain statement that might be misleading

2. these statements together present a true and fair view of the company's Affairs and are in compliance with existing accounting standards, applicable Laws and regulations.

B) There are, to the best of our knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or violate of the Company's code of conduct.

C) We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of the internal control systems of the company pertaining to the financial reporting and we have disclosed to auditors and Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify the deficiencies.

D) We have indicated to auditors and the Audit Committee

1. Significant changes in internal control over financial reporting during the year;

2. Significant changes in accounting policies during the year and same have been disclosed in the notes to the financial statements; and

3. Instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the company's internal control system over financial reporting.

	Dr S Manivannan	**K Anand Babu**
Place: Chennai	Managing Director	Chief Financial Officer
Date: May 29, 2026	DIN: 00910804	

COMPLIANCE CERTIFICATE ON CORPORATE GOVERNANCE

(Pursuant to Regulation 34(3) and Schedule V Para E of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members
KMC SPECIALITY HOSPITALS (INDIA) LIMITED

We have examined the compliance of conditions of Corporate Governance by **KMC SPECIALITY HOSPITALS (INDIA) LIMITED** ("the Company") for the period ended March 31, 2026, as stipulated under Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR").

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring compliance with the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanation given to us and the representations made by the Directors and the management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI LODR.

We further state that such compliance is neither an assurance as to the future viability of the company nor the efficiency or effectiveness with which the management has conducted the affairs of the company.

For **Alagar and Associates LLP**
(Formerly known as M. Alagar & Associates)
Company Secretaries
LLP Reg No: L2025TN019200
Peer Review Certificate No:6814/2025

D. Saravanan
Partner
FCS No: 13721
COP No. 22608
UDIN: F013721H000430720

Place: Chennai
Date: 21.05.2026

CORPORATE GOVERNANCE REPORT

1. COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE

At KMC Speciality Hospitals (India) Limited, we are committed to maintaining the highest standards of Corporate Governance. Our philosophy is rooted in the belief that strong governance is essential for achieving our mission of making great healthcare affordable. We are dedicated to ensuring that our actions reflect our core values which includes continual improvement, unwavering ethical conduct, and real accountability. The Company ensures good governance through implementation of effective policies and procedures, which are regularly reviewed by the Board and its Committees.

2. BOARD OF DIRECTORS:

The Board has an optimum combination of Executive, Non-Executive and Independent Directors, which ensures proper governance and management.

The Composition of the Board as on March 31, 2026 is in conformity with Regulation 17 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time ("SEBI Listing Regulations") read with Section 149 & Section 152 of the Companies Act, 2013.

Name of the Director	Designation	Attended previous AGM held on 26/09/2025	Total Board meetings entitled to attend	Total Board meetings attended	No. of Directorship in other public companies	Number of membership and Chairmanship in Audit/Stakeholder Relationship Committee(s) including this listed entity	
						Member**	Chairman*
Dr S Chandrakumar	Executive Chairman (Whole- Time)	Yes	4	4	1	1	0
Dr S Manivannan	Managing Director	Yes	4	4	1	2	0
Dr S Vijayabaskaran	Non–Executive Non-Independent Director	Yes	4	4	0	0	0
Dr T Senthil Kumar	Non–Executive Non-Independent Director	Yes	4	4	0	0	0
Mr Sunil Gulati	Independent Director	Yes	4	4	3	3	2
Mr Ravichandran Purushothaman	Independent Director	Yes	4	4	1	2	0
Mr Mohan Srinivasan	Independent Director	Yes	4	4	1	0	0
Mrs N Jeyanthei	Independent Director	Yes	4	4	0	1	1

**Pursuant to Regulation 26 of the SEBI Listing Regulations, the disclosure includes Chairmanship of Audit Committee and Stakeholders Relationship Committee in Public Companies whether Listed or Unlisted.*

***Pursuant to Regulation 26 of the SEBI Listing Regulations, the disclosure includes Membership of Audit Committee and Stakeholders Relationship Committee in Public Companies whether Listed or Unlisted.*

The Total strength of the Board as on March 31, 2026 - **8.**

3. NAME AND CATEGORY OF THE DIRECTORSHIP IN OTHER LISTED ENTITY

S. NO.	NAME OF THE DIRECTOR	NAME OF THE OTHER LISTED ENTITY	CATEGORY OF DIRECTORSHIP
1	Mr Sunil Gulati	Fedbank Financial Services Limited	Independent Director
		Suryoday Small Finance Bank Limited	Additional (Independent) Director

4. DISCLOSURE OF INTER-SE RELATIONSHIP OF DIRECTORS UNDER REGULATION 36 OF THE SEBI LISTING REGULATIONS

Dr S Vijayabaskaran, Director is the brother of Dr S Chandrakumar, Executive Chairman.

5. NUMBER OF SHARES AND CONVERTIBLE INSTRUMENTS HELD BY NON-EXECUTIVE DIRECTORS:

Dr T Senthil Kumar, Non-Executive Non-Independent Director holds 12,87,136 equity shares of the Company.

Mrs N Jeyanthei, Non-Executive Independent Director holds 50,100 equity shares of the Company.

6. DATES OF BOARD MEETINGS

Board Meetings were held during the financial year 2025 – 26 on the following dates: -

S. NO.	NAME OF THE DIRECTOR	May 28, 25	Aug 13, 25	Nov 12, 25	Feb 11, 26
1	Dr S Chandrakumar	PRESENT	PRESENT	PRESENT	PRESENT
2	Dr S Manivannan	PRESENT	PRESENT	PRESENT	PRESENT
3	Dr S Vijayabaskaran	PRESENT	PRESENT	PRESENT	PRESENT
4	Dr T Senthil Kumar	PRESENT	PRESENT	PRESENT	PRESENT
5	Mr Sunil Gulati	PRESENT	PRESENT	PRESENT	PRESENT
6	Mr Ravichandran Purushothaman	PRESENT	PRESENT	PRESENT	PRESENT
7	Mr Mohan Srinivasan	PRESENT	PRESENT	PRESENT	PRESENT
8	Mrs N Jeyanthei	PRESENT	PRESENT	PRESENT	PRESENT

7. LIST OF CORE SKILLS/ EXPERIENCE/COMPETENCIES IDENTIFIED BY THE BOARD

The Board of Directors have identified the following Core Skills/ Practical Experience/ Special Knowledge/ Competencies as required in the context of its business(es) and sector(s) for it to function effectively:

1. Accounting
2. Finance
3. Law
4. Business Management
5. Operations
6. Healthcare
7. Risk Management
8. Fund Management
9. General Administration
10. ESG & Sustainability
11. Any other matter, the special knowledge of, and practical experience in, which would be useful to the Company.

The eligibility of a person to be appointed as a Director of the Company is dependent on whether the person possesses the requisite skill sets identified by the Board as above and whether the person is a proven leader in running a business that is relevant to the Company's business or is an expert in the field relevant to the Company's business. The Directors so appointed are drawn from diverse backgrounds and possess special skills with regard to the industries / fields from where they come.

S. NO.	Name of the Directors	Areas of Expertise
1	Dr S Chandrakumar	Healthcare, Accounting, Finance, Law, Business Management, Operations, Risk Management, Fund Management, General Administration
2	Dr S Manivannan	Healthcare, Accounting, Finance, Law, Business Management, Operations, Risk Management, Fund Management, General Administration, ESG & Sustainability
3	Dr S Vijayabaskaran	Accounting, Finance, Business Management, Operations, Fund Management, General Administration
4	Dr T Senthil Kumar	Healthcare, Finance, Business Management, Operations, Fund Management, General Administration
5	Mr Sunil Gulati	Accounting, Finance, Banking, Business Management, Risk Management and General Administration
6	Mr Ravichandran Purushothaman	Finance, Business Management, Operations, Fund Management, General Administration, ESG & Sustainability
7	Mr Mohan Srinivasan	Accounting, Finance, Law, Risk Management, Fund Management, General Administration
8	Mrs N Jeyanthei	Accounting, Finance, Law, Fund Management, General Administration

8. CONFIRMATION BY THE BOARD ON FULFILLMENT OF SPECIFIED CONDITIONS AND INDEPENDENCE OF THE INDEPENDENT DIRECTORS

The Board also hereby confirms that the Independent Directors of the Company fulfills all the conditions specified in the SEBI Listing Regulations and are Independent of the Management. Disclosures are submitted by the Independent Directors confirming their independence criteria which are subsequently confirmed by the Board.

9. CRITERIA FOR APPOINTMENT OF INDEPENDENT DIRECTORS

The Nomination and Remuneration Committee while considering the proposal for appointment of Independent Directors also considers the criteria of independence prescribed under the Companies Act, 2013 and SEBI Listing Regulations.

The Independent Directors have confirmed that they meet the criteria of independence laid down under the Companies Act, 2013 and the SEBI Listing Regulations and they are independent from the Management.

10. DETAILED REASONS FOR THE RESIGNATION OF AN INDEPENDENT DIRECTOR WHO RESIGNS BEFORE THE EXPIRY OF HIS/HER TENURE ALONG WITH A CONFIRMATION BY SUCH DIRECTOR THAT THERE ARE NO OTHER MATERIAL REASONS OTHER THAN THOSE PROVIDED.

No Independent Director has resigned before the expiry of his/her tenure during FY 2025-26.

11. CERTIFICATION FROM COMPANY SECRETARY IN PRACTICE

M/s. Alagar & Associates LLP, Practicing Company Secretaries, has issued a certificate as required under the SEBI Listing Regulations, confirming that none of the Directors on the Board of the Company has been debarred or disqualified from being appointed or for continuing as a Director of the Company by the SEBI / Ministry of Corporate Affairs or any other statutory authority. The certificate is enclosed with this report as **Annexure 5.**

12. AUDIT COMMITTEE

The Audit Committee of the Company is constituted in line with the provisions of Regulation 18 of the SEBI Listing Regulations, read with Section 177 of the Companies Act, 2013. The Audit Committee consists of the following Directors–

Mr Sunil Gulati	Chairman
Mr Ravichandran Purushothaman	Member
Dr S Manivannan	Member

During the financial year 2025 – 26, the Audit Committee met as per the details given hereunder –

S. NO.	NAME OF THE DIRECTOR	May 27, 25	Aug 12, 25	Nov 11, 25	Feb 10, 26
1	Mr Sunil Gulati	PRESENT	PRESENT	PRESENT	PRESENT
2	Mr Ravichandran Purushothaman	PRESENT	PRESENT	PRESENT	PRESENT
3	Dr S Manivannan	PRESENT	PRESENT	PRESENT	PRESENT

Brief description of terms of reference of Audit Committee are as follows:

a) Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statements are correct, sufficient and credible;

b) Recommendation for appointment, remuneration and terms of appointment of auditors of the Company;

c) Approval of payment to Statutory Auditors for any other services rendered by the Statutory Auditors;

d) Reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the Board for approval, with particular reference to:

i. Matters required to be included in the Director's Responsibility Statement in the Board's report in terms of clause (c) of sub-section 3 of Section 134 of the Companies Act, 2013.

ii. Changes, if any, in accounting policies and practices and reasons for the same.

iii. Major accounting entries involving estimates based on the exercise of judgment by management.

iv. Significant adjustments made in the financial statements arising out of audit findings.

v. Compliance with listing and other legal requirements relating to financial statements

vi. Disclosure of any related party transactions

vii. Modified opinion(s) in the draft audit report;

e) Reviewing, with the management, the quarterly financial statements before submission to the board for approval;

f) Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public issue or rights issue or preferential issue or qualified institutions placement, and making appropriate recommendations to the Board to take up steps in this matter;

g) Review and monitor the auditor's independence and performance, and effectiveness of audit process;

h) Approval or any subsequent modification of transactions of the Company with related parties;

i) Scrutiny of inter – corporate loans and investments;

j) Valuation of undertakings or assets of the company, wherever it is necessary;

k) Evaluation of internal financial controls and risk management systems;

l) Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;

m) Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit;

n) Discussion with internal auditors of any significant findings and follow up thereon;

o) Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;

p) Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;

q) To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors;

r) To review the functioning of the Whistle Blower Mechanism;

s) Approval for appointment of Chief Financial Officer after assessing the qualifications, experience and background, etc. of the candidate;

t) Carrying out any other function as mentioned in the terms of reference of the Audit Committee.

u) Reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding Rs. 100 Crores or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision.

v) Consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders.

13. NOMINATION AND REMUNERATION COMMITTEE

The Nomination and Remuneration Committee of the Company is constituted in line with the provisions of Regulation 19 of the SEBI Listing Regulations, read with Section 178 of the Companies Act, 2013. The constitution of the Nomination and Remuneration Committee is as follows:

Mr Sunil Gulati	Chairman
Mr Ravichandran Purushothaman	Member
Dr T Senthilkumar	Member

During the financial year 2025 – 26, the Nomination & Remuneration Committee met as per the details given hereunder –

S. NO	NAME OF THE DIRECTOR	May 27, 25
1	Mr Sunil Gulati	PRESENT
2	Mr Ravichandran Purushothaman	PRESENT
3	Dr T Senthilkumar	PRESENT

Brief description of terms of reference of Nomination & Remuneration Committee are as follows:

a) Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board of Directors a policy, relating to, the remuneration of the directors, key managerial personnel and other employees.

b) For every appointment of an independent director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:

   a. Use the services of an external agencies, if required;

   b. Consider candidates from a wide range of backgrounds, having due regard to diversity; and

   c. Consider the time commitments of the candidates.]

c) Formulation of criteria for evaluation of Independent Directors and the Board.

d) Devising a policy on Board diversity.

e) Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down and recommend to the Board their appointment and removal.

f) Whether to extend or continue the terms of appointment of the independent directors, on the basis of the report of performance evaluation of independent directors.

g) Recommend to the board all remuneration, in whatever form, payable to senior management.

Performance evaluation criteria for independent directors

The performance evaluation of Independent Directors was completed. The Board of Directors have expressed their satisfaction with the outcome of the evaluation process. There has been no change in the circumstances affecting their status as Independent Directors of the Company.

14. STAKEHOLDERS RELATIONSHIP COMMITTEE

The Stakeholders Relationship Committee of the Company is constituted in line with the provisions of Regulation 20 of the SEBI Listing Regulations, read with Section 178 of the Companies Act, 2013. The constitution of Stakeholders Relationship Committee is as follows:

Mrs Jeyanthei N	Chairperson
Dr S Chandrakumar	Member
Dr S Manivannan	Member

During the financial year 2025 – 26, the Stakeholders Relationship Committee met as per the details given hereunder –

S. NO	NAME OF THE DIRECTOR	May 27, 25	Aug 12, 25	Nov 11, 25	Feb 10, 26
1	Mrs Jeyanthei N	PRESENT	PRESENT	PRESENT	PRESENT
2	Dr S Chandrakumar	LOA	LOA	PRESENT	PRESENT
3	Dr S Manivannan	PRESENT	PRESENT	PRESENT	PRESENT

The Stakeholders Relationship Committee oversees redressal of Shareholders and investor complaints on matters such as non-receipt of share certificates and non-receipt of Annual Reports, general meetings, ensures expeditious transfer/ transmission of shares and issue of new/ duplicate share certificates and approves demat /remat/ sub-division/consolidation/ transposition/transmission of shares etc.

Ms Sushma K was the Company Secretary & Compliance officer of the Company upto May 22, 2025.

Ms. Indumathi P is the Company Secretary & Compliance officer of the Company with effect from May 28, 2025.

The total number of complaints received during the financial year 2025 - 26 is categorized as under:

Number of shareholders' complaints as on April 01, 2025	0
Number of shareholders' complaints received during the year	13
Number of Complaints resolved during the year	13
Number of Complaints not resolved during the year	0
Number of Complaints pending as on March 31, 2026	0

M/s Cameo Corporate Services Limited, Subramanian Building, 1, Club House Road, Chennai – 600002 is the Registrar and Share Transfer Agent of the Company since June, 2008.

The Committee ensured that requests and grievances related to transfer/ transmission of shares, non-receipt of annual report, issue of new/ duplicate shares certificates, general meetings etc., are promptly addressed to as required under the provisions of the SEBI Listing Regulations.

15. RISK MANAGEMENT COMMITTEE

The Risk Management Committee of the Company is constituted in line with the provisions of Regulation 21 of the SEBI Listing Regulations. The constitution of Risk Management Committee is as follows:

Dr S Manivannan	Chairman
Mr Sunil Gulati	Member
Dr D Senguttuvan	Member

During the financial year 2025-26, the Risk Management Committee met as per the details given hereunder:

S. NO	NAME OF THE DIRECTOR/ MEMBER	Aug 05, 25	Feb 26, 26
1	Dr S Manivannan	PRESENT	PRESENT
2	Mr Sunil Gulati	PRESENT	PRESENT
3	Dr D Senguttuvan	PRESENT	PRESENT

Brief description of terms of reference of Risk Management Committee are as follows:

a) To formulate a detailed risk management policy which shall include:

   i. A framework for identification of internal and external risks specifically faced by the listed entity, in particular including financial, operational, sectoral, sustainability (particularly, ESG related risks), information, cyber security risks or any other risks as may be determined by the Committee.

   ii. Measures for risk mitigation including systems and processes for internal control of identified risks.

   iii. Business continuity plan.

b) To ensure that appropriate methodology, processes and systems are in place to monitor and evaluate risks associated with the business of the Company;

c) To monitor and oversee implementation of the risk management policy, including evaluating the adequacy of risk management systems;

d) To periodically review the risk management policy, at least once in two years, including by considering the changing industry dynamics and evolving complexity;

e) To keep the board of directors informed about the nature and content of its discussions, recommendations and actions to be taken;

f) The appointment, removal and terms of remuneration of the Chief Risk Officer (if any) shall be subject to review by the Risk Management Committee.

The Risk Management Committee shall coordinate its activities with other committees, in instances where there is any overlap with activities of such committees, as per the framework laid down by the Board of Directors.

16. CORPORATE SOCIAL RESPONSIBILITY COMMITTEE

The Corporate Social Responsibility Committee of the Company is constituted in line with the provisions of Section 135 of the Companies Act, 2013. The constitution of Corporate Social Responsibility Committee is as follows:

Dr S Chandrakumar	Chairman
Dr S Manivannan	Member
Mr Ravichandran Purushothaman	Member

During the financial year 2025 – 26, the Corporate Social Responsibility Committee met as per the details given hereunder –

S. NO	NAME OF THE DIRECTOR	Feb 10, 26
1	Dr S Chandrakumar	PRESENT
2	Dr S Manivannan	PRESENT
3	Mr Ravichandran Purushothaman	PRESENT

Brief description of terms of reference of Corporate Social Responsibility Committee are as follows:

a) Formulate and recommend to the Board, an Annual Action Plan in pursuance to its CSR Policy.

b) Recommend the amount of expenditure to be incurred on the activities referred to be undertaken by the Company;

c) Monitor the utilization of fund based on the report produced by the Chief Financial Officer of the Company from time to time.

d) Any other matter as the CSR Committee may deem appropriate after approval of the Board of Directors or as may be directed by the Board of Directors from time to time.

17. BORROWING AND BANKING COMMITTEE

The constitution of Borrowing and Banking Committee is as follows:

Dr S Chandrakumar	Member
Dr S Manivannan	Member
Dr S Vijayabaskaran	Member

Brief description of terms of reference of Borrowing & Banking Committee are as follows:

a) Exercise borrowing powers not exceeding Rs. 25,00,000/- (Rupees Twenty-Five Lakhs only)

b) Opening and closing of bank accounts, authorizing persons to sign cheques, documents and any other document for the operation of all present and future bank accounts of the Company.

The Borrowing and Banking Committee did not meet during the financial year 2025 – 26.

18. SENIOR MANAGEMENT

(i) Particulars of Senior Management Personnel:

The details of the Company's Senior Management Personnel (SMP) as on March 31, 2026 is given below:

S. NO	NAME OF SMP	DESIGNATION
1	Dr D Senguttuvan	KMP - Executive Director & Unit Head
2	Mr Anand Babu K	Chief Financial Officer
3	Ms Indumathi P	Company Secretary & Compliance Officer (w.e.f. May 28, 2025)

(ii) Changes in Senior Management Personnel:

The following are the changes in Senior Management Personnel during the FY 2025 – 26:

S. NO	NAME OF SMP	DESIGNATION	NATURE OF CHANGE	DATE OF CHANGE
1	Ms Sushma K Rajendran	Company Secretary & Compliance Officer	Cessation	May 22, 2025
2	Ms Indumathi P	Company Secretary & Compliance Officer	Appointment	May 28, 2025

19. REMUNERATION POLICY

As required under Regulation 19 (4) read with Part D of the Schedule II of the SEBI Listing Regulations, and Section 178 (3) of the Companies Act, 2013, the Board, on the recommendation of the Nomination and Remuneration Committee of the Company has formulated a policy termed as "Remuneration Policy", relating to the remuneration of the Directors, Key Managerial Personnel and Senior Management Personnel. The criteria of making payments to Non-Executive Directors is mentioned in the said policy which is available in the policies section of the Company's website at the weblink: https://www.kauveryhospital.com/download/investrer/Policies_Codes/NRC-Policy.pdf

I. DETAILS OF REMUNERATION TO DIRECTORS:

The Non-Executive directors do not draw any remuneration from the Company. The Independent Directors receive sitting fees for attending each meeting of the Board and Committees thereof. The Company pays sitting fees of Rs. 1,00,000/- to all the Independent Directors for attending each meeting of the Board and Rs. 50,000/-for attending each meeting of the Audit Committee and Rs 25,000/- for attending each meeting of the other Committees thereof which is within the limits prescribed under the Companies Act, 2013.

During the financial year 2025-26, the sitting fees paid to the Independent Directors were as under:

S. NO.	NAME OF THE INDEPENDENT DIRECTOR	SITTING FEES PAID (In Rs.)	OTHERS	TOTAL (In Rs.)
1	Mr Sunil Gulati	7,00,000	-	7,00,000
2	Mr Ravichandran Purushothaman	6,75,000	-	6,75,000
3	Mr Mohan Srinivasan	4,25,000	-	4,25,000
4	Mrs N Jeyanthei	5,25,000	-	5,25,000

There are no other pecuniary relationships for transactions of the Non-Executive Directors' vis -à- vis of the Company.

The Company pays remuneration by way of Salary, perquisites and allowances to the Executive Chairman (Whole-Time) and Managing Director.

Details of the remuneration and perquisites paid to the Executive Directors are as under:

S. No.	Name of Director	Salary Paid (in Rs.)	Stock Options	Performance linked incentives	Severance Fees	Others	Total (in Rs.)
1	Dr S Chandrakumar	84,00,000/-	-	-	-	-	84,00,000/-
2	Dr S Manivannan	84,00,000/-	-	-	-	-	84,00,000/-

II. REVIEW OF THE POLICY:

The Nomination and Remuneration Committee shall review this Policy to ensure its effectiveness and also compliance with the Companies Act, 2013 and Regulation 19(4) of the SEBI Listing Regulations.

20. SUBSIDIARY COMPANIES:

The Company has no Subsidiary Company.

21. ANNUAL GENERAL MEETINGS

I. Location, date and time for the last three Annual General Meetings held:

YEAR	DATE	VENUE	TIME
2024-2025	26.09.2025	through Video Conferencing("VC")/ Other Audio Visual Means ("OAVM")	10.30 AM
2023-2024	27.09.2024	through Video Conferencing("VC")/ Other Audio Visual Means ("OAVM")	10.30 AM
2022-2023	27.09.2023	through Video Conferencing("VC")/ Other Audio Visual Means ("OAVM")	10.30 AM

II. Special Resolutions passed in the last three Annual General Meetings

42nd Annual General Meeting held for the year 2024-25 on September 26, 2025

a) No Special Resolution was passed.

41st Annual General Meeting held for the year 2023-24 on September 27, 2024

Special Resolution was passed for the following items:

a) Re-appointment of Dr S Chandrakumar (DIN: 01867847) as Executive Chairman (Whole-Time) of the Company (Term Period: September 29, 2024 to September 28, 2027).

b) Re-appointment of Dr S Manivannan (DIN: 00910804) as Managing Director of the Company (Term Period: October 01, 2024 to September 30, 2027)

c) Appointment of Mr. Mohan Srinivasan (DIN: 00277477) as a Non – Executive Independent Director (Term Period: August 29, 2024 to August 28, 2027)

40th Annual General Meeting held for the year 2022-23 on September 27, 2023

a) No Special Resolution was passed.

III. Extraordinary General Meeting

No Extraordinary General Meeting of the members was held during the year 2025-26.

IV. Postal Ballot

During the Financial year, no resolutions have been approved by way of Postal Ballot.

22. MEETING OF INDEPENDENT DIRECTORS:

The Company's Independent Directors are required to meet at least once in every Financial Year in compliance with the provisions of the Companies Act, 2013. Such meetings are conducted formally to enable Independent Directors to discuss the matters pertaining to the Company's Affairs and to put forth their views. Further, Independent Directors also review the performance of the Non- Independent Directors, Chairman (after taking into account the views of Executive and Non-Executive Directors of the Company) and Board as a whole and also the access, quality, quantity and timeliness of the flow of information between the Company's management and the Board.

During the Financial Year under review, the Independent Directors met on February 16, 2026 and all the Independent Directors attended the Meeting without the presence of the non-independent directors and the members of the management.

23. DISCLOSURES

A. RELATED-PARTY TRANSACTIONS

There have been no materially significant related-party transactions that may have potential conflict with the interests of the Company at large, pecuniary transactions or relationships between your Company and the Directors, the Management or related parties except for those disclosed in the financial statements for the financial year ended March 31, 2026.

The policy on dealing with Related Party Transactions is published on the website of the Company which may be accessed at the following web link: http://www.kauveryhospital.com/investors#.

B. DETAILS OF NON-COMPLIANCE

No strictures or penalties have been imposed on the Company by any Stock Exchange or Securities and Exchange Board of India (SEBI) or any other statutory authority on any matter related to the capital markets during the last three years.

C. VIGIL MECHANISM/ WHISTLE BLOWER POLICY

Your Company has formulated and adopted a Vigil Mechanism/ Whistle Blower Policy as per Section 177 of the Companies Act, 2013 and Regulation 22 of the SEBI Listing Regulations and has established the necessary mechanism for employees to express to the management, their concerns and suggestions about the deficiencies in the systems and procedures or violation of any code of conduct or general ethics.

The details of establishment of Vigil Mechanism/ Whistle Blower Policy is published on the Company's website and the same may be accessed at the following web link: http://www.kauveryhospital.com/investors#

No personnel have been denied the access to the Audit Committee.

D. DETAILS OF COMPLIANCE WITH MANDATORY REQUIREMENTS AND ADOPTION OF THE NON-MANDATORY REQUIREMENTS

The Company has complied with all applicable mandatory requirements in terms of Regulations of SEBI Listing Regulations. The Company has also adopted the non-mandatory requirements to the extent and in the manner as stated elsewhere in the report.

E. RECONCILIATION OF SHARE CAPITAL AUDIT

A quarterly audit was conducted by a Practicing Company Secretary, reconciling the issued and listed capital of the Company with the aggregate of the number of shares held by investors in physical form and in the depositories and the said certificates were submitted to the stock exchange within the prescribed timelines. As on March 31, 2026, there was no difference between the issued / listed capital and the aggregate number of shares held by investors in both physical form and in electronic form with the depositories.

24. MEANS OF COMMUNICATIONS

The Company is publishing Unaudited quarterly/ Audited annual financial results in English Newspaper ("Business Standard") and in Tamil Newspaper ("Maalai Malar") promptly besides communicating the same to BSE Limited (BSE) through BSE Listing Centre where the shares of the Company are at present listed, immediately after each of the Board Meetings in which resolutions for adopting the accounts are passed. Besides, such financial results are also published in the Company's website. The Company also provides Investor presentations on a quarterly basis which are available on the Stock exchange Website and the Company's website at https://www.kauveryhospital.com/investors/#.

The Annual Report, shareholding pattern, corporate information and other documents as specified in Regulation 46 (2) of the SEBI Listed regulations are published in the website of the Company for the information of the shareholders at http://www.kauveryhospital.com/investors#.

25. GENERAL SHAREHOLDER INFORMATION:

a) Annual General Meeting Date, Time and Venue of the 43rd Annual General Meeting

The Date, Time and Venue of the 43rd Annual General Meeting shall be held on Monday, the 28th day of September, 2026, at 10:30 am through Video Conferencing (“VC”)/ Other Audio Visual Means (“OAVM”).

b) Financial Year

The Company’s financial year begins on April, 1 and ends on March, 31.

c) Dividends

The Company did not declare any dividend during the year and proposes to use the profits for business purposes.

d) Tentative Financial Calendar for the year 2026-27 (as amended from time to time)

Financial year	April 1, 2026 to March 31, 2027
First quarter results	On or before August 14, 2026
Second quarter results	On or before November 14, 2026
Third quarter results	On or before February 14, 2027
Fourth quarter and Annual Results	On or before May 30, 2027

e) Date of book closure

The Register of Members and Share Transfer Books of the Company will be closed suitably prior to holding Annual General Meeting.

f) Listing of Shares on Stock Exchange and Stock Code

The equity shares of the Company are listed with BSE Limited, P J Towers, Dalal Street, Fort, Mumbai – 400001. Stock Symbol: KMCSHIL; Scrip Code: 524520. The Company has paid the Annual Listing fee for the financial year 2025-26.

g) Market Price data and performance in comparison to broad based indices of BSE Sensex

The closing market price of equity shares on March 30, 2026 (last trading day of the year) was Rs. 78.75 on BSE.

h) Monthly share price movement during the financial year 2025-26.

https://www.bseindia.com/markets/equity/ eqreports/stockprchistori?expandable=7&scripcode=524520&flag=sp&Submit=G

https://www.bseindia.com/indices/IndexArchiveData.html

Month	KMC SPECIALITY HOSPITALS (INDIA) LIMITED			BSE LTD INDEX	
	High Price	Low Price	No. of Shares traded	High Price	Low Price
April-25	70.9	57	9,52,893	80,661.31	71,425.01
May-25	73.5	61	10,89,705	82,718.14	78,968.34
June-25	69.79	62.5	8,67,189	84,099.53	80,354.59
July-25	67.1	62.5	8,71,121	83,935.01	80,575.45
August-25	72	63.07	10,77,374	82,231.17	79,741.76
September-25	69.68	65.01	7,73,908	83,141.21	79,818.38
October-25	77.8	65.01	21,05,670	85,290.06	80,159.9
November-25	83.25	68.75	22,52,036	86,055.86	82,670.95
December-25	80	71.4	8,07,996	86,159.02	84,150.19
January-26	92.9	70.51	29,10,977	85,883.5	81,088.59
February-26	91.24	73.5	21,22,725	85,871.73	79,899.42
March-26	85	78	13,94,391	80,632.55	71,774.13

i) The Distribution Pattern of the Shareholdings as on 31.03.2026 is as follows:

Pattern of Holding Equity Shares	No. of Share Holders	Total Share capital	% of Holding to Total No. of Shares
1 – 5000	86,709	1,55,63,425	9.54
5001 – 10000	248	17,95,720	1.10
10001 – 20000	126	17,88,533	1.10
20001 – 30000	39	9,33,587	0.57
30001 – 40000	20	6,90,781	0.42
40001 – 50000	9	4,16,905	0.26
50001 – 100000	18	12,27,766	0.75
Above 100000	38	14,06,68,283	86.25
TOTAL	87,207	16,30,85,000	100

j) Dematerialization of shares and liquidity

Shares comprising of 95.5% of the Paid-up Capital have been dematerialized as on 31.03.2026.

k) Details of Registrar to an Issue and Share Transfer Agent:

M/s. Cameo Corporate Services Limited

No 1, Subramanian Building, Club House Road, Chennai - 600 002

Phone – 044-28460390

Email - investor@cameoindia.com

l) Share Transfer System

The share transfer activities are carried out by our Registrar to an Issue & Share Transfer Agent, the details of which are given above. Pursuant to Regulation 40 (1) of SEBI Listing Regulations, effective from April 01, 2019, transfer of shares in physical mode has been discontinued and accordingly the Company has not processed transfer of shares in physical mode from the time the said Regulation was applicable, and all the transfer of shares would be carried out only in dematerialized form by the respective Depository Participants of the shareholders.

m) Outstanding GDRS/ ADRS/ Warrants or any Convertible Instruments, conversion Date and likely impact on Equity

The Company does not have any Outstanding GDRs/ ADRs/ Warrants or any other Convertible instruments and hence this provision is not applicable during the financial year.

n) Commodity Price Risk or Foreign Exchange Risk and Hedging Activities

The Company does not have any foreign exchange transactions during the FY 2025-26.

The Company does not have hedging activities and hence this provision is not applicable during the financial year.

26. INFORMATION TO SHAREHOLDERS:

It is brought to the kind notice of the shareholders that SEBI vide its Circular dated October 03, 2024, had specified relaxations to Companies from dispatching physical copies of the financial statements (including Board’s report, Auditor’s report or other documents required to be attached therewith) to the shareholders, for the Annual General Meetings (AGMs) conducted till September 30, 2025.

Further, SEBI (LODR) Third Amendment Regulations effective from December 31, 2024 specifies the mode of sending the Annual Reports to the shareholders which replaces the dispatch of physical copies of the Annual reports:

a) For Shareholders with Registered Emails – Soft copy of full Annual Report to be sent to the shareholders.

b) For Shareholders without Registered Emails:

(i) A letter providing the web-link, including the exact path, where complete details of the Annual Report is available to be sent to the shareholders.

(ii) Hard copy of the full annual report to be sent to those shareholders, who specifically request for it.

Further, as per the provisions of the SEBI Circular No. SEBI/HO/ MIRSD/MIRSDPoD-1/P/CIR/2023/37 dated March 16, 2023 (subsumed as a part of the SEBI Master Circular No. SEBI/HO/MIRSD/POD1/P/CIR/2024/37 dated May 7, 2024), the physical folios wherein PAN, KYC and Nomination details are not registered shall be eligible for any payment including dividend, only through electronic mode with effect from April 1, 2024.

We therefore advise the shareholders to take immediate steps for dematerializing their shareholding in the Company. Additionally, holding shares in dematerialized form offers host of benefits like enhanced security, ease of handling, faster transfers, exemption from stamp duty, eliminating bad deliveries. In view of the above, in order to be able to deal in the securities hassle-free, the shareholders are requested to take necessary steps for dematerializing their shares at an early date.

The Board has delegated the authority for approving transfer, transmission, etc. to the Stakeholders Relationship Committee. The Company's shares are traded under compulsory dematerialized mode.

The shareholders are requested to contact the Registrar and Share Transfer Agents for any queries regarding the procedures for issue of new share certificates, dematerialization, transfers, nominations and address updation.

27. WEB LINK WHERE POLICY FOR DETERMINING 'MATERIAL' SUBSIDIARIES IS DISCLOSED

The Company does not have any material subsidiary and hence this provision is not applicable during the financial year.

28. PLANT LOCATIONS

The Company is a healthcare industry and is having two Hospital units, the locations of the said Units are provided below.

S. No	Locations of Hospital Units
1.	No. 6, Royal Road, Cantonment, Trichy – 620 001
2.	No. 27, Alexandria Road, Cantonment, Trichy - 620 001

29. CODE OF CONDUCT & INSIDER TRADING CODE

The Code of Conduct for Board Members & Senior Management Personnel of the Company has been adopted which applies to all the Board of Directors and Senior Management Personnel of the Company. The Board of Directors and Senior Management personnel have affirmed their compliance on an annual basis and their confirmations has been received in this regard. As required under Part D of Schedule V of the SEBI Listing Regulations, a declaration to this effect signed by the Managing Director is provided elsewhere in the Annual Report. The policy on Code of Conduct of Board and Senior Management is available on the Company's website at www.kauveryhospital.com/investors/

The Company also has in place a code for Prevention of Insider Trading of Securities termed as "Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons" in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. This Code is applicable to all Directors and designated persons. The Code ensures prevention of dealing in shares by persons having access to unpublished price sensitive information.

The Company maintains a Structured Digital Database (SDD) through "Vigilant" software provided by M/s. Cameo Corporate Services Limited wherein the details of all the designated persons and their immediate relatives (who is either dependent financially on such person or consults such person in taking decisions relating to trading in securities) are being captured and in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.

30. WEB LINK WHERE DETAILS OF FAMILIARISATION PROGRAMMES IMPARTED TO INDEPENDENT DIRECTORS IS DISCLOSED

The familiarization programme for the Independent Directors can be accessed in the web link: https://www.kauveryhospital.com/investors/

31. ADDRESS FOR CORRESPONDENCE

Registered Office	No. 6, Royal Road, Cantonment, Trichy – 620001 Ph: 0431 4077777
Website address	www.kauveryhospital.com
E-mail	corporatecompliance@kauveryhospital.com

32. LIST OF ALL CREDIT RATINGS OBTAINED BY THE ENTITY ALONG WITH ANY REVISIONS THERETO DURING THE RELEVANT FINANCIAL YEAR, FOR ALL DEBT INSTRUMENTS OF SUCH ENTITY OR ANY FIXED DEPOSIT PROGRAMME OR ANY SCHEME OR PROPOSAL OF THE LISTED ENTITY INVOLVING MOBILIZATION OF FUNDS, WHETHER IN INDIA OR ABROAD

The Company has obtained the credit rating for its bank facilities with respect to Working capital and Term Loan of Rs. 77.81 Crores. The credit rating obtained is "IND AA-/Stable" from India Ratings & Research Private Limited on March 18, 2026. This credit rating is an upgradation from the rating provided last year "IND A+/Positive" reflecting the Company's financial commitment towards the stakeholders".

33. DETAILS OF UTILIZATION OF FUNDS RAISED THROUGH PREFERENTIAL ALLOTMENT OR QUALIFIED INSTITUTIONS PLACEMENT AS SPECIFIED UNDER REGULATION 32 (7A) OF THE SEBI LISTING REGULATIONS

The Company has not allotted any securities under preferential allotment or qualified institutions placement as specified under regulation 32 (7A) of SEBI Listing Regulations and hence this provision is not applicable during the financial year.

34. WHERE THE BOARD HAD NOT ACCEPTED ANY RECOMMENDATION OF ANY COMMITTEE OF THE BOARD WHICH IS MANDATORILY REQUIRED, IN THE RELEVANT FINANCIAL YEAR, THE SAME TO BE DISCLOSED ALONG WITH REASONS THEREOF

There were no instances warranting this disclosure during the financial year.

35. TOTAL FEES FOR ALL SERVICES PAID BY THE LISTED ENTITY AND ITS SUBSIDIARIES, ON A CONSOLIDATED BASIS, TO THE STATUTORY AUDITOR AND ALL ENTITIES IN THE NETWORK FIRM/ NETWORK ENTITY OF WHICH THE STATUTORY AUDITOR IS A PART

Details relating to total fees paid to the statutory auditors are given in notes to financial statements of the Company.

36. DISCLOSURES IN RELATION TO THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

a) Number of complaints filed during the financial year - 0

b) Number of complaints disposed of during the financial year - 0

c) Number of complaints pending as on end of the financial year - 0

37. NON-COMPLIANCE OF ANY REQUIREMENT OF CORPORATE GOVERNANCE REPORT OF SUB-PARAS (2) TO (10) OF PART C OF SCHEDULE V, WITH REASONS THEREOF SHALL BE DISCLOSED.

All the required provisions are complied and there is no such non-compliance with respect to Corporate Governance requirements as required under Sub-Para (2) to (10) of Part C of Schedule V of the SEBI Listing Regulations.

38. THE EXTENT TO WHICH THE DISCRETIONARY REQUIREMENTS AS SPECIFIED IN PART E OF SCHEDULE II AS PER REGULATION 27(1) OF SEBI LISTING REGULATIONS HAVE BEEN ADOPTED.

The Internal Auditor is periodically reporting the Internal Audit Report directly to the Audit Committee of the Company. Further, the Company has one women Independent Director in the Board.

The Company has not adopted the other discretionary requirements as specified in Part E of Schedule II as per Regulation 27(1) of SEBI Listing Regulations.

39. THE DISCLOSURES OF THE COMPLIANCE WITH CORPORATE GOVERNANCE REQUIREMENTS SPECIFIED IN REGULATION 17 TO 27 AND CLAUSES (B) TO (I) OF SUB-REGULATION (2) OF REGULATION 46 OF SEBI LISTING REGULATIONS SHALL BE MADE IN THE SECTION ON CORPORATE GOVERNANCE OF THE ANNUAL REPORT.

The disclosure of the Corporate Governance requirements specified in Regulation 17 to 27 as mentioned above and Clauses (B) to (I) of sub-regulation (2) of Regulation 46 to the extent applicable to the Company has been complied with. The Company has obtained the Certificate for compliance of Corporate Governance from M/s. Alagar & Associates LLP, Practising Company Secretaries for the FY 2025-26.

40. DISCLOSURES WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT/ SUSPENSE ESCROW DEMAT ACCOUNT:

(a) Disclosures with respect to Demat Suspense Account/ Unclaimed Suspense Account:

The Company does not have any equity shares in the Demat suspense Account /Unclaimed Suspense account.

(b) Disclosures with respect to Suspense Escrow Demat Account:

As per SEBI circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, upon receipt of service request from shareholders and after approval of the same by the Company, the Letter of Confirmation is sent by the RTA to the Shareholder / Claimant. A time limit of 120 days from the issue of the Letter of Confirmation is given to the claimant, within which the claimant(s) shall submit the demat request, along with the original Letter of Confirmation or the digitally signed copy of the Letter of confirmation ("LoC"), to the Depository Participant ("DP"). The RTA / Company shall send three reminders informing the claimant(s) to submit the demat request. In case of non-receipt of demat request from the claimant(s) within 120 days of the date of issue of the LoC, the securities shall be credited to Suspense Escrow Demat Account ("SEDA A/c") of the Company.

Accordingly, the Company has opened a SEDA A/c to credit the securities in case of non-receipt of demat request from the shareholder within 120 days of issuance of the LoC by RTA. The voting rights on such unclaimed shares shall remain frozen till the rightful owner claims the shares.

During the Financial year under review, 200 shares have been transferred to the SEDA A/c of the Company.

As on date, 500 shares have been transferred to the SEDA A/c of the Company.

41. DISCLOSURE OF CERTAIN TYPES OF AGREEMENTS BINDING LISTED ENTITIES

The Company has not entered into any such agreements under the Clause 5A of paragraph A of Part A of Schedule III of the SEBI Listing Regulations.

For and on behalf of the Board of Directors

Dr S Manivannan
DIN: 00910804
Managing Director

Dr S Chandrakumar
DIN: 01867847
Executive Chairman (Whole time)

Place: Chennai
Date: May 29, 2026

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

[Pursuant to Regulation 34(3) and Schedule V Para C clause (10) (i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To
The Members
KMC SPECIALITY HOSPITALS (INDIA) LIMITED

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **KMC Speciality Hospitals (India) Limited** having CIN: **L85110TN1982PLC009781** and having its registered office at No 6 Royal Road Cantonment, Trichy, Tamil Nadu, India, 620001 (hereinafter referred to as **'the Company'**), produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Clause 10 Sub Clause (i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal http://www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, **we hereby certify that none of the Directors on the Board of the Company as stated below for the financial year ending on March 31, 2026 have been debarred or disqualified from being appointed or continuing as Directors of the Company** by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority;

S. No	Name	DIN	Designation	Date of appointment/ Re-appointment
1.	Mr. Sundararaj Chandrakumar	01867847	Executive Chairman - Whole time Director	30/05/2011 (Reappointment – 29/09/2024)
2.	Mr. Selvaraj Manivannan	00910804	Managing Director	20/07/2013 (Reappointment – 01/10/2024)
3.	Mr. Thirunavukkarasu Senthil Kumar	01742558	Director	20/09/2016
4.	Mr. Sundararaju Vijayabaskaran	05139565	Director	11/08/2023
5.	Mrs. Narayanasami Jeyanthei	07143462	Independent Director	31/03/2015 (Reappointment – 30/08/2023)
6.	Mr. Sunil Satyapal Gulati	00016990	Independent Director	01/04/2024
7.	Mr. Purushothaman Ravichandran	06584433	Independent Director	01/04/2024
8.	Mr. Srinivasan Mohan	00277477	Independent Director	29/08/2024

Ensuring the eligibility of the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Alagar & Associates LLP
(Formerly known as M. Alagar & Associates)
Company Secretaries
Firm Registration No.: L2025TN019200
Peer Review Certificate No.: 6814/2025

D. Saravanan
Partner
FCS No.: 13721
COP No.: 22608
UDIN: F013721H000430720

Place: Chennai
Date: 21.05.2026

BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT

SECTION A: GENERAL DISCLOSURES

I. Details of the listed entity

1. Corporate Identity Number (CIN) of the Listed Entity - **L85110TN1982PLC009781**
2. Name of the Listed Entity - **KMC Speciality Hospitals (India) Limited**
3. Year of incorporation - **1982**
4. Registered office address - **No 6 Royal Road Cantonment Trichy - 620001**
5. Corporate address - **No 6 Royal Road Cantonment Trichy - 620001**
6. E-mail - corporatecompliance@kauveryhospital.com
7. Telephone - **0431-4077777**
8. Website - www.kauveryhospital.com
9. Financial year for which reporting is being done - **2025-26**
10. Name of the Stock Exchange(s) where shares are listed - **BSE Limited**
11. Paid-up Capital - **Rs. 16,30,85,000/-**
12. Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report –

    Dr S Manivannan,

    Email: - corporatecompliance@kauveryhospital.com

    Ph: 0431- 4022525
13. Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together) - **Standalone**
14. Name of assurance provider - **Not applicable**
15. Type of assurance obtained - **Not applicable**

II. Products/services

16. Details of business activities (accounting for 90% of the turnover):

S. No.	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1	Hospital and Medical Care Services	Hospital activities	100%

17. Products/Services sold by the entity (accounting for 90% of the entity's Turnover):

S. No.	Product/Service	NIC Code	% of total Turnover contributed
1	Hospital and Medical Care Services	Hospital activities	100%

III. Operations

18. Number of locations where plants and/or operations/offices of the entity are situated:

Location	Number of Hospital units	Number of offices	Total
National	2	2	4
International	Nil	-	-

19. Markets served by the entity:

a. **Number of locations**

Locations	Number
National (No. of States)	Tamil Nadu (2 Hospital Units at Tiruchirappalli): **1. Cantonment Unit:** No. 6 Royal Road, Cantonment, Trichy – 620001, Tamil Nadu, India. **2. Maa Kauvery unit:** No.27, Alexandria Road, Cantonment Trichy – 620001, Tamil Nadu, India.
International (No. of Countries)	Nil

b. What is the contribution of exports as a percentage of the total turnover of the entity? - **Not Applicable** as the Company does not export.

c. A brief on types of customers – Patients seeking healthcare and wellness services.

IV. Employees

20. Details as at the end of Financial Year:

a. **Employees and workers (including differently abled):**

S. No.	Particulars	Total (A)	Male		Female	
			No. (B)	% (B / A)	No. (C)	% (C / A)
EMPLOYEES						
1.	Permanent (D)	1695	371	22%	1324	78%
2.	Other than Permanent (E)	47	23	49%	24	51%
3.	**Total employees (D + E)**	**1742**	**394**	**23%**	**1348**	**77%**
WORKERS						
4.	Permanent (F)					
5.	Other than Permanent (G)					Nil
6.	Total workers (F + G)					

b. **Differently abled Employees and workers:**

S. No	Particulars	Total (A)	Male		Female	
			No. (B)	% (B / A)	No. (C)	% (C / A)
DIFFERENTLY ABLED EMPLOYEES						
1.	Permanent (D)	6	6	100%	0	0%
2.	Other than Permanent (E)	0	0	0%	0	0%
3.	**Total differently abled employees (D + E)**	**6**	**6**	**100%**	**0**	**0%**
DIFFERENTLY ABLED WORKERS						
4.	Permanent (F)					
5.	Other than permanent (G)					Nil
6.	Total differently abled workers (F + G)					

21. Participation/Inclusion/Representation of women

	Total (A)	No. and percentage of Females	
		No. (B)	% (B / A)
Board of Directors	8	1	12.5%
Key Management Personnel	5	1	20%

22. Turnover rate for permanent employees and workers

(Disclose trends for the past 3 years)

	FY 2025-26 (Turnover rate in current FY)			FY 2024-25 (Turnover rate in previous FY)			FY 2023-24 (Turnover rate in the year prior to the previous FY)		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	7%	25%	32%	5.4%	21.3%	26.8%	6.0%	24.0%	30.0%
Permanent Workers									Nil

V. Holding, Subsidiary and Associate Companies (including joint ventures)

23. (a) Names of holding / subsidiary / associate companies / joint ventures

S. No.	Name of the holding / subsidiary / associate companies / joint ventures (A)	Indicate whether holding/ Subsidiary/ Associate/ Joint Venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1	Sri Kauvery Medical Care (India) Limited	Holding company	75%	Yes

VI. CSR Details

24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: **Yes**

(ii) Turnover (in Rs.): **305,76,81,694**

(iii) Net worth (in Rs.): **210,42,88,007**

VII. Transparency and Disclosures Compliances

25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/No) (If Yes, then provide web-link for grievance redress policy)	FY 2025-26 Current Financial Year			FY 2024-25 Previous Financial Year		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	Yes, based on internal Policy. Grievance redressal link https://www.kauveryhospital.com/contact-us/	Nil	Nil	Nil	Nil	Nil	Nil
Investors (other than shareholders)	Yes. https://www.kauveryhospital.com/investors/#KMCSH7	Nil	Nil	Not Applicable. The Company has not issued any debentures, bonds, or public deposits, and does not have any financial investors other than the shareholders.	Nil	Nil	Not Applicable. The Company has not issued any debentures, bonds, or public deposits, and does not have any financial investors other than the shareholders.
Shareholders	Yes. Stakeholders Relationship Committee oversees shareholder grievances through its terms of reference as per regulatory requirement. https://www.kauveryhospital.com/investors/#KMCSH7	13	NIL	All complaints were resolved during the year	17	NIL	All complaints were resolved during the year
Employees and workers	Yes, based on internal policy. We have a dedicated Software to address the employee grievances	Nil	Nil	Nil	Nil	Nil	Nil
Customers	Yes, based on internal Policy. Grievance redressal link https://www.kauveryhospital.com/contact	1955	Nil	The Complaints includes feedback also. All complaints and feedback were resolved during the FY	1538	Nil	The Complaints includes feedback also. All complaints and feedback were resolved during the FY
Value Chain Partners	Yes, based on internal policy. Grievance redressal link https://www.kauveryhospital.com/vendor-portal/	Nil	Nil	Nil	Nil	Nil	Nil
Other (please specify)	Nil	Nil	Nil	Nil	Nil	Nil	Nil

26. Overview of the entity's material responsible business conduct issues

Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with its financial implications, as per the following format

S. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
1	Access to affordable healthcare	O	Due to an increased demand for quality, affordable and preventive healthcare treatment over the last few decades, access to quality healthcare has increased. Our mother and child hospital, Maa Kauvery has been recognized as one of the best mother and child care brands of 2025. This recognition is a testament to our mission of making great quality healthcare more affordable.	NA	+ve
2	Privacy/ Cyber security	R	Entity handles sensitive patient records making them highly vulnerable to data breaches. Advancement of Digitalization has led to increased risk exposure of personal data and a high possibility of data breach, leading to possible loss of reputation and trust amongst stakeholders as well as legal implications.	1) The Company safeguards its digital ecosystem against cyber-attacks and data breaches through the implementation of robust cyber security and data privacy controls. These include server and database encryption, encryption of data in transit, role-based access controls, periodic security audits, and adherence to applicable data protection regulations. 2) Sustained and proactive investments in technology infrastructure. 3) Oversight by the Board and Risk Management committee to monitor and mitigate risks.	-ve
3	Supply chain management	R	Availability of raw materials and other supplies is crucial for running the healthcare sector. Further, increasing cost of resources and scarcity in the industry poses huge risks	The Company has in place a robust logistics system to ensure sufficient and timely availability of resources. The Company has also entered medium term contracts with certain key suppliers of resources for procurement of its supplies	-ve
4	Business ethics, Governance, Code of Conduct	O	Our Company is committed to the highest standards of quality, integrity, professionalism and ethics. Our Board is diverse with Independent Directors (including a Woman Independent Director), Executive /Promotor Directors, and Non-Executive Directors who are Professionals specialized in different domains, including healthcare sector. The Company is committed to good Corporate Governance	NA	+ve
5	Labour management	R	Talent acquisition, retention and management of Human capital is of utmost importance to run any business, especially when it comes to healthcare sector. High attrition rates and inability to find the right talent always poses risks in running the business	The Company has ongoing HR strategies focused on reducing attrition and promoting career development through various initiatives including the Kauvery Initiative for Leadership Transformation (KLIFT), Kauvery leadership initiative for excellence (KLIFE) and the Kauvery Talent Transformation (KTT) program. These programs aim to build a strong leadership pipeline and provide career advancement opportunities for employees. Further, we also sponsor the higher education of our employees ranging from 1 year certification course to 3 years course on public administration and various other classroom training & workshops.	-ve

Abbreviation:

R - Risk

O- Opportunity

SECTION B: MANAGEMENT AND PROCESS DISCLOSURES

This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements.

Disclosure Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
Policy and management processes									
1. a. Whether your entity's policy/ policies cover each principle and its core elements of the NGRBCs. (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
b. Has the policy been approved by the Board? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
c. Web Link of the Policies, if available	https://www.kauveryhospital.com/investors/								
2. Whether the entity has translated the policy into procedures. (Yes / No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3. Do the enlisted policies extend to your value chain partners? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
4. Name of the national and international codes/certifications/ labels/ standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustea) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.	KMC Specialty Hospitals (India) Limited confirms the following standards: 1) Great Place to Work Certification (Group Level) 2) LEED Silver rating by the U.S. Green Building Council (USGBC) for Maa Kauvery Unit 3) Quality of healthcare guidelines issued by NABH 4) NABH Full Accreditation 5) 5S Model Hospital Certification for Cantonment unit and Basic 5S – Platinum level Certification for Maa Kauvery unit 6) ISO 27001:2022 certification, an internationally recognized standard for information security management 7) NNF Accreditation from National Neonatology Forum – Level III A (Special Accreditation for NICU) for Maa Kauvery unit 8) Manyata – Certification for Compliance with FOGSI Quality Standards ensuring Safe Delivery for Maa Kauvery unit 9) NVG Guidelines issued by the Ministry of Corporate Affairs, GOI 10) Environment and Social Guidelines issued by IFC 11) Environment Guidelines as per ISO 14001 and Ministry of Environment and Forest 12) National Neonatal Forum guidelines issued by National Neonatal Forum								
5. Specific commitments, goals and targets set by the entity with defined timelines, if any.	1) To achieve 100% usage of renewable energy from the next financial year. 2) To integrate the ESG principles in our core operations.								
6. Performance of the entity against the specific commitments, goals and targets along-with reasons in case the same are not met.	We have been continuously working towards our Goals. **a. In the Environmental front:** 1) We have been awarded the "LEED Silver rating" by the U.S. Green Building Council (USGBC) for Maa Kauvery Unit. 2) Our Maa Kauvery Unit has been recognisied as "Green Hospital" by CII-TN Medclave in the above 100 beds category 3) We have achieved around 92% usage of renewable energy during FY 2025-26 and are on the path to achieve 100% from FY 2026-27. **b. In the Social front:** 1) We have been certified with "The Great Place to Work" Certification for the period from Feb 2026 to Feb 2027 at the Group Level. 2) We have been recognised as India's Best Workplaces™ in Hospitals 2026 under the Great Place To Work® workplace recognition program for the hospital sector in 2026 at the Group Level. 3) We have been awarded the "Most preferred workplace" for FY 2025-26 at the Group Level. 4) We have provided 100% free health insurance coverage for all the employees including their spouse and children 5) We have provided Free Medical checkups for all the employees. 6) We have introduced various programs for employees' well-being and for rewarding them as mentioned in the upcoming principles. 7) We have facilitated career progression / skill upgradation for employees through "Koach App". **c. In the Governance front, as part of our ongoing commitment to excellence:** 1) Our Maa Kauvery Unit has been awarded as one of the best mother and child care brands for 2025 by ETEdge; 2) We have obtained ISO 27001:2022 certification for our Cantonment Unit, an internationally recognized standard for information security management, which is a testament to our commitment to protecting the sensitive data entrusted to us by our patients and partners; 3) Our Maa Kauvery Unit has been awarded Platinum award in basic 5S certification; 4) We conduct various audits that go beyond regulatory requirements such as Self Zone Audit, cross zone audit, Stock audit, Electrical audit, Grand Facility & Safety rounds audit, Cross-unit Risk assessment audit, Bio Medical Waste Audit, Hazard Identification and Risk Assessment audit, Environmental, Social & Governance audit, Fire safety audit, thermal audit, facility audit, etc.								

Governance, leadership and oversight

7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements.

As the Managing Director of the Company, it gives me immense pleasure in presenting our ESG performance & achievements for this financial year. At our Company, BRSR and ESG is not viewed merely as a standalone compliance framework, but as an integral part of how we deliver healthcare with deep responsibility, resilience and long-term value creation. Throughout FY 2025-26, we have consistently strengthened our commitment to sustainable operations, patient-centric care, and employee wellbeing, all anchored by robust and ethical governance practices.

This year marks significant progress in our sustainable journey.

In the Environmental front:

- We have successfully increased our renewable energy consumption across our operations from 78% to 92% this financial year, and are on the path to achieve 100% from the next financial year, reflecting our focused efforts towards reducing carbon footprint and improving energy efficiency.
- We continue to invest in responsible resource optimization and sustainable infrastructure initiatives across our hospitals and healthcare facilities. Notably, our Maa Kauvery Unit was awarded the prestigious **LEED Silver rating by the U.S. Green Building Council (USGBC),** validating our commitment to eco-friendly building operations.
- We implemented a responsible plastic waste management system that ensures all plastic waste is systematically segregated, shredded and channeled to a cement manufacturing facility to be utilized as an alternative fuel in furnaces. This initiative effectively reduces landfill burdens while contributing to sustainable waste-to-energy solutions.
- To promote sustainable water management, all our hospital facilities are fully equipped with rainwater harvesting systems to recharge local groundwater.
- We are progressively upgrading our air conditioning systems to eco-friendly alternatives during routine maintenance and repairs.
- Battery-operated vehicles have been deployed within our hospital campuses to transport patients and attendants, thereby reducing carbon emissions and fostering green mobility.

In the Social front:

- We remain deeply committed to creating a people-first organization. We are proud to have received the **Great Place to Work Certification** at the Group level during the FY 2025-26 reflecting our inclusiveness, safe and growth-oriented workplace culture we strive to foster for our employees.
- We have "Project Kushi" in place for sustaining wellbeing of all employees. This Project focuses on Employee wellbeing sessions, counselling for employees, Creating WOW moments for employees, Walkaholic program to encourage physical fitness of employees, Creating awareness on the importance of mental health, etc.,

In the Governance front:

We have received several recognitions and industry awards for operational excellence such as **The Best Mother and Child Care Brands for 2025 and a Platinum award in basic 5S certification** for our Maa Kauvery Unit, reaffirming the trust placed in us by our stakeholders.

Most importantly, we have consistently outperformed several critical ESG dimensions, such as high renewable energy mix, hazardous waste generation intensity, higher gender diversity with low attrition rates, all employees and workers being trained on skills upgradation and health and safety measures and relatively high employment generated in rural and semi-urban areas, high average attendance of independent directors at Board and committee meetings and Nil whistle blower complaints. This not only validates our approach but also inspires us to set higher benchmarks for the future.

While we are encouraged by these achievements, we recognize that ESG is a continuous and evolving journey. We continue to face challenges in adapting to the dynamic regulatory landscapes and aligning the stakeholders' expectations with long-term sustainability goals. We choose to remain steadfast in our commitment to achieve excellence and make continuous progress in strengthening our practices to achieve our ESG goals.

Going forward, our efforts will remain aligned with building a sustainable, inclusive and responsible future for our business and the communities we serve. We believe our long-term success can only be achieved through ethical leadership, environmental stewardship and meaningful social impact, and we remain committed in advancing these priorities in the upcoming years ahead.

8.	Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies).	Dr S Manivannan Managing Director
9.	Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No). If yes, provide details.	Yes. Business Responsibility performance is reviewed as a part of the ongoing business review by the Management. The Board of Directors of the Company has constituted a Risk Management Committee to assist the Board to monitor various aspects of Governance and risk management of the Company, which covers the areas including Environmental Social and Governance aspects and risks. The Committee ensures that appropriate methodology, processes, and systems are in place to identify, monitor and evaluate various risks associated with the business of the Company including information and cyber security risks and compliance risks of the Company. The Committee also reviews the adequacy of the risk management practices and actions deployed by the management in respect of identification, impact assessment, monitoring, mitigation and reporting of key risks to the achievement of business objectives. The Corporate Social Responsibility committee of the Board governs and reviews the Corporate Social Responsibility activities of the Company. The Company's philosophy on Corporate Social Responsibility (CSR) is that "as the organization grows, the society and community around it should also grow". The Company's vision is to contribute to the social and economic development of the communities in which it operates, resulting in building a better and sustainable way of life for the society at large. The Stakeholder Relationship Committee considers and resolves the grievances of the shareholders of the Company, including complaints relating to non-receipt of Annual Report, transfer and transmission of securities and such other grievances.

10. Details of Review of NGRBCs by the Company:

Subject for Review	Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee									Frequency (Annually/ Half yearly/ Quarterly/ Any other – please specify)								
	P1	P2	P3	P4	P5	P6	P7	P8	P9	P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action	Business Responsibility (BR) performance is reviewed as a part of the ongoing business review by the Management. The Board/ committee assesses the BR performance annually.																	
Compliance with statutory requirements of relevance to the principles, and, rectification of any non-compliances	The Company is in compliances with applicable Regulations.																	

11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If yes, provide name of the agency.	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
	No. The policies are reviewed by the Board and/ Senior Management Team and is being amended periodically as may be required. The assessment/ evaluation of the working of the policy is being carried out by the Senior Management team of the Company.								

12. If answer to question (1) above is "No" i.e. not all Principles are covered by a policy, reasons to be stated:

Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8	P 9
The entity does not consider the Principles material to its business (Yes/No)	NOT APPLICABLE								
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)									
The entity does not have the financial or/human and technical resources available for the task (Yes/No)									
It is planned to be done in the next financial year (Yes/No)									
Any other reason (please specify)									

SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE

This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key processes and decisions. The information sought is categorized as "Essential" and "Leadership". While the essential indicators are expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically responsible.

PRINCIPLE 1 Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.

Essential Indicators

1. **Percentage coverage by training and awareness programmes on any of the Principles during the financial year:**

Segment	Total number of training and awareness programmes held	Topics / principles covered under the training and its impact	%age of persons in respective category covered by the awareness programmes
Board of Directors	4*	Periodic Regulatory Update -Changes in SEBI Regulations, Companies Act, 2013 and all other applicable sector specific laws	100%
Key Managerial Personnel	4	Periodic Regulatory Update -Changes in SEBI Regulations, Companies Act, 2013 and all other applicable sector specific laws	100%
Employees other than BoD and KMPs	6	• Awareness on Breast Cancer • Awareness on Cervical Cancer • General Awareness of Geriatric Patients • Awareness on Perimenopause • KAuvery Financial Fitness, Education & Empowerment (KAFFEE) • Awareness on POSH	100%
Workers	Not Applicable		

**In addition to the training and awareness programmes conducted for the Board of Directors as outlined in the table above, the Company has also circulated various notes and presentations, covering key regulatory updates from time to time as part of the ongoing familiarization and capacity-building programmes aimed at ensuring that the Board is kept abreast of significant regulatory developments on a continuous basis.*

2. Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website):

Monetary					
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (In Rs.)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Penalty/ Fine			Nil		
Settlement			Nil		
Compounding Fee			Nil		

Non-Monetary				
	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Brief of the Case	Has an appeal been preferred? (Yes/No)
Imprisonment		Nil		
Punishment				

3. **Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed.**

Case details	Name of the regulatory/ enforcement agencies / judicial institutions
Nil	

4. **Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web-link to the policy.**

Yes. https://www.kauveryhospital.com/investors/#

5. **Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:**

	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Directors	NIL	
KMPs		
Employees		
Workers	NA	NA

6. **Details of complaints with regard to conflict of interest:**

	FY 2025-26 (Current financial year)		FY 2024-25 (Previous financial year)	
	Number	Remarks	Number	Remarks
Number of complaints received in relation to issues of Conflict of Interest of the Directors	NIL			
Number of complaints received in relation to issues of Conflict of Interest of the KMPs				

7. Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest - **NIL**

8. **Number of days of accounts payables ((Accounts payable *365) / Cost of goods/services procured) in the following format:**

	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Number of days of accounts payables	25	36

9. **Open-ness of business Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties, in the following format:**

Parameter	Metrics	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Concentration of Purchases	a. Purchases from trading houses as % of total purchases	NA	NA
	b. Number of trading houses where purchases are made from	NA	NA
	c. Purchases from top 10 trading houses as % of total purchases from trading houses	NA	NA
Concentration of Sales	a. Sales to dealers / distributors as % of total sales	NA	NA
	b. Number of dealers / distributors to whom sales are made	NA	NA
	c. Sales to top 10 dealers / Distributors as % of total sales to dealers / distributors	NA	NA
Share of RPTs in	a. Purchases (Purchases with related parties / Total Purchases)	8 %	8.68 %
	b. Sales (Sales to related parties / Total Sales)	4 %	4.56 %
	c. Loans & advances (Loans & advances given to related parties / Total loans & advances)	Nil	Nil
	d. Investments (Investments in related parties / Total Investments made)	Nil	Nil

Leadership Indicators

1. **Awareness programmes conducted for value chain partners on any of the Principles during the financial year:**

Total no. of awareness programmes held	Topic / principles covered under the training	%age of value chain partners covered (by value of business done with such partners) under the awareness programmes
5	• Awareness on Breast Cancer • Awareness on Cervical Cancer • General Awareness of Geriatric Patients • Awareness on Perimenopause • KAuvery Financial Fitness, Education & Empowerment (KAFFEE)	95%

2. **Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No) If Yes, provide details of the same.**
   - Yes. The Company collects Annual Disclosures from Board members and also collects disclosures before the quarterly Board meetings whenever there is any change in the interest on the entities they are interested in.
   - The Company ensures requisite approvals as required under the applicable Acts as well as adherence to the Company's policies before transacting with such entities / individuals in which the Board members are interested.
   - Directors recuse themselves from participating in and discussing the agenda items in which they are interested.
   - All related party transactions are entered on arm's length basis and in the ordinary course of business.

PRINCIPLE 2 Businesses should provide goods and services in a manner that is sustainable and safe

Essential Indicators

1. **Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.**

	Current Financial Year	Previous Financial Year	Details of improvements in environmental and social impacts
R&D			Nil
Capex			

2. a. **Does the entity have procedures in place for sustainable sourcing?** No

   b. **If yes, what percentage of inputs were sourced sustainably?**

   We're looking to develop a framework that evaluates suppliers based on sustainability criteria, prioritizes vendors with recognized environmental certifications, and incorporates sustainable practices into our procurement policies in the near future. Although our entity hasn't fully implemented sustainable sourcing procedures yet, we're actively planning to integrate ESG initiatives into our operations.

3. **Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.**

   a) **Plastics -** The Company has eliminated single-use plastics across our operations, ensuring 100% adoption of reusable and recyclable plastic materials. Our hospital canteens replaced plastic packaging with biodegradable alternatives. Furthermore, usage of paper cups has been completely phased out and replaced with durable steel glasses, successfully driving waste minimization.

   b) **E-waste -** The e-waste, lead waste, and metal scraps generated at the facility are disposed through authorized recyclers/ dismantlers. Entire quantity of e-waste and lead wastes generated are handed over to TNPCB authorized vendor.

   c) **Hazardous waste –** As it is a healthcare industry, the hazardous waste from our healthcare operations is restricted to used Diesel generator (DG) oil. Through a strict take-back mechanism, all used oil is returned to respective vendors upon purchasing fresh oil, ensuring safe, legal, and eco-friendly recycling.

   d) **Other Waste –** All Bio-medical wastes generated across our healthcare facilities are strictly managed and disposed of through government authorized vendors. Our empaneled vendors operate under strict contractual obligations to handle, treat, and dispose of this waste in absolute compliance with the Bio-Medical Waste Management Rules and all other applicable statutory laws.

4. **Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same.**

   Not Applicable.

Leadership Indicators

1. **Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)? If yes, provide details in the following format?**

NIC Code	Name of Product / Service	% of total Turnover contributed	Boundary for which the Life Cycle Perspective / Assessment was conducted	Whether conducted by independent external agency (Yes/No)	Results communicated in public domain (Yes/No) If yes, provide the web-link.
		No			

2. If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same. - **The Company has not carried out any such activity during the financial year**

Name of Product / Service	Description of the risk / concern	Action Taken
	NA	

3. **Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry).**

Indicate input material	Recycled or re-used input material to total material	
	FY 2025-26 Current Financial Year	FY 2024-25 Previous Financial Year
	NA	NA

4. **Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely disposed, as per the following format:**

	FY 2025-26 Current Financial Year			FY 2024-25 Previous Financial Year		
	Re-Used	Recycled	Safely Disposed	Re-Used	Recycled	Safely Disposed
Plastics (including packaging)	NA	NA	NA	NA	NA	NA
E-waste	NA	NA	NA	NA	NA	NA
Hazardous waste	NA	NA	NA	NA	NA	NA
Other waste	NA	NA	NA	NA	NA	NA

5. **Reclaimed products and their packaging materials (as percentage of products sold) for each product category.**

Indicative product category	Reclaimed products and their packaging materials as % of total products sold in respective category
NA	NA

PRINCIPLE 3 Businesses should respect and promote the well-being of all employees, including those in their value chains

Essential Indicators

1. a. **Details of measures for the well-being of employees:**

Category	Total (A)	% of employees covered by									
		Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A)
Permanent employees											
Male	371	371	100%	371	100%	NA	NA	371	100%	371	100%
Female	1324	1324	100%	1324	100%	1324	100%	NA	NA	1324	100%
Total	**1695**	**1695**	**100%**	**1695**	**100%**	**1324**	**100%***	**371**	**100%***	**1695**	**100%**
Other than Permanent employees											
Male	23	0	0%	0	0%	0	0%	0	0%	23	100%
Female	24	0	0%	0	0%	0	0%	0	0%	24	100%
Total	**47**	**0**	**0%**	**0**	**0%**	**0**	**0%**	**0**	**0%**	**47**	**100%**

*Indicates the % calculated for all eligible employees.

b. **Details of measures for the well-being of workers:**

Category	Total (A)	% of workers covered by									
		Health insurance		Accident insurance		Maternity benefits		Paternity Benefits		Day Care facilities	
		Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A)
Permanent workers											
Male											
Female	Nil										
Total											
Other than Permanent workers											
Male											
Female	Nil										
Total											

c. **Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format –**

	FY 2025-26 Current Financial Year	FY 2024-25 Previous Financial Year
Cost incurred on well- being measures as a % of total revenue of the Company.	1%	1%

2. **Details of retirement benefits, for Current FY and Previous Financial Year.**

Benefits	FY 2025-26 Current Financial Year			FY 2024-25 Previous Financial Year		
	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)	No. of employees covered as a % of total employees	No. of workers covered as a % of total workers	Deducted and deposited with the authority (Y/N/N.A.)
PF	100%	NA	Yes	100%	NA	Yes
Gratuity	100%	NA	Yes	100%	NA	Yes
ESI	100%	NA	NA	100%	NA	NA
Others – please specify	Nil	NA	NA	Nil	NA	NA

3. **Accessibility of workplaces**

Are the premises / offices of the entity accessible to differently abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard?

Yes, the premises of the entity are accessible to differently abled employees in accordance with the applicable provisions of The Rights of Persons with Disabilities Act, 2016. We have implemented necessary accessibility features such as ramps with proper gradients, wheel chairs, accessible restrooms, wide doorways and lift for their movements. These measures ensure a barrier-free environment that promotes inclusion and equal opportunity for all employees, including persons with disabilities. There is also digital accessibility for all to voice their concerns.

4. **Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy.**

Yes, the entity has an Equal opportunity policy in place, in accordance with the applicable provisions of the Rights of persons with disabilities act, 2016. The Policy ensures non-discrimination and promotes Diversity, equity and Inclusion (DEI) by providing equal access to employment, facilities and opportunities for persons with disabilities. It also includes provisions for reasonable accommodation, accessible infrastructure and grievance redressal mechanisms.

The Policy can be accessed at https://www.kauveryhospital.com/investors/#KMCSH10

5. **Return to work and Retention rates of permanent employees and workers that took parental leave.**

Gender	Permanent employees		Permanent workers	
	Return to work rate	Retention rate	Return to work rate	Retention rate
Male	92% (11 employees out of 12 employees)	100% (11 employees out of 11 employees)	NA	NA
Female	94% (29 employees out of 31 employees)	100% (29 employees out of 29 employees)	NA	NA
Total	**93%**	**100%**		

6. **Is there a mechanism available to receive and redress grievances for the following categories of employees and workers? If yes, give details of the mechanism in brief.**

	Yes/No (If Yes, then give details of the mechanism in brief)
Permanent Workers	NA
Other than Permanent Workers	NA
Permanent Employees	Yes
Other than Permanent Employees	Yes

We are committed to providing a safe and responsive environment for all stakeholders. To uphold this commitment, we have established a structured Grievance redressal process designed to address and resolve concerns in a timely and efficient manner:

1. We have dedicated digital HR software designed for grievance redressal and employee support. This platform enables individuals to securely submit their grievances, share organizational feedback.
2. Once grievance is submitted, it will be initially handled by the Grievance handling team which comprises of staff involved in day-to-day operations relevant to the complaint
3. This team is responsible for understanding and analyzing the nature and scope of the issue
4. Following the initial review, the matter shall be escalated to the Unit HR, who is tasked with ensuring that grievance is addressed in accordance with the Company's Policies and ethical standards. They coordinate with the internal team to investigate and resolve the issue
5. Upon resolution, Unit HR ensures that the outcome is clearly communicated to the complainant through the online system or other appropriate channels
6. The grievance is formally closed after the complainant acknowledges satisfaction with the resolution, or after all possible avenues of redressal have been exhausted.
7. Further, our Company has also tied up with a platform which provides one-to-one help for the psychological and emotional well-being of our employees. It's available for all employees at free of charge.

7. **Membership of employees and workers in association(s) or Unions recognized by the listed entity:**

Category	FY 2025-26 (Current Financial Year)			FY 2024-25 (Previous Financial Year)		
	Total employees / workers in respective category (A)	No. of employees / workers in respective category, who are part of association(s) or Union (B)	% (B / A)	Total employees / workers in respective category (C)	No. of employees / workers in respective category, who are part of association(s) or Union (D)	% (D / C)
Total Permanent Employees						
• Male			Nil			
• Female						
Total Permanent Workers						
• Male			NA			
• Female						

8. **Details of training given to employees and workers:**

Category	FY 2025-26 Current Financial Year					FY 2024-25 Previous Financial Year				
	Total (A)	On Health and safety measures		On Skill upgradation		Total (D)	On Health and safety measures		On Skill upgradation	
		No. (B)	% (B / A)	No. (C)	% (C / A)		No. (E)	% (E / D)	No. (F)	% (F / D)
Employees										
Male	394	394	100%	394	100%	387	387	100%	387	100%
Female	1348	1348	100%	1348	100%	1242	1242	100%	1242	100%
Total	**1742**	**1742**	**100%**	**1742**	**100%**	**1629**	**1629**	**100%**	**1629**	**100%**
Workers										
Male										
Female					Not Applicable					
Total										

9. **Details of performance and career development reviews of employees and workers:**

Category	FY 2025-26 Current Financial Year			FY 2024-25 Previous Financial Year		
	Total (A)	No. (B)	% (B / A)	Total (C)	No. (D)	% (D / C)
Employees						
Male	394	394	100%	387	387	100%
Female	1348	1348	100%	1242	1242	100%
Total	**1742**	**1742**	**100%**	**1629**	**1629**	**100%**
Workers						
Male						
Female			Not applicable			
Total						

10. **Health and safety management system:**

a. Whether an occupational health and safety management system has been implemented by the entity? **(Yes/ No).** If yes, the coverage such system?

Yes, our Company being in healthcare sector has an Occupational Health & Safety Management System in place to ensure the well-being, safety and health of all employees and workers by having safety measures within the hospitals for staff and public. We also provide all our employees Annual health check-up as a preventive measure for their health & safety. Further, we undertake risk assessments, safety training (which covers 100% of all employees including non-permanent employees), emergency response procedures such as Fire drills, incident reporting mechanisms and compliance with applicable health and safety regulations. It is aligned with applicable legal and regulatory standards to maintain a safe and compliant working environment.

b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

Our company remains committed to maintaining a safe and healthy working environment through a comprehensive Occupational Health and Safety framework across both clinical and non-clinical areas.

Routine Risk assessment to identify work-related hazards:

- Routine Risk Assessment is periodically being conducted in Clinical & Non-Clinical areas including Wards, ICUs, Laboratories, Waste disposable zones and other operational areas to identify hazards including biological exposure, needle stick injuries, slips and falls, and ergonomic issues from prolonged and standing or patient handling activities.
- Regular inspections are carried out by the Safety officer and departmental supervisors to proactively identify hazards and ensure timely implementation of corrective and preventive measures.
- To promote employee well-being, annual health check-ups are conducted for the on-duty personnel to monitor occupational health and facilitate early identification of potential health concerns.
- We also conduct Periodic fire, chemical spill, and disaster management drills to assess emergency preparedness, strengthen response capabilities and refine protocol during hazardous situations.

Non-Routine Risk assessment to identify work-related hazards:

- A structured incident reporting mechanism is in place to enable employees to report accidents, unsafe conditions, and exposure incidents. All reported incidents are systematically reviewed to identify root causes and prevent recurrence.
- Further, personnel who are assigned to specific tasks such as handling bio-medical waste, administering injections or operating medical equipment, undergo Job safety analysis to identify task-specific risks and ensure appropriate safeguards.
- Continuous training programmes are conducted to enhance employee awareness and compliance with safety practices, including the training on Personal Protective Equipment (PPE) usage, infection control protocols, fire safety, chemical handling and emergency response practices.

c. Whether you have processes for workers to report the work-related hazards and to remove themselves from such risks. (Y/N)

Not applicable as the Company does not have any workers.

d. Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? (Yes/ No)

Yes, the employees of the entity have access to non-occupational medical and health care services through various provisions:

- Our organization provides Mediclaim Insurance coverage for all employees and their dependents (Spouse, Children).
- Employees covered under the ESI scheme are eligible to avail medical benefits as per ESI entitlements.
- An Accident coverage policy is in place for all employees, offering additional protection in case of accidental injuries.
- Employees are also eligible for discounted treatment as per the organization's discount policy, supporting affordability and access to healthcare services.

11. Details of safety related incidents, in the following format:

Safety Incident/Number	Category*	FY 2025-26 Current Financial Year	FY 2024-25 Previous Financial Year
Lost Time Injury Frequency Rate (LTIFR) (per one Million-person hours worked)	Employees	Nil	
	Workers		
Total recordable work-related injuries	Employees		
	Workers		
No. of fatalities	Employees		
	Workers		
High consequence work-related injury or ill-health (excluding fatalities)	Employees		
	Workers		

**Including in the contract workforce*

12. Describe the measures taken by the entity to ensure a safe and healthy work place.

Our organization is continuously committed to providing a safe and healthy workplace for its employees. We have taken several measures to ensure a safe and healthy workplace for all, some of which include:

a) Regular Safety audits and workplace inspections.

b) Provisions of Personal Protective Equipment's (PPE)

c) Periodic Fire and emergency evacuation drills.

d) Employee training on safety, hygiene and emergency response.

e) Regular Annual Checkups and Wellness programs.

f) Accident and Incident reporting with follow-up actions.

g) Safe infrastructure with fire extinguishers and signage.

13. Number of Complaints on the following made by employees and workers:

	FY 2025-26 (Current Financial Year)			FY 2024-25 (Previous Financial Year)		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Working Conditions	Nil					
Health & Safety						

14. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Health and safety practices	100% assessment by NABH and PCB
Working conditions	100% assessment by NABH and PCB

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions – No such incidents occurred.

Leadership Indicators

1. Does the entity extend any life insurance or any compensatory package in the event of death of:

(A) Employees - No

(B) Workers – Not applicable

2. Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners

a) We have obligated our value chain partners to remit the statutory dues and provide proof for the same as part of our contract terms.

b) Value Chain Partners will then submit PF & ESI remittance papers as acknowledgement.

c) We further check the man-days invoice of the value chain partners (for Housekeeping & Security) against soft punching of staff for validating wages payable to them as an additional measure.

3. Provide the number of employees / workers having suffered high consequence work- related injury / ill-health / fatalities (as reported in Q11 of Essential Indicators above), who have been rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment:

	Total no. of affected employees/ workers		No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Employees	0	0	0	0
Workers	NA	NA	NA	NA

4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? **(Yes/ No) – Yes.**

5. Details on assessment of value chain partners:

	% of value chain partners (by value of business done with such partners) that were assessed
Health and safety practices	Nil
Working conditions	

6. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners - Nil

PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders

Essential Indicators

1. **Describe the processes for identifying key stakeholder groups of the entity:**

   Key Stakeholder groups of the Company are identified as the ones:

   1. Who creates a significant impact / influence over the operations of the Company
   2. Who are responsible/ contribute significantly to the value chain of the Company
   3. Who are significantly impacted by the decisions made by the Company
   4. Who are dependent on the Company in any way

   Our Company has identified its Key Stakeholders viz., Customers/Patients, Suppliers/Vendors, regulatory/ governmental bodies, Community, Shareholders/investors, Healthcare professionals and employees, Board of Directors & Management.

2. **List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.**

Stakeholder group	Whether identified as vulnerable & marginalized group	Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / Others – please specify)	Purpose and scope of engagement including key topics and concerns raised during such engagement
Customers/ Patients	No	1. In person consultations 2. Phone calls 3. Emails 4. Social media 5. Website 6. Newspapers 7. Customer satisfaction surveys 8. Kauvery Kare App and other company apps	Throughout the year	1. Patient consultation 2. Providing healthcare / wellness services 3. Feedback 4. Grievance redressal
Employees & Healthcare professionals	No	1. In person meetings 2. Phone calls 3. Emails 4. Social media 5. Website 6. Company Apps 7. Newsletters	Throughout the year	1. Employee connect 2. Training & development 3. Rewards & recognition 4. Appraisals 5. Safety & well-being 6. Feedback 7. Grievance redressal
Suppliers/Vendors	No	1. In person meetings 2. Phone calls 3. Emails 4. Social media 5. Website 6. Contracts/ Agreements	Throughout the year	1. Business purposes 2. Supplier evaluation
Shareholders/ Investors	No	1. Investor meetings/ Investor Presentations 2. Phone calls 3. Emails 4. Social media 5. Website 6. Newspapers 7. Stock exchange communications 8. SCORES platform 9. Annual reports	Quarterly/ Annual	1. Corporate announcements 2. Grievance redressal 3. Update on Company's performance 4. Fundraising 5. Strategic & governance related initiatives
Community	Yes	1. In person meetings 2. Social media 3. Website 4. Stock exchange communications 5. Annual reports 6. Health camps 7. Awareness programmes	Periodically on a need basis	1. Community development & welfare initiatives through CSR 2. Grievance redressal 3. Health camps for providing healthcare benefits to marginalized & vulnerable groups and public in general
Regulatory/ Governmental bodies	No	1. In person meetings 2. Emails 3. Newspapers 4. Stock exchange communications 5. Annual reports 6. Filings and other submissions 7. Website	On a need basis	1. Compliance with legal & regulatory requirements 2. Advocacy & representations
Board of Directors & Management	No	1. Board and committee meetings 2. Management/ other meetings 3. Phone calls 4. Emails 5. Management reports	Throughout the year	1. Discussion on business performance matters 2. Annual operating plan 3. Discussion on Strategic business decisions, industry specific matters, etc. 4. Regulatory updates 5. Updates on stakeholder grievances 6. Review of other important matters

Leadership Indicators

1. **Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.**

   Being in the healthcare sector, the aspects of Economic, Environmental and Social (EES) topics are handled through various departments, and the material events are reported to the Board. A brief flow of the delegated consultation & feedback process is provided below:

   - The respective departments, on an ongoing basis use its interactions with various internal and external stakeholders and considering the regulatory requirements, arrive at significant topics impacting the business of the Company and its values.
   - The material events and stakeholder concerns on the specified topics are reported to the Board/ Committees every quarter for its review and comments.
   - The Board, after review, communicates its comments back to the delegates and the areas of improvement.
   - This process of effective consultation ensures addressing material events on EES topics, while respecting the time valuable of the Board.

2. **Whether stakeholder consultation is used to support the identification and management of environmental, and social topics (Yes / No). If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into policies and activities of the entity.**

   Yes. The Company takes operational and business decisions by considering the views of the concerned departmental heads. The concerned departments provide inputs to the Board based on their structured interactions with various internal and external stakeholders including regulators. The inputs received from these interactions are systematically used to arrive at critical decisions and implement changes conducive to the Company's ESG footprint. This process encourages open participation and ensures corporate decision-making is driven by stakeholder inclusiveness.

3. **Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized stakeholder groups**

   The Company has dealt with the concerns of vulnerable/ marginalized stakeholder groups in the following manner:

   a) Community development & welfare initiatives through CSR

   b) Health camps for providing healthcare benefits to marginalized & vulnerable groups and public in general

   c) 50 days' Class Room Training, Floor Observation, Roll Play, Workshop, Typing Skill, MS Office Skills, etc., to participants from financially challenged Rural background. The entire program is funded by the Company. Selected Participants were given Uniforms & Lunch / Refreshments at free of cost.

   d) Creating awareness among the students (Rural and Urban) for pursuing their higher education through **"Kalvi Vazhikatti"** programmes.

   e) Easily accessible grievance redressal mechanism

PRINCIPLE 5 Businesses should respect and promote human rights

Essential Indicators

1. **Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:**

Category	FY 2025-26 Current Financial Year			FY 2024-25 Previous Financial Year		
	Total (A)	No. of employees / workers covered (B)	% (B / A)	Total (C)	No. of employees / workers covered (D)	% (D / C)
Employees						
Permanent	1695	1695	100%	1573	1573	100%
Other than permanent	47	47	100%	56	56	100%
Total Employees	**1742**	**1742**	**100%**	**1629**	**1629**	**100%**
Workers						
Permanent	Nil					
Other than permanent						
Total Workers						

2. **Details of minimum wages paid to employees and workers, in the following format:**

Category	FY 2025-26 Current Financial Year					FY 2024-25 Previous Financial Year				
	Total (A)	Equal to Minimum Wage		More than Minimum Wage		Total (D)	Equal to Minimum Wage		More than Minimum Wage	
		No. (B)	% (B / A)	No. (C)	% (C / A)		No. (E)	% (E / D)	No. (F)	% (F / D)
Employees										
Permanent	1695	-	-	1695	100%	1573	-	-	1573	100%
Male	371	-	-	371	100%	366	-	-	366	100%
Female	1324	-	-	1324	100%	1207	-	-	1207	100%
Other than permanent	47	-	-	47	100%	56	-	-	56	100%
Male	23	-	-	23	100%	21	-	-	21	100%
Female	24	-	-	24	100%	35	-	-	35	100%
Workers										
Permanent	Nil									
Male										
Female										
Other than Permanent										
Male										
Female										

3. **Details of remuneration/salary/wages**

a. **Median remuneration / wages:**

	Male		Female	
	Number	Median remuneration/ salary/ wages of respective category	Number	Median remuneration/ salary/ wages of respective category
Board of Directors (BoD)	2	84,00,000	NA	-
Key Managerial Personnel	2	1,45,02,422	1	13,24,704
Employees other than BoD and KMP	367	2,94,168	1323	2,91,960
Workers	Nil			

b. Gross wages paid to females as % of total wages paid by the entity, in the following format:

	FY 2025-26 Current Financial Year	FY 2024-25 Previous Financial Year
Gross wages paid to females as % of total wages	64%	63%

4. Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)

Yes. The Human Resource Department is the focal point who is responsible for addressing the human rights or issues caused or contributed to by the Business.

The Company has adopted a Grievance Redressal Policy to develop and maintain an effective, timely, fair and Equitable Grievance handling system which is easily available and offered to all the employees of our Company. A Code of Conduct that outlines the norms, employee Responsibilities and acceptable employee conduct has also been formalized and compliance with the same is mandatory for all employees.

We have a zero tolerance for sexual harassment at workplace. We have constituted Internal complaints committees in accordance with the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 to handle any complaints or concerns with respect to sexual harassment.

Further, we have a Whistle blower policy and Vigil mechanism under the Companies Act, 2013 enabling all Directors/ employees to report in case of any unethical behavior, fraud, or violations happening within the Company.

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

The Company has online HR portal designed for speedy grievance redressal of all the grievances that are reported.

Apart from the online HR portal, the Company has in place strong grievance redressal mechanisms to reduce and resolve complaints and grievances of employees including the ones related to Human Rights.

a. The Company has a whistle blower policy in place and vigil mechanism which provides adequate safeguards against victimization of employees who avail of the vigil mechanism and provide for direct access to the Chairman of the Audit Committee, in exceptional cases.

b. We also have code of conduct and other policies in place that demonstrate the Human Rights of our employees. Some of them amongst others include:

- Policy on Sexual Harassment & Redressal at Work Place
- Policy for Kauvery Employee Grievance Redressal System
- Equal Opportunity Policy
- Policy for Prohibition of Child & Adolescense Labour
- Whistleblower Policy/ Vigil Mechanism
- Workplace Violence Policy
- Policy on Inclusion and Diversity

6. Number of Complaints on the following made by employees and workers:

	FY 2025-26 Current Financial Year			FY 2024-25 Previous Financial Year		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Sexual Harassment						
Discrimination at workplace						
Child Labour						
Forced Labour/Involuntary Labour			Nil			
Wages						
Other human rights related issues						

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

	FY 2025-26 Current Financial Year	FY 2024-25 Previous Financial Year
Total Complaints reported under Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)		
Complaints on POSH as a % of female employees / workers	Nil	
Complaints on POSH upheld		

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

The Company is committed to prohibiting discrimination, retaliation or harassment of any kind against any employee whose reports are concerned and participating in the investigation.

Under our Whistle Blower Policy, complete protection is guaranteed to the Whistle-blowers against any unfair practice, including retaliation, threat or intimidation of termination / suspension of service, disciplinary action, transfer, demotion, refusal of promotion, discrimination, any type of harassment, biased behaviour or the like including any direct or indirect use of authority to obstruct the Whistle-blower's right to continue to perform his / her duties / functions including making further Protected Disclosure.

We have constituted Internal Complaints Committee for redressing the grievances related to POSH at workplace. Any POSH complaint lodged will be taken up by the Committee seriously, investigated thoroughly and provided with appropriate action to the parties concerned. The management and the ICC are committed to safeguarding complainants from exposure to any adverse consequences. We confirm that we have not received any POSH related complaints till date.

A robust Code of Conduct, Prevention of Sexual Harassment (POSH) Policy, and Grievance Redressal Policy are actively in place. The Company strictly ensures in practice that complainant is fully protected from retaliation or threats against any complaint made.

9. Do human rights requirements form part of your business agreements and contracts? - Yes

10. Assessments for the year:

	% of your plants and offices that were assessed (by entity or statutory authorities or third parties
Child labour	
Forced labour	
Sexual harassment	**Others:** We obtained the Great Place to work certification at a Group level after a formal assessment this year.
Discrimination at workplace	
Wages	
Others- please specify	

11. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 10 above – Not applicable

Leadership Indicators

1. Details of a business process being modified / introduced as a result of addressing human rights grievances/complaints.

The Company has till date, not encountered with any such instances or violations, hence the need for modifying policies / processes does not arise.

However, the Company undertakes a regular review of its policies and business processes and updates are made as applicable, in line with regulatory changes or internal requirements. The periodicity of this review is based on the requirement for each policy in line with the regulatory requirements. Accordingly, the business processes, wherever feasible, are modified to the extent necessary, whenever there is a revision in the Policies.

2. Details of the scope and coverage of any Human rights due-diligence conducted – Nil.

3. Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

Yes, all premises and offices are accessible to differently abled visitors with all the necessary features for their safety embedded, as detailed in the answer to Question 3 of Principle 3 of this report.

4. Details on assessment of value chain partners:

	% of value chain partners (by value of business done with such partners) that were assessed
Sexual Harassment	Nil
Discrimination at workplace	Nil
Child Labour	Nil
Forced Labour/Involuntary Labour	Nil
Wages	Nil
Others – please specify	Nil

5. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 4 above – Not applicable.

PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment

Essential Indicators

1. Details of total energy consumption (in Mega Joules) and energy intensity, in the following format:

Parameter	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
From renewable sources		
Total electricity consumption (A)	15146643.60	13556937.60
Total fuel consumption (B)	0	0
Energy consumption through other sources (C)	0	0
Total energy consumed from renewable sources (A+B+C)	15146643.60	13556937.60
From non-renewable sources		
Total electricity consumption (D)	794642.40	3657211.2
Total fuel consumption (E)	0	0
Energy consumption through sources other (F)	520059.60	243619
Total energy consumed from non- renewable sources (D+E+F)	1314702.00	3900830
Total energy consumed (A+B+C+D+E+F)	16461345.60	17457768
Energy intensity per rupee of turnover (Total energy consumed / Revenue from operations) (MJ /Rupee in Lakh)	538.36	753.79
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total energy consumed / Revenue from operations adjusted for PPP)	10950.25	15573.45
Energy intensity in terms of physical Output (per occupied bed days)	0.51	2.98
Energy intensity (optional) – the relevant metric may be selected by the entity	NA	NA

The Revenue from operations has been adjusted according to the latest PPP conversion factors for India, as published by the International Monetary Fund. The conversion factor for the year ended, March 31, 2026, is 20.34 while for the year ended March 31, 2025, it is 20.66.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency - No

2. Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any – Not applicable

3. Provide details of the following disclosures related to water, in the following format:

Parameter	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Water withdrawal by source (in kilolitres)		
(i) Surface water	0	58144
(ii) Groundwater	208251	31117
(iii) Third party water	17417	16274
(iv) Seawater / desalinated water	0	0
(v) Others	0	0
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)	225668	105535
Total volume of water consumption (in kilolitres)	225668	105535
Water intensity per rupee of turnover (Total water consumption / Revenue from operations) (Kilolitres/Rupee in Lakhs)	7.38	4.55
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total water consumption / Revenue from operations adjusted for PPP)	150.12	107.38
Water intensity in terms of physical Output (per occupied bed days)	7.02	20.54
Water intensity (optional) – the relevant metric may be selected by the entity	NA	NA

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency - Yes, ABC techno labs India Private Limited.

4. Provide the following details related to water discharged:

Parameter	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Water discharge by destination and level of treatment (in kilolitres)		
(i) To Surface water	Nil	Nil
· No treatment		
· With treatment – please specify level of treatment		
(ii) To Groundwater	Nil	Nil
· No treatment		
· With treatment – please specify level of treatment		

Parameter	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
(iii) To Seawater	Nil	Nil
· No treatment		
· With treatment – please specify level of treatment		
(iv) Sent to third parties	Nil	Nil
· No treatment		
· With treatment – please specify level of treatment		
(v) Others	33776	35974
· No treatment	Nil	Nil
· With treatment – please specify level of treatment	33776	35974
Total water discharged (in kilolitres)	33776	35974

Water discharge quality from our facilities adheres to regulatory requirements as notified by State Pollution Control Boards. Water discharge done through Sewage Treatment plant is being reused for Garden watering and flushing purposes.

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency - Yes, ABC techno labs India Private Limited.

5. **Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation -** No

6. **Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:**

Parameter	Please specify unit	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
NOx	g/kw-hr	1.28*	37.6
SOx	mg/Nm^3	10*	16.51
Particulate matter (PM)	g/kw-hr	0.099*	109.8
Persistent organic pollutants (POP)	NA	NA	NA
Volatile organic compounds (VOC)	NA	NA	NA
Hazardous air pollutants (HAP)	NA	NA	NA
Others – please specify	NA	NA	NA

**The significant difference in data from previous year is due to the current year data being expressed by a different unit compared to last year (g/m^3). This is in line with the reports of the external agency.*

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency – yes, ABC techno labs India Private Limited.

7. **Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:**

Parameter	Unit	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Total Scope 1 emissions (Break-up of the GHG into CO_2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	tC02e	Nil	Nil
Total Scope 2 emissions (Break-up of the GHG into CO_2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	tC02e	292 t/Kwhr	580 t/Kwhr
Total Scope 1 and Scope 2 emission intensity per rupee of turnover (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations)	tC02e/Rs.	0	0
Total Scope 1 and Scope 2 emission intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total Scope 1 and Scope 2 GHG emissions / Revenue from operations adjusted for PPP)	tC02e/Rs. adjusted for PPP	0.19	0
Total Scope 1 and Scope 2 emission intensity in terms of physical output (per occupied bed days)	tC02e/bed occupied days	0	0
Total Scope 1 and Scope 2 emission intensity (optional) – the relevant metric may be selected by the entity	NA	NA	NA

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency - yes, ABC techno labs India Private Limited.

8. **Does the entity have any project related to reducing Green House Gas emission? If yes, then provide details –** None in the reporting year.

9. **Provide details related to waste management by the entity, in the following format:**

Parameter	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Total Waste generated (in metric tonnes)		
Plastic waste **(A)**	148	72
E-waste **(B)**	6	0
Bio-medical waste **(C)**	98	60.34
Construction and demolition waste **(D)**	91	139
Battery waste **(E)**	0	0
Radioactive waste **(F)**	0	0
Other Hazardous waste. Please specify, if any. **(G)**	0	0
Other non-hazardous waste generated **(H).** Please specify, if any. (Break-up by composition i.e. by materials relevant to the sector)	0	0
Total (A+B + C + D + E + F + G + H)	343	271.34
Waste intensity per rupee of turnover (Total waste generated / Revenue from operations) (Metric tonnes/Rupee in Lakhs)	0.011	0.011
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total waste generated / Revenue from operations adjusted for PPP)	0.228	0.242
Waste intensity in terms of physical output (per occupied bed days)	0	0.046
Waste intensity (optional) – the relevant metric may be selected by the entity	NA	NA
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)		
Category of waste		
(i) Recycled	Nil	Nil
(ii) Re-used	Nil	Nil
(iii) Other recovery operations	Nil	Nil
Total		
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)		
Category of waste		
(i) Incineration	Nil	Nil
(ii) Landfilling	91	139
(iii) Other disposal operations	148	Nil
Total	**239**	**139**

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency – No.

10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such waste.

Our Company has adopted an efficient waste management practice separately for general and Bio-medical wastes:

General Waste

(i) Includes non-hazardous, biodegradable, and non-biodegradable waste.

(ii) Segregated into green (biodegradable) and blue (non-biodegradable) bin covers at designated collection points.

(iii) For paper waste, we monitor paper usage through software called PaperCut and use Power BI to generate detailed reports for tracking and analyzing paper consumption and assess our progress in reducing the usage of papers.

Solid Waste

(i) All the solid general wastes are being sent to the common treatment facility located in Kondayampettai near Tiruvanai Kovil area, segregated into biodegradable and non-bio degradable waste.

(ii) While Bio-degradable wastes are processed through eco-friendly methods, the non-bio degradable wastes are segregated separately and sent to authorized cement factories for recycling and co-processing, ensuring safe and sustainable waste management.

Biomedical Waste (BMW)

(i) Handled safely following the Biomedical Waste Management Act.

(ii) Segregated using color-coded waste disposal bags and bins in all patient care areas.

(iii) Monitored daily by HIC nurses, HIC link nurses, and housekeeping supervisors.

(iv) Segregated in the hospital premises as per the Bio Medical Waste management rules recommended by the Pollution Control Board, transported and disposed through authorized Common Treatment Facility – Medicare Enviro Systems.

Waste Segregation & Handling

(i) Color-coded segregation is strictly followed in all patient care areas.

(ii) Appropriately coded waste bags are placed in designated bins.

(iii) Microbiology & Biotechnology waste is autoclaved before being sent for treatment.

(iv) Used and unused sharps are disinfected before disposal.

Waste Storage & Transportation

(i) Segregated biomedical waste is stored in a central waste collection area.

(ii) Waste is transported using covered containers to ensure secure handling.

(iii) General and biomedical waste is collected and transferred to Kauvery Hospital's integrated general waste treatment facility in Tiruvanai Kovil.

(iv) Waste is transported daily using a specialized vehicle designated for this purpose.

Treatment & Disposal

Hospital has signed MoUs with TNPCB authorized vendors for transportation and disposal of bio medical waste. The hospital visits the disposal site once in 6 months to ensure proper disposal methods are followed.

Compliance & Monitoring

(i) Hospital has obtained consent to operate under the pollution control board.

(ii) Waste management practices are monitored regularly by designated staff.

(iii) Adherence to government regulations and hospital policy ensures safety and environmental sustainability.

Strategy adopted by the entity to reduce usage of hazardous and toxic chemicals:

(i) We are shifting to biodegradable and non-toxic disinfectants to reduce chemical exposure to patients and staff.

(ii) We are using latex-free gloves, mercury-free thermometers which help reduce toxic substances in medical processes.

(iii) The hospital is classifying waste into plastic, hazardous, non-hazardous, bio medical and recyclable materials, ensuring safe handling and disposal of harmful substances.

(iv) Expired or unused drugs are returned to suppliers following strict protocols to prevent contamination of water sources.

(v) Advanced filtration and treatment methods help remove harmful chemicals from hospital wastewater before it enters public water supplies through STP & ETP

(vi) Staff are educated on best practices for reducing toxic waste, ensuring compliance with environmental safety regulations.

(vii) BPA-free, recyclable, and biodegradable plastics are being used to minimize environmental impact while maintaining hygiene standards in hospital canteen.

(viii) Reduction of Single use paper cups and plates in the office area.

(ix) Encouraging Paperless & digital communication with the help of departments like digital strategy. Streamlining of paperless registration through QR Code.

11. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required, please specify details in the following format:

S. No.	Location of operations/ offices	Type of operations	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
Not applicable.			

12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

Name and brief details of project	EIA Notification No.	Date	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
None for the reporting period.					

13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:

Yes. The Company is in compliance with applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder.

S. No.	Specify the law / regulation / guidelines which was not complied with	Provide details of the non-compliance	Any fines / penalties / action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any
NIL				

Leadership Indicators

1. Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):

For each facility / plant located in areas of water stress, provide the following information:

(i) Name of the area - NA

(ii) Nature of operations - NA

(iii) Water withdrawal, consumption and discharge in the following format:

Parameter	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Water withdrawal by source (in kilolitres)		
(i) Surface water	NA, as none of our units are located in water stress areas.	
(ii) Groundwater		
(iii) Third party water		
(iv) Seawater / desalinated water		
(v) Others		
Total volume of water withdrawal (in kilolitres)		
Total volume of water consumption (in kilolitres)		
Water intensity per rupee of turnover (Water consumed / turnover)		
Water intensity (optional) – the relevant metric may be selected by the entity		
Water discharge by destination and level of treatment (in kilolitres)		
(i) Into Surface water	NA, as none of our units are located in water stress areas.	
• No treatment		
• With treatment – please specify level of treatment		
(ii) Into Groundwater		
• No treatment		
• With treatment – please specify level of treatment		
(iii) Into Seawater		
• No treatment		
• With treatment – please specify level of treatment		
(iv) Sent to third-parties		
• No treatment		
• With treatment – please specify level of treatment		
(v) Others		
• No treatment		
• With treatment – please specify level of treatment		
Total water discharged (in kilolitres)		

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency – No.

2. Please provide details of total Scope 3 emissions & its intensity, in the following format:

Parameter	Unit	FY 2025-26 (Current Financial Year)	FY 2024-25 (Previous Financial Year)
Total Scope 3 emissions (Break-up of the GHG into CO_2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	Metric tonnes of CO_2 equivalent	Nil	
Total Scope 3 emissions per rupee of turnover			
Total Scope 3 emission intensity (optional) – the relevant metric may be selected by the entity			

Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency – No.

3. With respect to the ecologically sensitive areas reported at Question 11 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities – Not applicable.

4. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:

Sr. No	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative
None for the reporting year			

5. Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web link.

Yes. The Company is committed to ensuring uninterrupted delivery of critical healthcare services and in safeguarding the patients, employees, infrastructure and information assets of the Company during emergencies. The Risk Management Committee of the Company reviews Business continuity and disaster management and monitors financial, operational, legal, sectoral, sustainability (ESG related risks) information, cyber security risk etc. The Company also has Contingency Plan and comprehensive Business Continuity and Disaster Management Plan in place, specifically designed to address data recovery. The Company also conducts Periodic fire, chemical spill, and disaster management drills to assess emergency preparedness, strengthen response capabilities and refine protocol during hazardous situations. The Company also coordinates with various regulatory authorities, emergency service providers and key stakeholders to ensure effective response during crisis situations.

Through continuous monitoring and regular review of the risk control measures, the company seeks to maximize operational disruptions, protect stakeholder interests and maintain high standards of patient care under all circumstances.

6. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard – None for the Reporting period.

7. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts - None for the Reporting period.

8. How many Green Credits have been generated or procured:

a. By the listed entity – Nil. However, as part of our commitment to sustainable infrastructure, the entity successfully obtained a "LEED Silver rating" certification from the U.S. Green Building Council (USGBC) for Maa Kauvery Unit during the year.

b. By the top ten (in terms of value of purchases and sales, respectively) value chain partners - Nil

PRINCIPLE 7 Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

Essential Indicators

1. a. **Number of affiliations with trade and industry chambers/ associations** - 6

   b. **List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to.**

S. No.	Name of the trade and industry chambers/ associations	Reach of trade and industry chambers/ associations (State/ National)
1	National Human Resources	National
2	Bouncing Board	State
3	Madras Management Association	State
4	Confederation of Indian Industry (CII)	National
5	Federation of Indian Chambers of Commerce and Industry (FICCI)	National
6	Tamil Nadu Chamber of Commerce and Industry (TCCI)	State

2. **Provide details of corrective action taken or underway on any issues related to anti- competitive conduct by the entity, based on adverse orders from regulatory authorities.**

Name of authority	Brief of the case	Corrective action taken
Not applicable		

Leadership Indicators

1. **Details of public policy positions advocated by the entity:**

S. No.	Public policy advocated	Method resorted for such advocacy	Whether information is available in public domain? (Y/N)	Frequency of Review by Board (Annually/ Half-yearly/ Quarterly/ Others – Please specify)	Web link, if available
None for the reporting period					

PRINCIPLE 8 Businesses should promote inclusive growth and equitable development

Essential Indicators

1. **Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.**

Name and brief details of project	SIA Notification No.	Date of notification	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
Nil					

2. **Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:**

S. No.	Name of Project for which R&R is ongoing	State	District	No. of Project Affected Families (PAFs)	% of PAFs covered by R&R	Amounts paid to PAFs in the FY (In Rs.)
NA						

3. **Describe the mechanisms to receive and redress grievances of the community**

   The Company has mechanisms to receive and redress grievances received from the community.

   For Shareholders, grievances can be lodged through the SCORES platform under the SEBI guidelines. Shareholders can also access the company secretary's email id displayed in the Company's website for any queries/ complaints.

For Directors and employees, genuine grievances can be lodged through the whistle blowers' email id displayed in the company's website to report any complaint related to any unethical behavior, fraud, or violations happening within the Company.

Both the above grievances will be taken up by the company and reviewed by the committees every quarter.

For employees, we have an internal policy and process to resolve the grievances raised by them as detailed in point 6 of Principle 3 of this report.

For the general public, grievances can be lodged and accessed at https://www.kauveryhospital.com/contact-us/

The Company periodically reviews the grievance redressing process to identify any areas for further improvement.

4. **Percentage of input material (inputs to total inputs by value) sourced from suppliers:**

	FY 2025-26 Current Financial Year	FY 2024-25 Previous Financial Year
Directly sourced from MSMEs/ small producers	17%	15%
Directly from within India	100%	100%

5. **Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost**

Location	FY 2025-26 Current Financial Year	FY 2024-25 Previous Financial Year
Rural	30%	30%
Semi-urban	25%	25%
Urban	25%	25%
Metropolitan	20%	20%

Leadership Indicators

1. **Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments (Reference: Question 1 of Essential Indicators above):**

Details of negative impacts identified	Corrective action taken
Nil	

2. **Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies:**

S. No.	State	Aspirational District	Amount allocated (In Rs.)
Nil			

3. (a) **Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized /vulnerable groups? (Yes/No)** - No

   (b) **From which marginalized /vulnerable groups do you procure?** – None

   (c) **What percentage of total procurement (by value) does it constitute?** – None

4. **Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge:**

S. No	Intellectual property based on traditional knowledge	Owned/ Acquired (yes/No)	Benefit shared (Yes/ No)	Basis of calculating benefit share
Nil				

5. **Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes wherein usage of traditional knowledge is involved.**

Name of the authority	Brief of the case	Corrective action taken
	Nil	

6. **Details of beneficiaries of CSR Projects:**

S. No.	CSR Project	No. of persons benefitted from CSR Projects	% of beneficiaries from vulnerable and marginalized groups
1	Building Infrastructure for Educational Institution through Kauvery Foundation	NA, since it is an ongoing project	NA, since it is an ongoing project

PRINCIPLE 9 Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators

1. **Describe the mechanisms in place to receive and respond to consumer complaints and feedback.**

Our organization has established a comprehensive and responsive system to ensure that patient complaints and feedback are addressed promptly and effectively.

Google Reviews: Patients and their families can share their experiences and concerns through google reviews. These reviews are monitored regularly to identify areas of improvement and responded appropriately.

Floor – Frontline coordinator & Voice of Patient: We have designated frontline coordinators on each floor who engage directly with patients to collect real-time feedback. They are trained to listen empathetically, document concerns and initiate immediate redressal measures wherever possible.

24/7 Patient Support Platform: A dedicated 24/7 platform is available for patients to raise complaints and share their requirements at any time. This system ensures that all issues are logged, tracked and resolved in a timely manner with transparency and accountability.

2. **Turnover of products and/ services as a percentage of turnover from all products/service that carry information about:**

	As a percentage to total turnover
Environmental and social parameters relevant to the product	Not applicable
Safe and responsible usage	
Recycling and/or safe disposal	

3. **Number of consumer complaints in respect of the following:**

	FY 2025-26 (Current Financial Year)		Remarks	FY 2024-25 (Previous Financial Year)		Remarks
	Received during the year	Pending resolution at end of year		Received during the year	Pending resolution at end of year	
Data privacy	Nil	Nil	-	Nil	Nil	-
Advertising	Nil	Nil	-	Nil	Nil	-
Cyber-security	Nil	Nil	-	Nil	Nil	-
Delivery of essential services	1955	Nil	-	1538	Nil	-
Restrictive Trade Practices	Nil	Nil	No trade associated complaints received from Govt/Public	Nil	Nil	No trade associated complaints received from Govt/Public
Unfair Trade Practices	Nil	Nil		Nil	Nil	
Other	Nil	Nil	-	Nil	Nil	-

**Note: The Complaints include feedback also. All complaints and feedback were resolved during the FY*

4. **Details of instances of product recalls on account of safety issues:**

	Number	Reasons for recall
Voluntary recalls	Nil	
Forced recalls		

4. **Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/ No)** If available, provide a web-link of the policy – Yes. The entity has comprehensive data privacy and cyber security framework covering patient health information. Link to the Privacy Policy: https://www.kauveryhospital.com/privacy/

5. **Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services –** Not applicable.

7. **Provide the following information relating to data breaches:**

a. **Number of instances of data breaches -** Nil

b. **Percentage of data breaches involving personally identifiable information of customers -** Nil

c. **Impact, if any, of the data breaches -** No instances of data breaches were reported during the reporting period; hence, there was no material impact on patient data, operations, or financial performance.

Leadership Indicators

1. **Channels / platforms where information on products and services of the entity can be accessed (provide web link, if available)**

Company's website: www.kauveryhospital.com

2. **Steps taken to inform and educate consumers about safe and responsible usage of products and/ or services –**

a) Before undergoing any treatment in our hospitals, the patients are duly informed about the details of treatment proposed to be undergone.

b) Consent forms are obtained wherever necessary from the Patients before proceeding with the treatment.

c) Patients are also informed of the precautions and manner of usage of medicines while prescribing them by the Doctors.

3. **Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services**

Our company, being in the healthcare sector, is available 24X7 to the needs of the patients and ensures that there is no discontinuation/disruption of services. However, if there are any such events, it will be informed to the public via social media, Notice Boards, etc.

4. **Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable) If yes, provide details in brief –** Not applicable, as company is in healthcare service sector.

5. **Did your entity carry out any survey with regard to consumer satisfaction relating to the major products / services of the entity, significant locations of operation of the entity or the entity as a whole? (Yes/No)**

Yes, we have a patient feedback mechanism to carry out surveys with regard to customer satisfaction.

INDEPENDENT AUDITOR'S REPORT

To The Members of KMC Speciality Hospitals (India) Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of **KMC Speciality Hospitals (India) Limited** (the "Company"), which comprise the Balance Sheet as at March 31, 2026, and the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Cash Flows and the Statement of Changes in Equity for the year ended on that date, and notes to the financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, its profit and other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing ("SA"s) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. We have determined that there are no key audit matters to communicate in our report.

Information Other than the Financial Statements and Auditor's Report Thereon

- The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board of Director's Report including Annexures to Board of Director's report, Management Discussion and Analysis, Business Responsibility and Sustainability Report and Corporate Governance Report but does not include the financial statements and our auditor's report thereon.
- Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
- In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.
- If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Board of Directors for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income / (loss), cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including Ind AS specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Company's Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal financial controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:

    a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

    b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

    c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive income, the Statement of Cash Flows and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account.

d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.

e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164(2) of the Act.

f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to financial statements.

g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended,

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position.

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

iv. (a) The Management has represented that, to the best of its knowledge and belief, other than as disclosed in the note 44(d) to the financial statements no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The Management has represented, that, to the best of its knowledge and belief, other than as disclosed in the note 44(e) to the financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

v. The Company has not declared or paid any dividend during the year and has not proposed final dividend for the year.

vi. Based on our examination, which included test checks, the Company has used accounting software systems for maintaining its books of account for the financial year ended March 31, 2026 which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software systems. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with and the audit trail has been preserved by the Company as per the statutory requirements for record retention.

2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)

Rekha Bai
Partner
(Membership No. 214161)
(UDIN: 26214161ZMPZDG7888)

Place: Colombo, Sri Lanka
Date: May 29, 2026

ANNEXURE “A” TO THE INDEPENDENT AUDITOR’S REPORT

(Referred to in paragraph 1(f) under ‘Report on Other Legal and Regulatory Requirements’ section of our report of even date)

Report on the Internal Financial Controls with reference to financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (the “Act”)

We have audited the internal financial controls with reference to financial statements of **KMC Speciality Hospitals (India) Limited** (the “Company”) as at March 31, 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management’s and Board of Directors’ Responsibilities for Internal Financial Controls

The Company’s management and Board of Directors are responsible for establishing and maintaining internal financial controls with reference to financial statements based on the internal control with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor’s Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls with reference to financial statements.

Meaning of Internal Financial Controls with reference to financial statements

A Company's internal financial control with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to financial statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial control with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at March 31, 2026, based on the criteria for internal financial control with reference to financial statements established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **Deloitte Haskins & Sells**
Chartered Accountanats
(Firm's Registration No. 008072S)

Rekha Bai
Partner
(Membership No. 214161)
(UDIN: 26214161ZMPZDG7888)

Place: Colombo, Sri Lanka
Date: May 29, 2026

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in Paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

(i) In respect of Company's Property, Plant and Equipment and Intangible Assets:

(a) (i) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment, investment properties and relevant details of right-of-use assets.

(ii) The Company has maintained proper records showing full particulars of Intangible Assets.

(b) The Company has a program of verification of property, plant and equipment, so to cover all the items once every two years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, no such assets were due for physical verification during the year. Since no physical verification of property, plant and equipment was due during the year the question of reporting on material discrepancies noted on verification does not arise.

(c) Based on the examination of the registered sale deed provided to us, we report that, the title deeds of all the immovable properties of land and buildings (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the Company) disclosed in the financial statements included in property, plant and equipment, and investment properties are held in the name of the Company as at the balance sheet date. Immovable properties of land and buildings whose title deeds have been pledged as security for loans etc., are held in the name of the Company based on the confirmations directly received by us from lenders.

(d) The Company has not revalued any of its property, plant and equipment (including Right-of-Use assets) and intangible assets during the year.

(e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2026 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.

(ii) (a) The inventories were physically verified during the year by the Management at reasonable intervals. In our opinion and according to the information and explanations given to us, the coverage and procedure of such verification by the Management is appropriate having regard to the size of the Company and the nature of its operations. No discrepancies of 10% or more in the aggregate for each class of inventories were noticed on such physical verification of inventories when compared with books of account.

(b) According to the information and explanations given to us, at any point of time of the year, the Company has not been sanctioned any working capital facility from banks or financial institutions and hence reporting under clause (ii)(b) of the Order is not applicable.

(iii) The Company has made investments in, provided guarantee to companies during the year, in respect of which:

(a) The Company has stood guarantee during the year and details of which are given below:

Particulars	Guarantees (Amount in Rs. Lakhs)
Aggregate amount granted / provided during the year:	
Sri Kauvery Medical Care (India) Limited (Holding Company)	9,857.21
Balance outstanding as at balance sheet date in respect of above cases:	
Sri Kauvery Medical Care (India) Limited (Holding Company)	9,857.21

(b) The investments made, guarantees provided, and the terms and conditions of the guarantees provided, during the year are, in our opinion, prima facie, not prejudicial to the Company's interest.

(c) The Company has not provided any loans or advances in the nature of loans, or provided security to any other entity during the year, and hence reporting under clause (iii)(c) to (f) of the Order is not applicable.

(iv) The Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of loans granted, investments made and guarantees and securities provided, as applicable.

(v) The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, reporting under clause (v) of the Order is not applicable.

(vi) The maintenance of cost records has been specified by the Central Government under section 148(1) of the Companies Act, 2013. We have broadly reviewed the books of account maintained by the Company pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended, prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Companies Act, 2013, and are of the opinion that, prima facie, the prescribed cost records have been made and maintained by the Company. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.

(vii) According to the information and explanations given to us in respect of statutory dues:

(a) Undisputed statutory dues, including Goods and Service tax, Provident Fund, Employees' State Insurance, Income-tax, duty of Custom, cess and other material statutory dues applicable to the Company have generally been regularly deposited by it with the appropriate authorities though there has been a delay in respect of remittance of Provident Fund, Employees' State Insurance and Income-tax dues.

There were no undisputed amounts payable in respect of Goods and Services Tax, Employees' State Insurance, Provident Fund, Income-tax, duty of custom, cess and other material statutory dues in arrears as at March 31, 2026 for a period of more than six months from the date they became payable.

(b) Details of Statutory dues referred to in sub-clause (a) above which have not been deposited as on March 31, 2026 on account of disputes are given below:

Name of the Statute	Nature of the dues	Amount involved (Rs. Lakhs)	Amount unpaid (Rs. Lakhs)#	Period to which the amount relates	Forum where disputes is pending
Central Goods and Service Tax Act, 2017	Goods and Services Tax	73.56	58.85	2017-2018	The Deputy Commissioner (appeals)
Central Goods and Service Tax Act, 2017	Goods and Services Tax	21.65	19.48	2017-2019	The Deputy Commissioner (appeals)
Central Goods and Service Tax Act, 2017	Goods and Services Tax	81.28	73.15	2018-2019	The Joint Commissioner (appeals)
Central Goods and Service Tax Act, 2017	Goods and Services Tax	22.66	20.39	2019-2020	The Deputy Commissioner (appeals)
Central Goods and Service Tax Act, 2017	Goods and Services Tax	7.87	7.08	2020-2021	The Joint Commissioner (appeals)
Central Goods and Service Tax Act, 2017	Goods and Services Tax	10.07	9.06	2021-2022	The Joint Commissioner (appeals)
Central Goods and Service Tax Act, 2017	Goods and Services Tax	11.15	10.04	2022-2023	The Joint Commissioner (appeals)
Central Goods and Service Tax Act, 2017	Goods and Services Tax	10.07	9.06	2023-2024	The Joint Commissioner (appeals)

#The amount unpaid is net of amount deposited under protest amounting to Rs. 31.19 Lakhs as at March 31, 2026.

**The above does not include interest, penalties and show cause notices pending formal demands received by the company.*

(viii) There were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income tax Act, 1961 (43 of 1961) during the year.

(ix) (a) In our opinion, the Company has not defaulted in the repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year.

(b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

(c) To the best of our knowledge and belief, in our opinion, term loans availed by the Company were, applied by the Company during the year for the purposes for which the loans were obtained.

(d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie not been used during the year for long-term purposes by the Company.

(e) The Company did not have any subsidiary or associate or joint venture during the year and hence, reporting under clause (ix)(e) and (ix)(f) of the Order is not applicable.

(x) (a) The Company has not issued any of its securities (including debt instruments) during the year and hence reporting under clause (x)(a) of the Order is not applicable.

(b) During the year the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause (x)(b) of the Order is not applicable to the Company.

(xi) (a) To the best of our knowledge, no fraud by the Company and no material fraud on the Company has been noticed or reported during the year.

(b) To the best of our knowledge, no report under sub-section (12) of section 143 of the Companies Act, 2013 has been filed in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.

(c) As represented to us by the Management, there were no whistle blower complaints received by the Company during the year.

(xii) The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.

(xiii) In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the financial statements etc. as required by the applicable accounting standards.

(xiv) (a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.

(b) We have considered, the internal audit reports issued to the Company during the year and covering the period upto December 31, 2025 and the draft of the internal audit report were issued after the balance sheet date covering the period from January 1, 2026 to March 31, 2026, for the period under audit.

(xv) In our opinion, during the year, the Company has not entered into any non-cash transactions with any of its directors or persons connected with such directors and hence provision of section 192 of the Companies Act, 2013 are not applicable to the Company.

(xvi) (a) (b) (c) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause (xvi)(a), (b) and (c) of the Order is not applicable.

(d) The Group does not have any Core Investment Company as part of the group and accordingly reporting under clause (xvi)(d) of the Order is not applicable.

(xvii) The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.

(xviii) There has been no resignation of the statutory auditors of the Company during the year.

(xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

(xx) The Company has fully spent the required amount towards Corporate Social Responsibility (CSR) and there are no unspent CSR amount for the year requiring a transfer to a Fund specified in Schedule VII to the Companies Act or special account in compliance with the provision of sub-section (6) of section 135 of the said Act. Accordingly, reporting under clause (xx) of the Order is not applicable for the year.

(xxi) The Company does not have any requirement to prepare consolidated financial statements and hence reporting under clause (xxi) of the Order is not applicable for the year.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No. 008072S)

Rekha Bai
Partner
(Membership No. 214161)
(UDIN: 26214161ZMPZDG7888)

Place: Colombo, Sri Lanka
Date: May 29, 2026

BALANCE SHEET

as at March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

Particulars	Note	As at March 31, 2026	As at March 31, 2025
A Assets			
1 Non-current assets			
(a) Property, plant and equipment	4	23,509.94	23,968.63
(b) Right-of-use assets	5	1,233.84	756.26
(c) Investment property	6	40.43	40.43
(d) Other intangible assets	7	2.62	4.41
(e) Financial assets			
(i) Investments	8	0.72	0.38
(ii) Other financial assets	9	266.82	250.70
(f) Income tax assets (net)	11	-	238.46
(g) Other non-current assets	12	36.65	16.45
Sub-total - Non-current assets		**25,091.02**	**25,275.72**
2 Current assets			
(a) Inventories	13	387.93	350.21
(b) Financial assets			
(i) Trade receivables	14	735.31	597.85
(ii) Cash and cash equivalents	15	5,002.07	919.04
(iii) Bank balances other than cash and cash equivalents above	16	467.19	15.06
(iv) Loans	17	29.34	25.97
(v) Other financial assets	9	1,198.04	1,263.70
(c) Other current assets	12	300.86	152.31
Sub-total - Current assets		**8,120.74**	**3,324.14**
Total - Assets		**33,211.76**	**28,599.86**
B Equity and liabilities			
1 Equity			
(a) Equity share capital	18	1,630.85	1,630.85
(b) Other equity	19	19,412.02	14,802.24
Sub-total - Equity		**21,042.87**	**16,433.09**
Liabilities			
2 Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	22	6,142.97	7,232.67
(ii) Lease liabilities	23	978.03	552.09
(iii) Other financial liabilities	27	36.73	10.36
(b) Provisions	24	399.92	249.69
(c) Deferred tax liabilities (net)	10	344.15	327.90
Sub-total - Non-current liabilities		**7,901.80**	**8,372.71**
3 Current liabilities			
(a) Financial liabilities			
(i) Borrowings	22	960.00	960.00
(ia) Lease liabilities	23	286.64	199.99
(ii) Trade payables			
· Total outstanding dues of micro enterprises and small enterprises	26	101.67	246.16
· Total outstanding dues of creditors other than micro enterprises and small enterprises	26	910.21	1,162.18
(iii) Other financial liabilities	27	605.58	558.27
(b) Other current liabilities	25	626.39	421.31
(c) Provisions	24	297.59	246.15
(d) Current tax liabilities (net)	11	479.01	-
Sub-total - Current liabilities		**4,267.09**	**3,794.06**
Total - Liabilities		**12,168.89**	**12,166.77**
Total - Equity and liabilities		**33,211.76**	**28,599.86**

See accompanying notes forming part of the financial statements

In terms of our report attached

for **Deloitte Haskins & Sells**
Chartered Accountants
Firm's registration No. 008072S

for and on behalf of the board of directors of
KMC Speciality Hospitals (India) Limited
CIN: L85110TN1982PLC009781

Rekha Bai
Partner
Membership No. 214161

Dr. S. Manivannan
Managing Director
DIN: 00910804

Dr. S. Chandrakumar
Executive Chairman (Whole-Time)
DIN: 01867847

K. Anand Babu
Chief Financial Officer

Indumathi P
Company Secretary

Place: Colombo, Sri Lanka
Date: May 29, 2026

Place: Chennai
Date: May 29, 2026

STATEMENT OF PROFIT AND LOSS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

Particulars	Note	For the year ended March 31, 2026	For the year ended March 31, 2025
Income			
a) Revenue from operations	29	30,576.82	23,159.76
b) Other income	30	507.59	308.64
Total income		**31,084.41**	**23,468.40**
Expenses			
a) Cost of materials consumed	31	1,464.19	991.15
b) Purchases of stock-in-trade	32	3,062.04	2,453.14
c) Changes in inventories of stock-in-trade	33	(25.12)	(76.64)
d) Employee benefits expense	34	6,581.43	5,189.02
e) Finance costs	35	830.73	941.59
f) Depreciation and amortisation expense	36	2,167.09	1,895.25
g) Other expenses	37	10,701.69	8,914.55
Total expenses		**24,782.05**	**20,308.06**
Profit before tax		**6,302.36**	**3,160.34**
Tax expense	10		
a) Current tax (including prior years)		1,591.25	730.79
b) Deferred tax		37.67	286.84
Total tax expense		**1,628.92**	**1,017.63**
Profit for the year		**4,673.44**	**2,142.71**
Other comprehensive income/(loss)	10		
Items that will not be reclassified subsequently to profit / (loss)			
a) Re-measurement of defined benefit plans (net)		(85.08)	(90.32)
b) Income tax relating to items that will not be reclassified to profit or loss		21.42	22.73
Total other comprehensive income/(loss), net of tax		**(63.66)**	**(67.59)**
Total comprehensive income		**4,609.78**	**2,075.12**
Earnings per share (Equity shares of nominal value of Rupee 1 each)	21		
Basic		2.87	1.31
Diluted		2.87	1.31

See accompanying notes forming part of the financial statements

In terms of our report attached

for **Deloitte Haskins & Sells**
Chartered Accountants
Firm's registration No. 008072S

for and on behalf of the board of directors of
KMC Speciality Hospitals (India) Limited
CIN: L85110TN1982PLC009781

Rekha Bai
Partner
Membership No. 214161

Dr. S. Manivannan
Managing Director
DIN: 00910804

Dr. S. Chandrakumar
Executive Chairman (Whole-Time)
DIN: 01867847

K. Anand Babu
Chief Financial Officer

Indumathi P
Company Secretary

Place: Colombo, Sri Lanka
Date: May 29, 2026

Place: Chennai
Date: May 29, 2026

STATEMENT OF CASH FLOWS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

	Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
A	**Cash flows from operating activities**		
	Profit before tax	**6,302.36**	**3,160.34**
	Adjustments:		
	Depreciation and amortisation expense	2,167.09	1,895.25
	Provision for loss allowance	38.43	39.34
	Bad debts written off	29.64	13.16
	Provision utilised for write off	(29.64)	(13.16)
	Finance costs	830.73	941.59
	Interest income from banks	(201.64)	(75.69)
	Interest income from others	(14.34)	(9.45)
	(Profit)/loss on sale of property, plant and equipment (net)	(1.51)	(1.12)
	Operating profit before working capital / other changes	**9,121.12**	**5,950.26**
	Adjustment for (increase)/decrease in operating assets		
	Inventories	(37.72)	(145.36)
	Trade receivables	(175.89)	(199.01)
	Other financial assets and other assets - Non-current	(44.07)	(46.51)
	Other financial assets, loans and other assets - Current	(297.81)	(227.54)
	Adjustment for increase/(decrease) in operating liabilities		
	Trade payables	(396.46)	873.81
	Liabilities and provisions	600.19	227.08
	Cash generated from operations	**8,769.36**	**6,432.73**
	Direct taxes paid (net)	(859.44)	(674.31)
	Net cash flow from operating activities (A)	**7,909.92**	**5,758.42**
B	**Cash flows from investing activities**		
	Acquisition of property, plant and equipment (including capital advances, net of capital creditors)	(1,664.08)	(6,388.30)
	Proceeds from sale of property, plant and equipment	11.36	1.12
	(Investment in)/redemption of bank deposits (net)	(146.93)	1,209.08
	Interest received	106.89	84.34
	Investment made during the period	(0.34)	-
	Net cash used in investing activities (B)	**(1,693.10)**	**(5,093.76)**
C	**Cash flows from financing activities**		
	Proceeds from non-current borrowings	-	1,868.37
	Repayment of non-current borrowings	(1,095.09)	(915.74)
	Payment of lease liabilities	(307.59)	(260.75)
	Interest and finance charges paid	(731.11)	(922.07)
	Net cash used in financing activities (C)	**(2,133.79)**	**(230.19)**
	Net increase in cash and cash equivalents (A+B+C)	**4,083.03**	**434.47**
	Cash and cash equivalents at the beginning of the year	919.04	484.57
	Cash and cash equivalents at the end of the year	**5,002.06**	**919.04**

STATEMENT OF CASH FLOWS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

	As at March 31, 2026	As at March 31, 2025
Components of cash and cash equivalents:		
Cash on hand	52.57	44.34
Balances with banks		
• on current accounts	146.22	292.70
• on deposit accounts (original maturity of three months or less)	4,803.28	582.00
	5,002.07	**919.04**

Reconciliation of change in liabilities arising from financing activities is given in note 22.4

See accompanying notes forming part of the financial statements

In terms of our report attached

for **Deloitte Haskins & Sells**
Chartered Accountants
Firm's registration No. 008072S

Rekha Bai
Partner
Membership No. 214161

Place: Colombo, Sri Lanka
Date: May 29, 2026

for and on behalf of the board of directors of
KMC Speciality Hospitals (India) Limited
CIN: L85110TN1982PLC009781

Dr. S. Manivannan
Managing Director
DIN: 00910804

Dr. S. Chandrakumar
Executive Chairman (Whole-Time)
DIN: 01867847

K. Anand Babu
Chief Financial Officer

Indumathi P
Company Secretary

Place: Chennai
Date: May 29, 2026

STATEMENT OF CHANGES IN EQUITY

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

a. Equity share capital

Particulars	Amount
Balance as at April 1, 2024	**1,630.85**
Movement during the year	-
Balance as at March 31, 2025	**1,630.85**
Movement during the year	-
Balance as at March 31, 2026	**1,630.85**

b. Other equity

Particulars	Reserves and surplus	Other comprehensive income	Total
	Retained earnings	Remeasurement of net defined benefit liability	
Balance as at April 1, 2024	**12,824.44**	**(97.32)**	**12,727.12**
Profit for the year	2,142.71	-	2,142.71
Total other comprehensive income/(loss), net of tax	-	(67.59)	(67.59)
Balance as at March 31, 2025	**14,967.15**	**(164.91)**	**14,802.24**
Profit for the year	4,673.44	-	4,673.44
Total other comprehensive income/(loss), net of tax	-	(63.66)	(63.66)
Balance as at March 31, 2026	**19,640.59**	**(228.57)**	**19,412.02**

See accompanying notes forming part of the financial statements

In terms of our report attached

for **Deloitte Haskins & Sells**
Chartered Accountants
Firm's registration No. 008072S

for and on behalf of the board of directors of
KMC Speciality Hospitals (India) Limited
CIN: L85110TN1982PLC009781

Rekha Bai
Partner
Membership No. 214161

Dr. S. Manivannan
Managing Director
DIN: 00910804

Dr. S. Chandrakumar
Executive Chairman (Whole-Time)
DIN: 01867847

K. Anand Babu
Chief Financial Officer

Indumathi P
Company Secretary

Place: Colombo, Sri Lanka
Date: May 29, 2026

Place: Chennai
Date: May 29, 2026

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

1. Company information

KMC Speciality Hospitals (India) Limited ("the Company") was originally incorporated as Advanced Medical Care Private Limited on December 31, 1982 under the Companies Act, 1956 and was converted into a Public Limited Company on July 15, 1988. The name of the Company was changed to Seahorse Hospitals Limited on March 21, 1995 and to its current name with effect from October 24, 2008. The Company is a super speciality hospital based in Trichy, belonging to the Kauvery Hospitals group. The Company is primarily engaged in the business of rendering medical and healthcare services.

2. Basis of Preparation

A. Statement of Compliance

The financial statements of the Company have been prepared and presented in accordance with the Generally Accepted Accounting Principles (GAAP). GAAP comprises of Indian Accounting Standards (Ind AS) as specified in Section 133 of the Companies Act, 2013 ('the Act') read together with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 ("the Rules") and the relevant amendment rules issued thereafter, pronouncements of regulatory bodies applicable to the Company and other provisions of the Act.

B. Application of new and revised Ind AS

In the current year, the Company has applied the below amendments to the Ind ASs that are effective for an annual period that begins on or after April 1, 2025.

Amendments to Ind AS 21 The Effect of Changes in Foreign Exchange Rates titled Lack of Exchangeability

The amendments specify how to assess whether a currency is exchangeable, and how to determine the exchange rate when it is not. The adoption of this amendment did not have any material impact on the disclosures or on the amounts reported in these financial statements.

Amendments to Ind AS 7 Statement of Cash Flows and Ind AS 107 Financial Instruments: Disclosures titled Supplier Finance Arrangements

The amendments add a disclosure objective to Ind AS 7 stating that an entity is required to disclose information about its supplier finance arrangements that enables users of financial statements to assess the effects of those arrangements on the entity's liabilities and cash flows.

In addition, Ind AS 107 is amended to add supplier finance arrangements as an example within the requirements to disclose information about an entity's exposure to concentration of liquidity risk.

The same is not applicable to the company.

Amendments to Ind AS 1 Presentation of Financial Statements

The amendments affect only the presentation of liabilities as current or non-current in the Balance Sheet and not the amount or timing of recognition of any asset, liability, income or expenses.

The amendments clarify that the classification of liabilities as current is based on rights that are in existence at the end of the reporting period, specify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability, explain that rights are in existence if covenants are complied with at the end of the reporting period, and introduce a definition of 'settlement' to make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services.

Further, the amendments specify that only covenants that an entity is required to comply with on or before the end of the reporting period affect the entity's right to defer settlement of a liability for at least twelve months after the reporting date (and therefore must be considered in assessing the classification of the liability as current or non-current). Such covenants affect whether the right exists at the end of the reporting period, even if compliance with the covenant is assessed only after the reporting date (e.g. a covenant based on the entity's financial position at the reporting date that is assessed for compliance only after the reporting date). However, the amendments do not affect classification where there is a breach of a material covenant of a long-term loan arrangement on or before the end of the reporting period with the effect that the liability becomes payable on demand on the reporting date, until the annual periods beginning prior to April 1, 2026.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

The amendments also specify that the right to defer settlement of a liability for at least twelve months after the reporting date is not affected if an entity only has to comply with a covenant after the reporting period. However, if the entity's right to defer settlement of a liability is subject to the entity complying with covenants within twelve months after the reporting period, an entity discloses information that enables users of financial statements to understand the risk of the liabilities becoming repayable within twelve months after the reporting period. This would include information about the covenants (including the nature of the covenants and when the entity is required to comply with them), the carrying amount of related liabilities and facts and circumstances, if any, that indicate that the entity may have difficulties complying with the covenants.

The management do not expect that the adoption of the standards listed above will have a material impact on the financial statements of the Company in future periods.

Amendments to Ind AS 12 Income Taxes titled International Tax Reform—Pillar Two Model Rules

The amendments clarify that the Standard applies to income taxes arising from tax law enacted or substantively enacted to implement the Pillar Two model rules published by the OECD, including tax law that implements qualified domestic minimum top-up taxes described in those rules.

The amendments introduce a temporary exception to the accounting requirements for deferred taxes in Ind AS 12, so that an entity would neither recognize nor disclose information about deferred tax assets and liabilities related to Pillar Two income taxes.

The above does not have any material impact on the company.

C. Accounting convention and assumptions

These financial statements have been prepared on the historical cost basis, except for certain financial instruments which are measured at fair values at the end of each reporting period, as explained in accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

Going Concern

The directors have, at the time of approving the financial statements, a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the financial statements.

D. Basis of presentation

The Balance sheet, the Statement of Profit and Loss, and the Statement of Changes in Equity, are presented in the format prescribed under Division II of Schedule III of the Act, as amended from time to time, for Companies that are required to comply with Ind AS. The Statement of Cash Flows has been presented as per the requirements of Ind AS 7 - Statement of Cash Flows.

Transactions and balances with values below the rounding off norm adopted by the Company have been reflected as "0" in the relevant notes in these financial statements.

E. Functional and presentation currency

Items included in the Financial statements of the Company are measured using the currency of the primary economic environment in which the Company operates (i.e. the "functional currency"). The financial statements are presented in Indian Rupees (Rs.) the national currency of India, which is the functional currency of the company. All amounts are in Indian Rupees Lakhs except share data or as stated.

F. Use of estimates and judgements

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively.

Assumptions and estimation uncertainties

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment is included in the following notes:

- Note 10 – recognition of deferred tax assets/ liabilities;
- Note 28 – measurement of defined benefit obligations: key actuarial assumptions;
- Notes 39 – recognition and measurement of provisions and contingencies: key assumptions about likelihood and magnitude of an outflow of resources;
- Note 4 – Useful life of Property, Plant and Equipment
- Note 14 – Provision for loss allowance on trade receivables.

G. Measurement of fair values

A number of the Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities.

Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows.

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs, other than quoted prices included in Level 1, that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

Management uses various valuation techniques to determine fair value of financial instruments (where active market quotes are not available). This involves developing estimates and assumptions consistent with how market participants would price the instrument. Management based on its assumptions on observable data as far as possible but where it not available, the management uses the best information available.

The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

H. Operating cycle

Any asset or liability is classified as current if it satisfies any of the following conditions:

(i) The asset / liability is expected to be realized / settled in the Company's normal operating cycle;

(ii) The asset is intended for sale or consumption;

(iii) The asset / liability is held primarily for the purpose of trading;

(iv) The asset / liability is expected to be realized / settled within twelve months after the reporting period;

(v) The asset is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date;

(vi) In the case of a liability, the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realization in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

3. Material accounting policies

A. Financial instruments

Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the instruments.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

(i) Initial recognition

Financial assets and financial liabilities are initially measured at fair value, plus in the case of financial assets not recorded at fair value through profit or loss (FVTPL), transaction costs that are attributable to the acquisition of the financial asset. However, trade receivables that do not contain a significant financing component are measured at transaction price.

Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in the Statement of profit and loss.

(ii) Subsequent measurement

(1) Financial assets

All recognized financial assets are subsequently measured in their entirety at either amortized cost or fair value, depending on the classification of the financial assets, except for investments forming part of interest in subsidiaries / associates, which are measured at cost.

Classification of financial assets

The Company classifies its financial assets in the following measurement categories:

a) Those to be measured subsequently at fair value (either through other comprehensive income, or through Statement of profit and loss), and

b) Those measured at amortized cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

Amortized cost

Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. A gain or loss on these assets that is subsequently measured at amortized cost is recognized in Statement of profit and loss when the asset is derecognized or impaired. Interest income from these financial assets is included in finance income using the effective interest rate method.

Fair value through other comprehensive income (FVTOCI)

Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets cash flows represent solely payments of principal and interest, are measured at fair value through other comprehensive income (FVTOCI). Movements in the carrying amount are taken through OCI. When the financial asset is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to Statement of profit and loss and recognized in other income / (expense).

Fair value through profit or loss (FVTPL)

Assets that do not meet the criteria for amortized cost or FVTOCI are measured at fair value through profit or loss. A gain or loss on these assets that is subsequently measured at fair value through profit or loss is recognized in the Statement of profit and loss.

Impairment of financial assets

Expected credit loss (ECL) is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e., all cash shortfalls).

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss on the financial assets that are measured at amortised cost e.g., cash and bank balances, investment in equity instruments of subsidiary companies, trade receivables and loans etc.

At each reporting date, the Company assesses whether financial assets carried at amortised cost is credit-impaired. A financial asset is ‘credit-impaired’ when one or more events that have detrimental impact on the estimated future cash flows of the financial assets have occurred.

Evidence that the financial asset is credit-impaired includes the following observable data:

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

- significant financial difficulty of the borrower or issuer;
- the breach of contract such as a default or being past due as per the ageing brackets;
- it is probable that the borrower will enter bankruptcy or other financial re-organisation; or
- the disappearance of active market for a security because of financial difficulties.

The Company follows ‘simplified approach’ for recognition of impairment loss allowance on Trade receivables. The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognizing impairment loss allowance based on 12-month ECL.

Lifetime ECL are the expected credit losses resulting from all possible default events over the expected life of a financial asset. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

ECL impairment loss allowance (or reversal) recognized during the period is recognized as expense/income in the statement of profit and loss. ECL for financial assets measured as at amortized cost and contractual revenue receivables is presented as an allowance, i.e., as an integral part of the measurement of those assets in the financial statements. The allowance reduces the net carrying amount. Until the asset meets write-off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

Write off policy:

The Company writes off a financial asset when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery. Any recoveries made are recognised in Statement of profit and loss.

(2) Financial liabilities and equity instruments:

Classification as equity or financial liability

Equity and Debt instruments issued by the Company are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

All financial liabilities are subsequently measured at amortized cost using the effective interest method or at FVTPL.

Equity instruments:

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue costs.

Financial liabilities at amortized cost

Financial liabilities that are not held-for-trading and are not designated as at FVTPL are measured at amortized cost at the end of subsequent accounting periods. The carrying amounts of financial liabilities that are subsequently measured at amortized cost are determined based on the effective interest method. Interest expense that is not capitalized as part of costs of an asset is included in the 'Finance costs' line item.

Financial liabilities at FVTPL

Liabilities that do not meet the criteria for amortized cost are measured at fair value through profit or loss. A gain or loss on these assets that is subsequently measured at fair value through profit or loss is recognized in the Statement of profit and loss.

(iii) Derecognition

(1) Derecognition of financial assets

A financial asset is derecognized only when the Company has transferred the rights to receive cash flows from the financial asset. Where the Company has transferred an

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

asset, it evaluates whether it has transferred substantially all risks and rewards of ownership of the financial asset. Where the Company has neither transferred a financial asset nor retains substantially all risks and rewards of ownership of the financial asset, the financial asset is derecognised if the Company has not retained control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

(2) Derecognition of financial liabilities

The Company derecognizes financial liabilities when, and only when, the Company's obligations are discharged, cancelled or have expired. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable is recognized in Statement of profit and loss.

The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in Statement of profit and loss.

(iv) Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

B. Foreign currency transactions and translations

Transactions in foreign currencies are translated into the respective functional currency of company at the exchange rates at the dates of the transactions or an average rate if the average rate approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Non-monetary assets and liabilities that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Exchange differences are recognised in Statement of profit and loss, except for such exchange differences arising from the translation of specific items which are recognised in OCI, as the case may be.

C. Property, plant and equipment (PPE)

(i) Recognition and measurement

Items of property, plant and equipment are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and accumulated impairment losses, if any.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in Statement of profit and loss.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

(ii) Capital work in progress and Capital advances

Advances paid toward the acquisition of property, plant and equipment outstanding at each balance sheet date are disclosed as "Capital Advances" under Other Non-current Assets and the cost of property, plant and equipment not ready to use before such date are disclosed under "Capital work in progress".

(iii) Subsequent expenditure

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company. Costs in nature of repairs and maintenance are recognized in the Statement of Profit and Loss as and when incurred.

(iv) Depreciation

Depreciation is calculated on cost of items of property, plant and equipment less their estimated residual values over their estimated useful lives using the straight-line method and is generally recognised in the statement of profit and loss. Assets acquired under finance leases are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. Freehold land is not depreciated.

The estimated useful lives of items of property, plant and equipment are as follows:

Asset category	Minimum years	Maximum years	Useful life as per Schedule II
Buildings	10	61	60
Surgical and other equipment's	5	10	13
Electrical installations	5	5	10
Computers & accessories	1	6	3
Office Equipments	5	5	5
Books	10	10	10
Furniture, fixtures and fittings	1	5	10
Vehicles	4	4	6

Leasehold improvements are being depreciated over the term of the lease, or estimated useful life of the assets, whichever is lower on a straight-line basis.

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate. Based on technical evaluation and consequent advice, the management believes that its estimates of useful lives as given above best represent the period over which management expects to use these assets.

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (upto) the date on which asset is ready for use (disposed of).

Assets individually costing Rs. 5,000 and less are fully depreciated in the year of purchase based on the technical evaluation, the management believes that it represents the relevant useful life of these assets.

D. Intangible assets

(i) Measurement

Intangible assets are initially measured at cost. Such intangible assets are subsequently measured at cost less accumulated amortisation and any accumulated impairment losses.

(ii) Subsequent expenditure

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure is recognised in Statement of profit and loss as incurred.

(iii) Amortisation

Amortisation is calculated to write off the cost of intangible assets less their estimated residual values over their estimated useful lives using the straight-line method and is included in depreciation and amortisation in Statement of Profit and Loss.

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

The estimated useful lives are as follows:

Asset category	Management estimate of useful life
Software	3

E. Investment property

Investment property is property held either to earn rental income or for capital appreciation or for both, but not for sale in the ordinary course of business, use in the production or supply of goods or services or for administrative purposes. Upon initial recognition, an investment property is measured at cost. Subsequent to initial recognition, investment property is measured at cost less accumulated depreciation and accumulated impairment losses, if any.

Any gain or loss on disposal of an investment property is recognized in Statement of profit and loss.

The fair values of investment property is disclosed in the notes. The fair value of investment property has been determined in accordance with the requirements of Ind AS 113 - Fair value measurement.

F. Inventories

Inventory comprises of pharmacy stock and consumables. Pharmacy stock is valued at the lower of cost and net realisable value including necessary provision for obsolescence. Consumables are valued at cost. Cost comprises purchase price and all incidental expenses incurred in bringing the inventory to its present location and condition. The cost of consumables is charged to the Statement of profit and loss in the year of purchase. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. The comparison of cost and net realisable value is made on an item-by-item basis.

The Company follows the first-in-first out method of determining the cost of inventories.

Due allowance is estimated and made by the Management for slow moving / non-moving items of inventory, wherever necessary, based on the past experience and such allowances are adjusted against the carrying inventory value.

G. Impairment of PPE and intangible assets

The Company's non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

The Company's corporate assets do not generate independent cash inflows. To determine impairment of a corporate asset, recoverable amount is determined for the CGUs to which the corporate asset belongs.

An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the statement of profit and loss. Impairment loss recognised in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

In respect of other assets for which impairment loss has been recognized in prior periods, the Group reviews at each reporting date whether there is any indication that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. Such a reversal is made only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

H. Employee benefits

(i) Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid e.g., under short-term cash bonus, if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the amount of obligation can be estimated reliably.

(ii) Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. The Company makes specified monthly contributions towards Government administered provident fund scheme. Obligations for contributions to defined contribution plans are recognised as an employee benefit expense in Statement of profit and loss in the periods during which the related services are rendered by employees.

(iii) Defined benefit plans

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The Company's net obligation in respect of defined benefit plans is calculated separately for each plan by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets.

The calculation of defined benefit obligation is performed annually by a qualified actuary using the projected unit credit method. When the calculation results in a potential asset for the Company, the recognised asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan ('the asset ceiling'). In order to calculate the present value of economic benefits, consideration is given to any minimum funding requirements.

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognised in OCI. The Company determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability (asset), taking into account any changes in the net defined benefit liability (asset) during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognised in Statement of profit and loss.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service ('past service cost' or 'past service gain') or the gain or loss on curtailment is recognised immediately in Statement of profit and loss. The Company recognises gains and losses on the settlement of a defined benefit plan when the settlement occurs.

(iv) Other long-term employee benefits

The Company's net obligation in respect of long-term employee benefits other than post-employment benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value, and the fair value of any related assets is deducted. The obligation is measured on the basis of an annual independent actuarial valuation using the projected unit credit method. Remeasurements gains or losses are recognised in Statement of profit and loss in the period in which they arise.

(v) Termination benefits

Termination benefits are expensed at the earlier of when the Company can no longer withdraw the offer of those benefits and when the Company recognises costs for a restructuring. If benefits are not expected to be settled wholly within 12 months of the reporting date, then they are discounted.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

I. Provisions (other than for employee benefits)

A provision is recognised if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows (representing the best estimate of the expenditure required to settle the present obligation at the balance sheet date) at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognised as finance cost. Expected future operating losses are not provided for.

J. Contingent liability and contingent assets

Contingent liability is disclosed for:

(i) A possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity or

(ii) Present obligations arising from past events where it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made. When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Contingent assets are neither recognised nor disclosed in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

K. Revenue

The Company derives its revenue primarily from rendering medical and healthcare services. Income from medical and healthcare services comprises of income from hospital services and sale of pharmacy products.

Inpatient and outpatient revenue

Inpatient and outpatient revenue is recognized as and when the related services are rendered. Revenue is also recognised in relation to the services rendered to the patients who are undergoing treatment/ observation on the balance sheet date to the extent of services rendered. Revenue towards satisfaction of a performance obligation is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligation. The transaction price of goods sold and services rendered is net of variable consideration on account of discounts and concessions offered by the Company.

'Unbilled revenue' represents the value of medical and healthcare services rendered in excess of amounts billed to the patients as at the balance sheet date.

Sale of traded goods – Pharmacy items

Revenue from sale of pharmacy items are recognized on delivery of items to the customers which is when the Company satisfies a performance obligation by transferring a promised good to a patient. Pharmacy items are transferred when the patient obtains control of such items.

The Company collects Goods & Service Tax (GST) on behalf of the government and, therefore, these are not economic benefits flowing to the Company. Hence, they are excluded from revenue.

L. Leases

The Company's lease asset classes primarily consist of leases for buildings. The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether: (i) the contract involves the use of an identified asset (ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease and (iii) the Company has the right to direct the use of the asset.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

At the date of commencement of the lease, the Company recognizes a right-of-use asset ("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases) and low value leases. For these short-term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease.

Certain lease arrangements includes the options to extend or terminate the lease before the end of the lease term. ROU assets and lease liabilities includes these options when it is reasonably certain that they will be exercised.

The right-of-use assets are initially recognized at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset. Right of use assets are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the Cash Generating Unit (CGU) to which the asset belongs.

The lease liability is initially measured at amortized cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates in the country of domicile of these leases. Lease liabilities are re-measured with a corresponding adjustment to the related right of use asset if the Company changes its assessment if whether it will exercise an extension or a termination option.

Lease liability and ROU asset have been separately presented in the Balance Sheet and lease payments have been classified as financing cash flows.

The Company has elected not to recognise right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months. The Company recognizes the lease payments associated with these leases as an expense over the lease term.

M. Other income

(i) Interest income

Interest income from a financial asset is recognized when it is probable that the economic benefit will flow to the Company and the amount of income can be measured reliably.

Interest income or expense is accrued on a time basis, by reference to the principle/ outstanding using the effective interest rate applicable.

The 'effective interest rate' is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument to:

- the gross carrying amount of the financial asset; or
- the amortised cost of the financial liability.

In calculating interest income and expense, the effective interest rate is applied to the gross carrying amount of the asset (when the asset is not credit-impaired) or to the amortised cost of the liability. However, for financial assets that have become credit-impaired subsequent to initial recognition, interest income is calculated by applying the effective interest rate to the amortised cost of the financial asset. If the asset is no longer credit-impaired, then the calculation of interest income reverts to the gross basis.

(ii) Dividend income

Dividend income is recognized when the right to receive the income is established.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

N. Income tax

Income tax comprises current and deferred tax. It is recognised in Statement of profit and loss except to the extent that it relates to a business combination or to an item recognised directly in equity or in other comprehensive income.

(i) Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

(ii) Deferred tax

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding amounts used for taxation purposes. Deferred taxes is also recognised in respect of carried forward tax losses and tax credits.

Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which they can be used. The existence of unused tax losses is strong evidence that future taxable profit may not be available. Therefore, in case of a history of recent losses, the Company recognises a deferred tax asset only to the extent that it has sufficient taxable temporary differences or there is convincing other evidence that sufficient taxable profit will be available against which such deferred tax asset can be realised. Deferred tax assets – unrecognised or recognised, are reviewed at each reporting date and are recognised/ reduced to the extent that it is probable/ no longer probable respectively that the related tax benefit will be realised.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date.

The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

O. Borrowing cost

Borrowing costs include interest, amortisation of ancillary costs incurred and exchange differences relating to foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs. Cost in connection with the borrowing of funds to the extent not directly related to the acquisition of qualifying assets are charged to the statement of Profit and Loss over the tenure of the loan. Borrowing costs allocated to and utilised for qualifying assets, pertaining to the period from commencement of activities relating to construction/ development of the qualifying asset up to the date of capitalisation of such assets are added to the cost of the assets. Capitalisation of borrowing costs is suspended and charged to the statement of profit and loss during extended periods when active development activity on the qualifying assets is interrupted.

Interest income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is adjusted against the borrowing costs eligible for capitalisation.

All other borrowing costs eligible are recognised in Statement of profit and loss in the period in which they incurred.

P. Earnings per share

Basic earnings per share is computed by dividing the net profit / (loss) after tax (including the post tax effect of exceptional items, if any) for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post tax effect of exceptional items, if any) for the year attributable to equity shareholders as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares.

Q. Operating segment

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company's other components, and for which discrete financial information is available. Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The Company's Managing Director is responsible for allocating resources and assessing performance of the operating segments and accordingly is identified as the Chief Operating Decision Maker ('CODM'). The Company's CODM reviews financial information presented, for purposes of making operating decisions and assessing financial performance of the Company. Therefore, the Company has determined that it operates in a single operating and reportable segment.

R. Cash and cash equivalents

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

S. Cash flow Statement

Cash flows are reported using the indirect method, whereby profit / (loss) is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information. In cash flow statement, cash and cash equivalents include cash in hand, balances with banks in current accounts and other short-term highly liquid investments with original maturities of three months or less.

T. Insurance claims

Insurance claims are accounted for on the basis of claims admitted / expected to be admitted and to the extent that the amount recoverable can be measured reliably and it is reasonable to expect ultimate collection.

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026

All amounts are in Rs. Million, unless otherwise stated

4 Property, plant and equipment and capital work-in-progress

Particulars	Land (freehold)	Buildings	Leasehold improvements	Surgical and other equipment	Electrical installation	Computers	Books	Furniture, fixtures and fittings	Vehicles	Total (A)	Capital work-in-progress
Gross block											
As at April 1, 2024	**3,866.51**	**9,944.90**	**1,290.80**	**4,193.16**	**3,190.74**	**367.93**	**0.61**	**247.63**	**273.44**	**23,375.72**	**64.45**
Additions	**680.12**	2,380.75	350.81	2,235.39	145.68	111.25	-	158.22	35.49	6,097.71	2,671.39
Disposals	-	-	-	-	-	-	-	-	(3.18)	(3.18)	-
Capitalised during the year	-	-	-	-	-	-	-	-	-	-	(2,735.84)
As at March 31, 2025	**4,546.63**	**12,325.65**	**1,641.61**	**6,428.55**	**3,336.42**	**479.18**	**0.61**	**405.85**	**305.75**	**29,470.25**	**-**
Additions	-	279.47	270.86	570.46	131.73	58.68	-	77.67	61.30	1,450.17	574.06
Disposals	-	-	-	(24.08)	-	-	-	-	(50.00)	(74.08)	-
Capitalised during the year	-	-	-	-	-	-	-	-	-	-	(574.06)
As at March 31, 2026	**4,546.63**	**12,605.12**	**1,912.47**	**6,974.93**	**3,468.15**	**537.86**	**0.61**	**483.52**	**317.05**	**30,846.34**	**-**
Accumulated depreciation											
As at April 1, 2024	**-**	**264.62**	**667.40**	**1,773.33**	**593.57**	**233.84**	**0.45**	**118.30**	**169.07**	**3,820.58**	**-**
Depreciation for the year	-	209.51	131.86	549.90	614.60	82.14	0.06	57.43	38.72	1,684.22	-
Disposals	-	-	-	-	-	-	-	-	(3.18)	(3.18)	-
As at March 31, 2025	**-**	**474.13**	**799.26**	**2,323.23**	**1,208.17**	**315.98**	**0.51**	**175.73**	**204.61**	**5,501.62**	**-**
Depreciation for the year	-	230.48	198.61	651.73	606.05	91.23	0.04	71.21	49.66	1,899.01	-
Disposals	-	-	-	(14.23)	-	-	-	-	(50.00)	(64.23)	-
As at March 31, 2026	**-**	**704.61**	**997.87**	**2,960.73**	**1,814.22**	**407.21**	**0.55**	**246.94**	**204.27**	**7,336.40**	**-**
Net carrying value											
Balance as at March 31, 2025	**4,546.63**	**11,851.52**	**842.35**	**4,105.32**	**2,128.25**	**163.20**	**0.10**	**230.12**	**101.14**	**23,968.63**	**-**
Balance as at March 31, 2026	**4,546.63**	**11,900.51**	**914.60**	**4,014.20**	**1,653.93**	**130.65**	**0.06**	**236.58**	**112.78**	**23,509.94**	**-**

4.1 Capital work-in-progress ageing schedule (CWIP)

As at March 31, 2026

Particulars	Amount in CWIP for a period				
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Projects in progress	-	-	-	-	-

As at March 31, 2025

Particulars	Amount in CWIP for a period				
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Projects in progress	-	-	-	-	-

There are no projects which are under suspension. With regards to ongoing projects there are no projects where completion is over due or has exceeded the cost as compared to its original plan and consequent amendments approved by the Board thereon.

4.2 Refer Note 22.2 for Property, plant and equipment pledged / hypothecated as securities for borrowings

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

5 Right-of-use asset

Particulars	Land	Buildings	Total
Gross block			
As at April 01, 2024	**47.39**	**1,213.01**	**1,260.40**
Additions	-	73.09	73.09
Disposals / adjustments during the year	-	(78.86)	(78.86)
As at March 31, 2025	**47.39**	**1,207.24**	**1,254.63**
Additions	159.33	638.12	797.45
Disposals / adjustments during the year	(20.91)	(57.72)	(78.63)
As at March 31, 2026	**185.81**	**1,787.64**	**1,973.45**
Accumulated depreciation			
As at April 01, 2024	**20.65**	**274.81**	**295.46**
Depreciation for the year	10.76	192.15	202.91
Disposals / adjustments during the year	-	-	-
As at March 31, 2025	**31.41**	**466.96**	**498.37**
Depreciation for the year (Refer Note 36)	52.19	213.56	265.75
Disposals / adjustments during the year	(3.69)	(20.82)	(24.51)
As at March 31, 2026	**79.91**	**659.70**	**739.60**
Net carrying value			
As at March 31, 2025	**15.98**	**740.28**	**756.26**
As at March 31, 2026	**105.90**	**1,127.94**	**1,233.84**

6 Investment property

A Reconciliation of carrying amount

Cost	Land#
Balance as at April 1, 2024	40.43
Additions	-
Disposals	-
Balance as at March 31, 2025	**40.43**
As at April 01, 2025	40.43
Additions	-
Disposals	-
Balance as at March 31, 2026	**40.43**
As at March 31, 2025	40.43
As at March 31, 2026	**40.43**

#Investment property represents freehold land in Trichy towards which depreciation charge is not applicable. Accordingly, the carrying amount (net) is equivalent to the gross carrying amount as at the respective balance sheet date. There is no impairment in respect of investment property. There were no immovable properties where the title deeds are not held in the name of the Company.

Also refer Note 22.2 for investment property pledged / hypothecated as securities for borrowings.

B Fair value

Level of hierarchy	Level 2
As at March 31, 2025	2,877.00
As at March 31, 2026	3,098.00

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

Fair valuation of investment property is based on the valuation by a registered valuer as defined under Rule 2 of Companies (Registered Valuers and Valuation) Rules, 2017 using market comparable approach, based on recent market prices without any significant adjustments being made to the market observable data. There has been no change to the valuation technique during the year. The fair value measurement for the investment property has been categorised as a Level 2.

C Information regarding income and expenditure related to investment property

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Rental income from the investment property	16.53	1.44

7 Other intangible assets

Particulars	Software
Gross block	
As at April 1, 2024	**220.40**
Additions	6.05
Disposals	-
As at March 31, 2025	**226.45**
Additions	0.54
Disposals	-
As at March 31, 2026	**226.99**
Accumulated amortisation	
As at April 1, 2024	**213.92**
Amortisation for the year	8.12
Disposals	-
As at March 31, 2025	**222.04**
Amortisation for the year	2.33
Disposals	-
As at March 31, 2026	**224.37**
Net carrying value	
As at March 31, 2025	**4.41**
As at March 31, 2026	**2.62**

Particulars	As at March 31, 2026	As at March 31, 2025
Investments in equity shares - Others at fair value through profit and loss (FVTPL)		
Unquoted equity shares fully paid		
4,600 (March 31, 2025: 3,800) Equity shares of Nazca Energy Private Limited	0.46	0.38
2,600 (March 31, 2025: 0) Equity shares of Gardenia Energy Private Limited	0.26	-
Total unquoted investments	**0.72**	**0.38**
Aggregate carrying amount of unquoted investments	0.72	0.38

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

9 Other financial assets

Particulars	As at March 31, 2026	As at March 31, 2025
Non-current		
Security deposits	251.78	236.76
Bank deposits with more than 12 months maturity	13.79	13.94
Interest accrued on fixed deposits but not due (due to mature after 12 months from the original date)	1.25	-
Total non-current financial assets	**266.82**	**250.70**
Current		
Unbilled revenue	606.15	406.78
Bank deposits with less than 12 months maturity	476.94	781.99
Interest accrued on fixed deposits but not due (due to mature within 12 months from the original date)	114.95	21.45
Other receivable from holding company (Refer note 42)	-	53.48
Total current financial assets	**1,198.04**	**1,263.70**

10 Income tax

A Amounts recognised in statement of profit and loss

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Current tax (a)		
Current tax	1,591.25	730.79
Deferred tax (b)		
Attributable to -		
Origination and reversal of temporary differences	37.67	286.84
Tax expense (a) + (b)	**1,628.92**	**1,017.63**

B Income tax recognised in other comprehensive income (OCI)

Particulars	As at March 31, 2026			As at March 31, 2025		
	Amount	Tax (expense) / benefit	Net of tax	Amount	Tax (expense) / benefit	Net of tax
Remeasurements of defined benefit plan liability (net)	(85.08)	21.42	(63.66)	(90.32)	22.73	(67.59)

C Reconciliation of effective tax rate

Particulars	For the year ended March 31, 2026		For the year ended March 31, 2025	
	%	Amount	%	Amount
Profit before tax		6,302.36		3,160.34
Tax using the Company's domestic tax rate	25.17%	1,586.18	25.17%	795.39
Effect of:				
Expenses not deductible for tax purpose		42.74		222.24
Effective tax rate / tax expense		**1,628.92**		**1,017.63**

The tax rate used for the aforesaid reconciliation is the corporate tax rate of 25.17% under Section 115BAA of the Income-tax Act, 1961 payable by corporate entities in India.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

D Recognised deferred tax assets and liabilities

Movement in temporary differences for the year ended March 31, 2026 and March 31, 2025

Particulars	Balance as at April 1, 2024	Recognized in statement of profit and loss (FY 2024-25)	Recognized in other comprehensive income (FY 2024-25)	Balance as at March 31, 2025	Recognized in statement of profit and loss (FY 2025-26)	Recognized in other comprehensive income (FY 2025-26)	Balance as at March 31, 2026
Property, plant and equipment	(235.42)	(321.88)	-	**(557.30)**	(99.31)	-	**(656.61)**
Provision for employee benefits	125.91	36.93	22.73	**185.57**	51.20	21.42	**258.19**
Loss allowance on trade receivables	39.85	6.59	-	**46.44**	2.21	-	**48.65**
Lease liability net of right-of-use assets	5.87	(6.92)	-	**(1.05)**	8.81	-	**7.76**
Security Deposit (Liability)	-	(1.56)	-	**(1.56)**	(0.58)	-	**(2.14)**
Deferred tax asset / (liabilities) (net)	**(63.79)**	**(286.84)**	**22.73**	**(327.90)**	**(37.67)**	**21.42**	**(344.16)**

11 Income tax assets (net)

Particulars	As at March 31, 2026	As at March 31, 2025
Income tax advance (net)	-	238.46
Total income tax assets (net)	**-**	**238.46**

**Provision for income tax Rs.6,470.29 Lakhs, As at March 31,2025: Rs. 4,879.04 Lakhs.*

Particulars	As at March 31, 2026	As at March 31, 2025
Current tax liabilities (net)		
Income tax (net)	(479.01)	-
Total Current tax liabilities (net)	**(479.01)**	**-**

12 Other assets

Particulars	As at March 31, 2026	As at March 31, 2025
(Unsecured, considered good)		
Non-current		
Capital advances	23.21	14.67
Prepaid expenses	13.44	1.78
Total non-current assets	**36.65**	**16.45**
Current		
Prepaid expenses	250.60	148.15
Advance to suppliers	50.26	4.16
Total current assets	**300.86**	**152.31**

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

13 Inventories

Particulars	As at March 31, 2026	As at March 31, 2025
Stock-in-trade (Pharmacy items)	219.88	194.75
Consumables (Surgical material and medical stores)	168.05	155.46
Total inventories	**387.93**	**350.21**

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
1. The cost of inventories recognised as an expenses during the year (Refer notes 31, 32 and 33)	4,501.11	3,367.65
2. The cost of inventories recognised as an expense, includes write downs of inventory to net realisable value, amounting to	-	-
3. The mode of valuation of inventories has been stated in note 3(F)	-	-

14 Trade receivables

Particulars	As at March 31, 2026	As at March 31, 2025
(Unsecured)		
Undisputed trade receivables - Considered good	735.31	597.85
Undisputed trade receivables - Which have significant increase in credit risk	123.22	109.81
Less: Provision for loss allowance	(123.22)	(109.81)
	735.31	597.85
Undisputed trade receivables - Credit impaired	70.07	74.69
Less: Provision for loss allowance	(70.07)	(74.69)
Total trade receivables	**735.31**	**597.85**

Note : Includes receivable from related parties. Refer note 42.

14.1 Credit period and risk

Credit is provided mainly to insurance companies, corporate customers, customers with insurance coverage and customers covered by Government accorded health benefits. The insurance companies are required to maintain minimum reserve levels and pre-approve the insurance claim, Government undertakings and the corporate customers are enterprises with high credit ratings. Accordingly, the Company's exposure to credit risk in relation to trade receivables is low. Further creditworthiness of customers on a continuous basis to whom credit has been granted after obtaining necessary approvals for credit. The collection from the trade receivables are monitored on a continuous basis by the receivables team.

Trade receivables are non-interest bearing. The trade receivables, include certain customers having more than 5% of the total outstanding trade receivable balance:

Particulars	As at March 31, 2026	As at March 31, 2025
Number of customers	5	7
Amount outstanding	622.54	576.99
Percentage of amount outstanding to total outstanding dues	67%	74%

There are no other customers who represent more than 5% of the total balance of trade receivables. There are no customers who has accounted more than 10% of revenue for the year ended March 31, 2026 and March 31, 2025.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

Note : No trade receivable are due from directors or other officers of the Company either severally or jointly with any other person. Nor any trade receivable are due from firms or private companies respectively in which any director is a partner, a director or a member.

14.2 Expected credit loss allowance

The expected credit loss allowance is based on the ageing of the days the receivables are due and the rates as given in the provision matrix, considering the amounts due from the government undertakings and the other undertakings. Further the Company also establishes an allowance for credit loss that represents its estimate of expected losses in respect of trade and other receivables based on the past and recent collection trend.

14.3

Particulars	As at March 31, 2026	As at March 31, 2025
Movement of loss allowance in trade receivable		
Opening balance	184.51	158.32
Add: Provision for loss allowance (Also refer note 37)	38.43	39.35
Less: Utilization of provision for loss allowance (Also refer note 37)	(29.64)	(13.16)
Closing balance	**193.30**	**184.51**

The Company's exposure to credit risk and loss allowances relating to trade receivables are disclosed in note 38(B)(ii).

14.4 Trade receivable ageing schedule

As at March 31, 2026:

Particulars	Outstanding for following periods from due date of payment						
	Within the credit period	Less than 6 months	6 months - 1 year	1 - 2 years	2-3 years	More than 3 years	Total
(a) Undisputed trade receivables -Considered good	559.35	157.27	18.69	-	-	-	735.31
(b) Undisputed trade receivables -Which have significant increase in credit risk	61.96	40.25	21.01	-	-	-	123.22
(c) Undisputed trade receivables -Credit impaired	-	-	-	26.26	9.07	34.74	70.07
(d) Disputed trade receivables -Considered good	-	-	-	-	-	-	-
(e) Disputed trade receivables -Which have significant increase in credit risk	-	-	-	-	-	-	-
(f) Disputed trade receivables -Credit impaired	-	-	-	-	-	-	-
Total	**621.31**	**197.52**	**39.70**	**26.26**	**9.07**	**34.74**	**928.60**
Less : Allowance for credit Loss							(193.29)
Net trade receivables							**735.31**

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

As at March 31, 2026, Unbilled revenue is disclosed under note 9 amounting to Rs. 606.15 Lakhs.

As at March 31, 2025:

Particulars	Outstanding for following periods from due date of payment						
	Within the credit period	Less than 6 months	6 months - 1 year	1 - 2 years	2-3 years	More than 3 years	Total
(a) Undisputed trade receivables -Considered good	484.71	97.35	15.79	-	-	-	597.85
(b) Undisputed trade receivables -Which have significant increase in credit risk	56.35	27.76	25.70	-	-	-	109.81
(c) Undisputed trade receivables -Credit impaired	-	-	-	29.49	19.22	25.98	74.69
(d) Disputed trade receivables -Considered good	-	-	-	-	-	-	-
(e) Disputed trade receivables -Which have significant increase in credit risk	-	-	-	-	-	-	-
(f) Disputed trade receivables -Credit impaired	-	-	-	-	-	-	-
Total	**541.06**	**125.11**	**41.49**	**29.49**	**19.22**	**25.98**	**782.35**
Less : Allowance for credit Loss							(184.51)
Net trade receivables							**597.84**

As at March 31 2025, Unbilled revenue is disclosed under note 9 amounting to Rs. 406.78 Lakhs, ageing less than 6 months.

15 Cash and cash equivalents

Particulars	As at March 31, 2026	As at March 31, 2025
Cash on hand	52.57	44.34
Balances with banks		
· on current accounts	146.22	292.70
· on deposit accounts (original maturity of three months or less)	4,803.28	582.00
Total cash and cash equivalents	**5,002.07**	**919.04**

16 Bank balances other than cash and cash equivalents above

Particulars	As at March 31, 2026	As at March 31, 2025
Balances with banks		
· on deposit accounts (original maturity of more than three months but less than 12 months)	467.19	15.06
Total bank balances other than cash and cash equivalents above	**467.19**	**15.06**

17 Loans

Particulars	As at March 31, 2026	As at March 31, 2025
(Unsecured, considered good)		
Current		
Employee advances	29.34	25.97
Total current loans	**29.34**	**25.97**

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

Note: There are no loans due by directors or other officers of the company or any of them either severally or jointly with any other person or amounts due by firms or private companies respectively in which any director is a partner or a director or a member.

18 Equity share capital

Particulars	As at March 31, 2026	As at March 31, 2025
Authorised		
25,00,00,000 (March 31, 2025: 25,00,00,000) equity shares of Rs. 1/- each	2,500.00	2,500.00
	2,500.00	**2,500.00**
Issued, subscribed and fully paid up		
16,30,85,000 (March 31, 2025: 16,30,85,000) equity shares of Rs. 1/- each fully paid up	1,630.85	1,630.85
Total equity share capital	**1,630.85**	**1,630.85**

a. Reconciliation of shares outstanding at the beginning and at the end of the reporting period

Equity shares

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of shares (in full numbers)	Amount	No. of shares (in full numbers)	Amount
Equity shares of Rs. 1/- each fully paid up				
At the beginning of the year	16,30,85,000	1,630.85	16,30,85,000	1,630.85
At the end of the year	**16,30,85,000**	**1,630.85**	**16,30,85,000**	**1,630.85**

b. Rights, preferences and restrictions attached to shares

The Company has only one class of equity shares having a par value of Rs. 1 each. Each holder is entitled to one vote per equity share. Dividends are paid in Indian Rupees. Dividend proposed by the Board of Directors, if any, is subject to the approval of the shareholders at the Annual General Meeting, except in the case of interim dividend.

In the event of liquidation of the company, the holder of the equity shares will be entitled to receive any of the remaining assets of the company in proportion to the number of equity shares held by the shareholders, after distribution of all preferential amount.

The Board of Directors of the Company have not recommended dividend for the financial year ended March 31, 2026 and March 31, 2025.

c. Shares held by holding company

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of shares (in full numbers)	Amount	No. of shares (in full numbers)	Amount
Equity shares of Rs. 1/- each fully paid up with voting rights				
Sri Kauvery Medical Care (India) Limited, the Holding Company	12,23,13,750	1,223.14	12,23,13,750	1,223.14

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

d. Details of share holders holding more than 5% of equity shares Rs. 1/- each fully paid in the Company

Particulars	As at March 31, 2026		As at March 31, 2025	
	No. of shares (in full numbers)	% of total equity shares	No. of shares (in full numbers)	% of total equity shares
Equity shares of Rs. 1/- each fully paid up with voting rights				
Sri Kauvery Medical Care (India) Limited, the Holding Company	12,23,13,750	75%	12,23,13,750	75%

e. Bonus shares/ buy-back for consideration other than cash allotted during a period of five years immediately preceding the financial year ended March 31, 2026:

a) The Company has not allotted any shares without payment being received in cash.

b) The Company has not allotted paid bonus shares.

c) The Company has not bought back any shares during the aforesaid period.

f. Shareholding of promoters*

(i) Equity shares with voting rights

As at March 31, 2026

Promoter name	No. of shares (in full numbers)	% of total Shares	% of Change during the year#
Sri Kauvery Medical Care (India) Limited	12,23,13,750	75%	-

As at March 31, 2025

Promoter name	No. of shares (in full numbers)	% of total Shares	% of Change during the year#
Sri Kauvery Medical Care (India) Limited	12,23,13,750	75%	-

**Promoter means promoter as defined in the Companies Act, 2013.*

#%change during the year represents the % change in total holding when compared to the previous year end.

19 Other equity

Particulars	As at March 31, 2026	As at March 31, 2025
Reserves and surplus		
Retained earnings		
At the beginning of the year	14,967.15	12,824.44
Add: Profit for the year	4,673.44	2,142.71
At the end of the year	**19,640.59**	**14,967.15**
Other comprehensive income		
Remeasurement of net defined benefit liability		
At the beginning of the year	(164.91)	(97.32)
Add/(less): other comprehensive income/(loss), net of tax	(63.66)	(67.59)
At the end of the year	**(228.57)**	**(164.91)**
Total other equity	**19,412.02**	**14,802.24**

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

19.1 Notes: Nature and purpose of other reserves

Retained earnings

Retained earnings represents the profits generated by the Company post distribution of dividends (if any) to the shareholders. The reserve can be utilised for distribution of dividend by the Company considering the requirements of the Companies Act, 2013.

Other comprehensive income

Other items of other comprehensive income consist of remeasurement of net defined benefit liability.

20 Capital management

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. It sets the amount of capital required on the basis of annual business and long-term operating plans which include capital and other strategic investments. The funding requirements are met through a mixture of equity and other borrowings. The Company's policy is to use current and non-current borrowings to meet anticipated funding requirements. The Company monitors capital using a ratio of 'adjusted net debt' to 'adjusted equity'. For this purpose, adjusted net debt is defined as total liabilities, comprising interest-bearing loans and borrowings less cash and cash equivalents. Adjusted equity comprises all components of equity.

The Company's adjusted net debt to equity ratio is as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
Debt*	7,102.97	8,192.67
Less: Cash and cash equivalents**	(5,469.26)	(934.10)
Adjusted net debt	**1,633.71**	**7,258.57**
Total equity#	21,042.87	16,433.09
Adjusted net debt to adjusted equity ratio	**0.08**	**0.44**

**Debt is defined as non-current borrowings including current maturities of long term borrowings, current borrowings and Lease liabilities (current and non-current portion).*

***Cash and cash equivalents includes other bank balances (current portion).*

#Equity includes all capital and reserves of the Company that are managed as capital.

Going concern:

The Financial statements have been drawn on a going concern basis in view of the arrangement made with the bankers for the project payments. Under such funding arrangement on submission of such project related bills 70% will be funded under the sanctioned term loan and paid over period as disclosed in borrowings.

21 Earnings per share (EPS)

Basic and diluted earnings per share

The calculation of basic earnings per share is based on profit attributable to ordinary shareholders and weighted-average number of ordinary shares outstanding as follows:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Profit for the year attributable to the equity shareholders (A) (Rs. in Lakhs)	4,673.44	2,142.71
Weighted average number of equity shares outstanding as at reporting date (B) (in full numbers)	16,30,85,000	16,30,85,000
Basic earnings per share (A/B) (in Rs.)	**2.87**	**1.31**
Diluted earnings per share (A/B) (in Rs.)	**2.87**	**1.31**

The Company does not have any potential equity shares. Accordingly, basic and dilutive EPS would remain the same.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

22 Borrowings

Particulars	As at March 31, 2026	As at March 31, 2025
Non-current		
Secured		
Term loans from banks	6,142.97	7,232.67
Total non-current	**6,142.97**	**7,232.67**
Current		
Secured		
Current maturities of non-current borrowings	960.00	960.00
Total current	**960.00**	**960.00**

22.1 Terms of secured loans from banks

Particulars	Interest Rate	Outstanding Instalment as on date	Nature of security	Repayment Terms	As at March 31, 2026	As at March 31, 2025
(i) Term loan from State Bank of India:						
Term loan 1	8.95% to 8.20%	March 31, 2026 - 30 Quarters March 31, 2025 - 34 Quarters	Refer Note 22.2 (i) to (iv)	Principal quarterly and interest monthly	4,177.76	4,829.48
Term loan 2	8.00% to 8.20%	March 31, 2026 - 24 Quarters March 31, 2025 - 28 Quarters	Refer Note 22.2 (i) to (iv)	Principal quarterly and interest monthly	2,925.21	3,363.19
Grand total of borrowings					**7,102.97**	**8,192.67**
Less: Current maturities of non-current borrowings					(960.00)	(960.00)
Total borrowings (Non-current)					**6,142.97**	**7,232.67**

22.2 Security information

(i) Hypothetication of property, plant and equipments created / purchased out of bank finance.

(ii) Equitable mortgage over commercial land belonging to the Company and hospital building on the land measuring 60,598 sq.ft. belonging to Survey No. 13, 14/1, 14/2 part and 32 situated at No. 27, Alexinderia Road, Cantonment, Trichy - 620001.

(iii) Equitable mortgage over commercial building belonging to the Company with build-up area 1,11,083 sq.ft., built on Land measuring 24,864 sq.ft., at: 5 royal road, belonging to Sri Kauvery Medical Care (India) Limited (Title deed No. 3171/2008) situated in Ward K, Block No.17, New TS No. 5, Trichy Jt I & II, Sub Regional District of K Abhishekapuram Trichy - 620001.

(iv) Corporate guarantee from Sri Kauvery Medical Care (India) Limited, the Holding Company.

22.3 Additional information

a. The Company does not have any borrowings secured against current assets, therefore the disclosure of the difference between quarterly statement submitted to banks and balance as per books is not applicable.

b. The Company does not have any charges or satisfaction of charge which is yet to be registered with the Registrar of Companies beyond the statutory period.

c. The Company has not been declared a wilful defaulter by any bank or financial institution or other lender.

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

d. The Company has utilised the borrowing amount taken from financial institutions for the purpose as stated in the sanction letter.

22.4 Reconciliation of change in liabilities arising from financing activities:

i) For the year ended March 31, 2026

Particulars	As at April 1, 2025	Proceeds	Repayments	Others^	New lease additions	As at March 31, 2026
Non-current borrowings	7,232.67	-	(1,089.70)	-	-	6,142.97
Current borrowings*	960.00	960.00	(960.00)	-	-	960.00
Lease liabilities (Non-current and current)	752.07		(307.59)	34.22	785.97	1,264.67

Current borrowings represents current maturities of non-current borrowing

^ *Others includes interest on lease liabilities and other adjustments*

ii) For the year ended March 31, 2025

Particulars	As at April 1, 2024	Proceeds	Repayments	Others^	New lease additions	As at March 31, 2025
Non-current borrowings	6,385.20	908.37	(60.90)	-	-	7,232.67
Current borrowings*	854.84	960.00	(854.84)	-	-	960.00
Lease liabilities (Non-current and current)	941.61	-	(260.75)	0.76	70.45	752.07

Current borrowings represents current maturities of non-current borrowing

^ *Others includes interest on lease liabilities and other adjustments*

23 Lease liabilities

(a) The Company, at the inception of a contract assesses whether a contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

In adopting Ind AS 116, the Company has applied the below practical expedients:

(i) The Company has applied a single discount rate to a portfolio of leases with reasonably similar characteristics.

(ii) The Company has treated the leases with remaining lease term of less than 12 months as if they were “”short term leases””.

(iii) The Company has not applied the requirements of Ind AS 116 for leases of low value assets.

(b) The Company has taken land and buildings on leases having lease terms of more than 1 year to 37 years, with the option to extend the term of leases. Refer note 5 for carrying amount of right-to-use assets at the end of the reporting period by class of underlying asset.

A. Break-up of current and non-current lease liabilities:

The following is the break-up of current and non-current lease liabilities:

Particulars	As at March 31, 2026	As at March 31, 2025
Current lease liabilities	286.64	199.99
Non-current lease liabilities	978.03	552.09
Total	**1,264.67**	**752.08**

B. Movement in lease liabilities

The following is the movement in lease liabilities :

Particulars	Amount
Balance as on April 01, 2024	**941.61**
Additions	70.45
Finance costs charged to Statement of Profit and Loss	76.42
Finance costs capitalised	-
Adjustments	(75.66)
Payment of Lease liabilities	(260.75)
Balance as on March 31, 2025	**752.07**
Additions	785.97
Finance costs charged to Statement of Profit and Loss	94.24
Finance costs capitalised during the year	-
Adjustments	(60.02)
Payment of Lease liabilities	(307.59)
Balance as on March 31, 2026	**1264.67**

C. The table below provides details regarding the contractual maturities of lease liabilities on an undiscounted basis:

Particulars	As at March 31, 2026	As at March 31, 2025
Less than one year	386.32	200.04
One to five years	1,101.00	709.65
More than five years	50.22	58.05
Total	**1,537.54**	**967.74**

D. Amounts recognised in the Statement of Profit and Loss:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Interest on lease liabilities	94.24	76.42
Expenses relating to short term leases	162.39	168.03
Depreciation on right-of-use assets	265.76	202.91
Total	**522.39**	**447.36**

E. Amounts recognised in the Cash Flow Statement:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Total cash outflow for leases	307.59	260.75

24 Provisions

Particulars	As at March 31, 2026	As at March 31, 2025
Non-current		
Provision for employee benefits		
Compensated absences (Refer note 28.3)	191.61	154.27
Gratuity (Refer note 28.2)	208.31	95.42
Total non-current provisions	**399.92**	**249.69**

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

Particulars	As at March 31, 2026	As at March 31, 2025
Current		
Provision for employee benefits		
Compensated absences (Refer note 28.3)	99.18	70.62
Gratuity (Refer note 28.2)	198.41	175.53
Total current provisions	**297.59**	**246.15**

25 Other liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Current		
Advance from patients	414.36	240.03
Statutory liabilities	212.03	181.28
Total current liabilities	**626.39**	**421.31**

26 Trade payables

Particulars	As at March 31, 2026	As at March 31, 2025
Total outstanding dues of micro enterprises and small enterprises*	101.67	246.16
'Total outstanding dues of creditors other than micro enterprises and small enterprises**	910.21	1,162.18
Total	**1,011.88**	**1,408.34**

**For dues to micro and small enterprises, (Refer note 41)*

***Includes trade payables from related parties (Refer note 42)*

26.1 Trade payables ageing schedule

As at March 31, 2026

Particulars	Outstanding from due date of payment				Total
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) MSME	98.91	-	-	2.76	101.67
(ii) Others	910.21	-	-	-	910.21
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
Total	**1,009.12**	**-**	**-**	**2.76**	**1,011.88**

As at March 31, 2025

Particulars	Outstanding from due date of payment				Total
	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) MSME	246.08	0.08	-	-	246.16
(ii) Others	1,159.42	-	-	2.76	1,162.18
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-
Total	**1,405.50**	**0.08**	**-**	**2.76**	**1,408.34**

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

27 Other financial liabilities

Particulars	As at March 31, 2026	As at March 31, 2025
Non-Current		
Security deposits	36.73	10.36
Total non-current financial liabilities	**36.73**	**10.36**
Current		
Liabilities towards purchase of property, plant and equipment	38.87	243.72
Employee benefits payable	400.92	314.55
Other payable to holding company (Refer note 42)	165.79	-
Total current financial liabilities	**605.58**	**558.27**

28 Assets and liabilities relating to employee benefits

28.1 Defined contribution plan

Company's (employer's) contribution to defined contribution plans recognised as expenses in the statement of profit and loss are:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Employer's contribution to provident fund	365.45	265.25
Employer's contributions to employee state insurance	95.42	70.73
Total	**460.87**	**335.98**

Provident fund benefits:

The Company makes contributions, determined as a specified percentage of employee salaries, in respect of qualifying employees towards provident fund, which is defined contribution plan. The Company has no obligations other than to make the specified contributions. The contributions are charged to the Statement of Profit and Loss as they accrue. The amount recognised as an expense towards contribution to provident fund is included in "Contribution to provident and other funds".

Employee state insurance benefits:

The Company makes contributions, determined as a specified percentage of employee salaries, in respect of qualifying employees towards Employee State Insurance, which is defined contribution plan. The Company has no obligations other than to make the specified contributions. The contributions are charged to the Statement of Profit and Loss as they accrue. The amount recognised as an expense towards contribution to Employee state Insurance is included in "Contribution to provident and other funds".

28.2 Defined benefit plans - Gratuity

The Company operates a gratuity plan covering qualifying employees. The benefit payable is the amount calculated as per the Payment of Gratuity Act, 1972. The benefit vests upon completion of five years of continuous service and once vested it is payable to employees on retirement or on termination of employment. In case of death while in service, the gratuity is payable irrespective of vesting. The Company makes annual contribution to the group gratuity scheme administered by the Life Insurance Corporation of India.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

These plans typically expose the Company to actuarial risks such as: investment risk, interest rate risk, longevity risk and salary risk.

Investment risk	The present value of the defined benefit plan liability is calculated using a discount rate which is determined by reference to market yields at the end of the reporting period on government bonds. When there is a deep market for such bonds; if the return on plan asset is below this rate, it will create a plan deficit. Investments for these plans are carried out by Life Insurance Corporation of India.
Interest risk	A decrease in the bond interest rate will increase the plan liability; however, this will be partially offset by an increase in the return on the plan's investments.
Longevity risk	The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.
Salary risk	The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.

In respect of the above plans, the actuarial valuation of the plan assets and the present value of the defined benefit obligation were carried out as at March 31, 2026 and March 31, 2025 by an independent member firm of the Institute of Actuaries of India. The present value of the defined benefit obligation and the related current service cost and past service cost, were measured using the projected unit credit method.

The amount included in the Balance Sheet arising from the entity's obligation in respect of defined benefit plan is as follows :

Particulars	As at March 31, 2026	As at March 31, 2025
Net (asset) / liability recognised in the balance sheet:		
Gratuity:		
Present value of defined benefit obligation	808.40	575.35
Fair value of plan assets	(401.68)	(304.40)
Net liability recognised in the balance sheet	**406.72**	**270.95**
Current portion of the above	198.41	175.53
Non-current portion of the above	208.31	95.42

For details about the related employee benefit expenses (Refer note 34).

A. Funding

The funding requirements are based on the gratuity fund's actuarial measurement framework set out in the funding policies of the plan. The funding of Plan is based on a separate actuarial valuation for funding purposes for which the assumptions may differ from the assumptions set out in (E). Employees do not contribute to the plan.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

B. Reconciliation of the net defined benefit (asset) liability

The following table shows a reconciliation from the opening balances to the closing balances for the net defined benefit (asset) liability and its components.

Particulars	As at March 31, 2026	As at March 31, 2025
Reconciliation of present value of defined benefit obligation		
Balance at the beginning of the year	575.35	423.37
Benefits paid	(30.18)	(39.30)
Current service cost	138.21	69.80
Interest cost	37.37	30.25
Actuarial (gains)/ losses recognised in other comprehensive income		
changes in demographic assumptions	(29.97)	28.61
changes in financial assumptions		10.60
experience adjustments	117.52	52.02
Transfer In/Out	0.11	-
Balance at the end of the year	**808.41**	**575.35**
Reconciliation of fair value of plan assets		
Balance at the beginning of the year	304.40	261.81
Contributions paid into the plan	105.22	62.28
Benefits paid	(30.18)	(39.30)
Interest income	19.77	18.70
Return on plan assets recognised in other comprehensive income	2.47	0.91
Balance at the end of the year	**401.68**	**304.40**
Net defined benefit liability	**406.72**	**270.95**

C. Amount recognised in the total comprehensive income in respect of the defined benefit plan are as follows :

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
i. Expense recognised in profit or loss		
Current service cost	138.21	69.80
Interest cost	37.37	30.25
Interest income	(19.77)	(18.70)
Total gratuity expense recognised in statement of profit and loss	**155.81**	**81.35**
ii. Remeasurement recognised in other comprehensive income		
Actuarial (gain)/ loss on defined benefit obligation	87.55	91.23
Return on plan assets excluding interest income	(2.47)	(0.91)
Total other comprehensive income	**85.08**	**90.32**

D. Plan assets

The entire plan assets are managed by the insurer. The details with respect to the composition of investments in the fair value of plan assets have not been disclosed in the absence of the necessary information.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

E. The principal assumptions used for the purpose of actuarial valuation were as follows:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Discount rate	6.50%	6.50%
Future salary growth	12%	12.00%
Attrition rate		
Upto 30 years	39%	25%
31 - 44 years	27%	25%
Above 44 years	16%	25%
Normal retirement age	60 Years	60 Years
Mortality rate*	100%	100.00%
	(% of IALM 2012 -2014)	(% of IALM 2012 -2014)

**Based on India's standard mortality table with modification to reflect the expected changes in mortality/others.*

(a) *The estimate of future salary increase takes into account inflation, seniority, promotion and other relevant factors.*

(b) *Discount rate is based on the prevailing market yields of Indian Government bonds as at the balance sheet date for the estimated term of the obligation.*

Sensitivity analysis

Significant actuarial assumptions for the determination of defined benefit obligation are discount rate, expected salary increase rate, attrition rate and mortality. The sensitivity analysis below have been determined based on reasonably possible changes of the respective assumptions occurring at the end of the reporting Year while holding all other assumptions constant :

(Increase) / decrease on the defined benefit obligation	As at March 31, 2026	As at March 31, 2025
(i) Discount rate		
Increase by 1%	34.25	21.45
Decrease by 1%	(37.39)	(23.20)
(ii) Future salary growth		
Increase by 1%	(30.58)	(19.75)
Decrease by 1%	29.10	18.90
(iii) Attrition rate		
Increase by 50%	84.76	48.85
Decrease by 50%	(206.21)	(118.32)
(iv) Mortality rate		
Increase by 10%	0.14	0.07
Decrease by 10%	(0.16)	(0.07)

(a) The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligations as it is unlikely that the change in assumptions would occur in isolation of one another as some of the assumptions may be correlated.

(b) Furthermore, in presenting the above sensitivity analysis the present value of defined benefit obligation has been calculated using the projected unit credit method at the end of the reporting period which is the same as that applied in calculating the defined benefit obligation liability recognised in the Balance Sheet.

(c) There is no change in the methods and assumptions used in preparing the sensitivity analysis from the prior years.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

F. Experience adjustments

Amounts of the current year and previous four periods are as follows:

Particulars	As at March 31, 2026	As at March 31, 2025	As at March 31, 2024	As at March 31, 2023	As at March 31, 2022
Defined benefit obligation	808.40	575.35	423.37	321.15	278.18
Plan asset	(401.68)	(304.40)	(261.81)	(123.88)	(134.17)
Deficit/(Surplus)	**406.72**	**270.95**	**161.56**	**197.27**	**144.01**
Experience adjustments					
· in plan liabilities (loss) / gain	117.52	52.02	16.17	18.89	23.60
· in plan assets (loss) / gain	-	-	-	-	-

G. Effect of plan on Company's future cash flows

(a) Funding Arrangements and Funding Policy

The Company has purchased an insurance policy to provide for payment of gratuity to the employees. Every year, the insurance Company carries out a funding valuation based on the latest employee data provided by the Company. Any deficit in the assets arising as a result of such valuation is funded by the Company.

(b) Expected contributions to post-employment benefit plans for the next year from the respective year end date is as follows:

Year ended	Amount
March 31, 2026	518.67
March 31, 2025	350.85

(c) The weighted average duration of the defined benefit obligation during the respective year end is as follows:.

Year ended	No. of years
March 31, 2026	4 Years
March 31, 2025	4 Years

(d) Maturity profile of defined benefit obligation on an undiscounted basis is as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
1 Year	202.03	175.53
2 to 5 years	451.33	316.46
6 to 10 years	275.33	182.32
More than 10 years	197.65	90.46
Total	**1,126.34**	**764.77**

28.3 Compensated absences

The compensated absences cover the Company's liability for earned leave. Based on past experience, the Company does not expect all employees to take the full amount of accrued leave or require payment within the next 12 months. Accordingly, the Company has accounted for provision for compensated absences as below:

Particulars	As at March 31, 2026	As at March 31, 2025
Non-current portion	191.61	154.27
Current portion	99.18	70.62
Total	**290.79**	**224.89**

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

The key assumptions used in the computation of provision for compensated absences as per the actuarial valuation done by an independent actuary are as given below:

Particulars	As at March 31, 2026	As at March 31, 2025
Discount rate	6.50%	6.50%
Future salary growth	12.00%	12%
Attrition rate		
Upto 30 years	39%	25%
31 - 44 years	27%	25%
Above 44 years	16%	25%
Normal retirement age	60 Years	60 Years
Mortality rate*	100.00%	100%
	(% of IALM 2012 -2014)	(% of IALM 2012 -2014)

**Based on India's standard mortality table with modification to reflect the expected changes in mortality / others.*

(i) The estimate of future salary increase takes into account inflation, seniority, promotion and other relevant factors.

(ii) Discount rate is based on the prevailing market yields of Indian Government bonds as at the balance sheet date for the estimated term of the obligation.

29 Revenue from operations

A. Revenue from contracts with customers:

The Company generates revenue primarily from the hospital services and sale of pharmacy products to its customers. Other operating revenue includes income from ancillary services, sale of scraps, annual maintenance contract services and ambulance services.

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Revenue from medical and healthcare services		
Sale of services:		
Income from hospital services	28,375.78	21,648.68
Sale of goods:		
Sale of pharmacy products	1,903.71	1,282.28
Other operating revenue		
Income from ancillary services	192.21	139.62
Sale of scraps	11.67	7.68
Others	93.45	81.50
Total revenue from operations	**30,576.82**	**23,159.76**

B. Disaggregation of revenue

Revenue from contract with customers is disaggregated by primary geographic market, major service and product lines and timing of revenue recognition, as set out below:-

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Primary geographical markets		
India	30,576.82	23,159.76
Total revenue from operations	**30,576.82**	**23,159.76**
Major service lines / products		
Revenue from in-patient services	24,121.96	18,818.86
Revenue from out-patient services	4,253.82	2,829.82
Sale of pharmacy products	1,903.71	1,282.28
Income from attender stay	192.21	139.62
Sale of scraps	11.67	7.68
Others	93.45	81.50
Total revenue from operations	**30,576.82**	**23,159.76**
Timing of revenue recognition		
Services transferred over time	24,407.62	19,039.98
Services transferred at a point in time	4,253.82	2,829.82
Products transferred at a point in time	1,915.38	1,289.96
Total revenue from operations	**30,576.82**	**23,159.76**

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

C. Reconciliation of revenue recognised with contract price:

(i) Income from hospital services (including other operating revenue):

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Contract price (as reflected in the invoice raised on customer as per terms of the contract with customer)	29,172.24	22,214.91
Reduction in form of discounts and allowances	(510.80)	(345.11)
Revenue recognised in statement of profit and loss	**28,661.44**	**21,869.80**

(ii) Pharmaceutical products (including sale of scrap) :

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Contract price (as reflected in the invoice raised on customer as per terms of the contract with customer)	1,965.57	1,309.50
Reduction in form of discounts and allowances	(50.19)	(19.54)
Revenue recognised in statement of profit and loss	**1,915.38**	**1,289.96**
Total revenue from operations	**30,576.82**	**23,159.76**

D. Contract balances

The following disclosure provides information about receivables, contract assets and liabilities from contracts with customers:

Particulars	As at March 31, 2026	As at March 31, 2025
Receivables which are included in Trade receivables* (Refer note 14)	928.60	782.35
Contract assets - Unbilled revenue (Refer note 9)	606.15	406.78
Contract liabilities - Advance from patients (Refer note 25)	(414.36)	(240.03)

**Represents gross trade receivables without considering expected credit loss allowance.*

30 Other income

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Interest income from bank deposits	201.64	75.69
Interest income from others	17.85	9.45
Rental income (refer note 42)	34.31	21.16
Profit on disposal of property, plant and equipment, (net)	1.51	1.12
Miscellaneous income	252.28	201.22
Total other income	**507.59**	**308.64**

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

31 Cost of materials consumed

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Inventories at the beginning of the year	155.46	86.73
Add: Purchases of consumables*	1,476.78	1,059.88
Less: Inventories at the end of the year (refer note 13)	(168.05)	(155.46)
Total cost of materials consumed	**1,464.19**	**991.15**

**Includes consumables for in-patient services as well as for sale of pharmacy products.*

32 Purchases of stock-in-trade

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Purchase of stock-in-trade*	3,062.04	2,453.14
Total purchase of stock-in-trade	**3,062.04**	**2,453.14**

**Comprises pharmacy products for in-patient services as for well as sale of pharmacy products*

33 Changes in inventories of stock-in-trade

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Opening stock-in-trade	194.76	118.12
Closing stock-in-trade	(219.88)	(194.76)
Total changes in inventories of stock-in-trade	**(25.12)**	**(76.64)**

34 Employee benefits expense

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Salaries, wages and bonus	5,583.58	4,408.63
Contribution to provident and other funds (Refer note 28.1& 28.2)	614.11	417.33
Staff welfare expenses	383.74	363.06
Total employee benefits expense	**6,581.43**	**5,189.02**

35 Finance costs

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Interest		
· on term loans	736.49	860.07
· on lease liabilities (Refer note 23)	94.24	76.42
· on others	-	5.10
Total finance costs	**830.73**	**941.59**

The Company has capitalised borrowing cost towards qualifying assets during the year amounting to Nil (for the year ended March 31, 2025 - Rs.180 Lakhs) at a rate of 9.23% per annum.

36 Depreciation and amortisation expense

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Depreciation of property, plant and equipment (Refer note 4)	1,899.01	1,684.22
Depreciation of right-of-use assets (Refer note 5)	265.75	202.91
Amortisation of intangible assets (Refer note 7)	2.33	8.12
Total depreciation and amortisation expense	**2,167.09**	**1,895.25**

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

37 Other expenses

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Hospital operating expenses		
Professional fees paid to consultants	5,964.86	4,906.18
Power and fuel	633.71	585.68
Repairs and maintenance	-	-
· Buildings	60.10	53.89
· Plant and machinery	343.86	260.74
· Others	765.23	651.59
Sub-contracting charges	517.38	317.89
Medical gas	47.91	43.08
Rent	162.39	168.03
Blood and medical record scan charges	64.29	78.57
Patient diet expenses	184.31	142.15
Total (A)	**8,744.04**	**7,207.80**
Administrative expenses		
Rates and taxes	138.24	153.05
Business promotion and publicity	723.09	578.36
Communication expenses	50.52	43.52
Travelling and conveyance	173.39	140.77
Printing and stationery	187.51	173.61
Legal and professional charges	140.10	93.01
Payment to auditors (Refer note (i) below)	32.00	32.00
Security charges	68.91	104.01
Bad debts written off	29.64	13.16
Less: Provision utilised (Refer note 14.3)	(29.64)	(13.16)
Net bad debts written off	-	-
Corporate social responsibility (Refer note (ii) below)	73.00	74.00
Provision for loss allowance (Refer note 14.3)	38.43	39.35
Insurance	131.39	60.44
Bank charges	58.14	60.06
Directors sitting fees	23.25	21.50
Loss on disposal of property, plant and equipment (net)	-	-
Miscellaneous expenses	118.72	133.07
Total (B)	**1,957.65**	**1,706.75**
Grand Total (A + B) - Operating expenses	**10,701.69**	**8,914.55**

Note: Other expenses capitalized during the year is Nil (Year ended March 31, 2025 - Rs. 30 Lakhs)

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
(i) Payment to auditors (excluding goods and services tax)		
Statutory audit	24.50	24.50
Limited reviews	7.50	7.50
Total	**32.00**	**32.00**

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
(ii) Details of corporate social responsibility expenditure (CSR)		
(a) Amount required to be spent by the Company during the year	73.00	74.00
(b) Amount of expenditure incurred		
(i) Construction / acquisition of any assets	-	-
(ii) On purposes other than (i) above	73.00	74.00
(c) Provisions w.r.t CSR expenditure pursuant to contractual obligation*#	-	74.00
(d) Shortfall/(excess) at the end of the year		
(e) Total of previous years short fall	-	-
(f) Nature of CSR activities		
• Promoting education	73.00	-
(g) Details of related party transactions		
Kauvery Foundation	73.00	-

The Company has transferred the amount to unspent CSR account within the prescribed time limit after the balance sheet date.

#The Company has spent, during the current year, the amount that had been transferred to the Unspent CSR Account as at March 31, 2025 towards promoting education.

38 Financial instruments - Fair value and risk management

A. Accounting classification and fair values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy.

March 31, 2026	At cost	Amortised cost	Financial assets/ liabilities at fair value through Profit or Loss	Financial assets at fair value through OCI	Total carrying value
Financial Assets:					
Investments	-	-	0.72	-	0.72
Loans	-	29.34	-	-	29.34
Trade receivables	-	735.31	-	-	735.31
Cash and cash equivalents	-	5,002.07	-	-	5,002.07
Bank balances other than cash and cash equivalents above	-	467.19	-	-	467.19
Other financial assets	-	1,464.86	-	-	1,464.86
	-	**7,698.77**	**0.72**	**-**	**7,699.49**
Financial liabilities					
Borrowings	-	7,102.97	-	-	7,102.97
Lease liabilities	-	1,264.67	-	-	1,264.67
Trade payables	-	1,011.88	-	-	1,011.88
Other financial liabilities	-	642.31	-	-	642.31
	-	**10,021.83**	**-**	**-**	**10,021.83**

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

March 31, 2025	At cost	Amortised cost	Financial assets/ liabilities at fair value through Profit or Loss	Financial assets at fair value through OCI	Total carrying value
Financial assets					
Investments	-	-	0.38	-	0.38
Loans	-	25.97	-	-	25.97
Trade receivables	-	597.85	-	-	597.85
Cash and cash equivalents	-	919.04	-	-	919.04
Bank balances other than cash and cash equivalents above	-	15.06	-	-	15.06
Other financial assets	-	1,514.40	-	-	1,514.40
	-	**3,072.32**	**0.38**	**-**	**3,072.70**
Financial liabilities					
Borrowings	-	8,192.67	-	-	8,192.67
Lease Liabilities	-	752.08	-	-	752.08
Trade payables	-	1,408.34	-	-	1,408.34
Other financial liabilities	-	558.27	-	-	558.27
	-	**10,911.36**	**-**	**-**	**10,911.36**

The Company has not disclosed fair values of financial instruments such as investments, trade receivables, cash and cash equivalents, bank balances other than cash and cash equivalents, other financial assets, borrowings, trade payables and other financial liabilities, since their carrying amounts are reasonable approximates of fair values due to the short-term maturities of these instruments.

The fair value of the financial assets and liabilities is included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The following method and assumption was used to estimate the fair value / amortized cost:

The fair value of unquoted instruments, loans from banks and other financial liabilities, as well as other non-current financial liabilities are estimated by discounting future cash flows using rates currently available for debt on similar terms, credit risk and remaining maturities.

The following table presents the fair value measurement hierarchy of financial assets and liabilities measured at fair value on recurring basis as at March 31, 2026 and March 31, 2025:

Particulars	Total	Fair value measurement using		
		Level 1	Level 2	Level 3
Financial assets measured at fair value:				
FVTPL financial assets designated at fair value:				
Investment in equity instruments (unquoted)				
March 31, 2026	**0.72**	-	0.72	-
March 31, 2025	**0.38**	-	0.38	-

B. Financial risk management

The Company has exposure to the following risks arising from financial instruments:

a) credit risk (see (B)(ii));

b) liquidity risk (see (B)(iii));

c) Interest Rate Risk (see (B)(iv))

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

i. Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The board of directors along with the top management are responsible for developing and monitoring the Company's risk management policies.

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The Company's audit committee oversees how management monitors compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company,

ii. Credit risk

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its operating activities (primarily trade receivables) and from its investing activities, including deposits with banks and financial institutions and other financial instruments.

The carrying amount of financial assets represents the maximum credit exposure.

Particulars	Carrying amount	
	As at March 31, 2026	As at March 31, 2025
Investments	0.72	0.38
Trade receivables	735.31	597.85
Loans	29.34	25.97
Cash and cash equivalents	5,002.07	919.04
Bank balances other than cash and cash equivalents above	467.19	15.06
Other financial assets	1,464.86	1,514.40
Total	**7,699.49**	**3,072.70**

Investments

The Investment made by the Company in other Companies are subject to the uncertainty of their ability to generate profits from their operations and provide returns to the Company against the investment made.

Trade receivables (Refer note 14)

Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom credit has been granted after obtaining necessary approvals for credit. The collection from the trade receivables are monitored on a continuous basis by the receivables team.

The Company establishes an allowance for credit loss that represents its estimate of expected losses in respect of trade and other receivables based on the past and recent collection trend. The Company's exposure to credit risk for trade receivables and other receivables is as follows:

Particulars	As at March 31, 2026	As at March 31, 2025
Trade receivables (gross)	928.60	782.35
Less : Provision for loss allowance	(193.29)	(184.51)
Total	**735.31**	**597.84**

Loans

This balance primarily constitute of employee advances. The Company does not expect any losses from non-performance by these counter parties.

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

Cash and cash equivalents

The Company held cash and cash equivalents with credit worthy banks and financial institutions as at the reporting dates which has been measured on the 12-month expected loss basis. The credit worthiness of such banks and financial institutions are evaluated by the management on an ongoing basis and is considered to be good with low credit risk.

Other financial assets (including other bank balances)

Other financial assets comprises of rental deposits given to lessors, unbilled revenue, bank deposits (due to mature within and after 12 months from the reporting date), interest accrued on fixed deposits, electricity deposit given to Tamil Nadu Electricity Board and receivables from related parties. These fixed deposits are held with credit worthy banks and financial institutions. The credit worthiness of such banks and financial institutions are evaluated by the management on an ongoing basis and is considered to be good with low credit risk.

iii. Liquidity risks

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its financial liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, including contractual interest.

As at March 31, 2026

Particulars	1 year or less	1-5 years	More than 5 years	Total	Carrying amount
Borrowings	960.00	4,560.00	1,615.36	7,135.36	7,102.97
Lease liabilities	386.32	1,101.00	50.22	1,537.54	1,264.67
Trade payables	1,011.88	-	-	1,011.88	1,011.88
Other financial liabilities	642.31	-	-	642.31	642.31
Total	**3,000.51**	**5,661.00**	**1,665.58**	**10,327.09**	**10,021.83**

As at March 31, 2025

Particulars	1 year or less	1-5 years	More than 5 years	Total	Carrying amount
Borrowings	960.00	4,320.00	2,950.45	8,230.45	8,192.67
Lease liabilities	200.04	709.65	58.05	967.74	941.61
Trade payables	1,408.34	-	-	1,408.34	1,408.34
Other financial liabilities	558.27	-	-	558.27	558.27
Total	**3,126.65**	**5,029.65**	**3,008.50**	**11,164.80**	**11,100.89**

Also refer Note 20.

iv. Interest rate risks

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's debt obligations with floating interest rates.

Interest rate sensitivity analysis

If interest rates had been 1% higher and all other variables were held constant, the company's profit for the year ended would have impacted in the following manner:

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Decrease in the profit for the year	76.48	65.89

If interest rates were 1% lower, the company's profit would have increased by the equivalent amount as shown in the above table.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

39 Contingent liabilities and commitments

a) Contingent liabilities

Contingent liabilities and commitments	As at March 31, 2026	As at March 31, 2025
(i) Claims against the Company not acknowledged as debts	-	-
(ii) Guarantees given outstanding		
• Guarantees given to bankers on behalf of the holding company Sri Kauvery Medical Care (India) Limited	9,857.21	8,000.00

(iii) The Company, is empaneled under TNCMCHIS, Medi Assist Health Care Service and MD India - TN Govt NHIS for all the services offered by the hospital including Cardiology and Cardiothoracic Surgery. Heart patients under this scheme are treated by the Company in its hospital and wherever the patients require Angioplasty or Heart Surgeries like Bypass Surgery, Valve Replacement, etc., is outsourced to the Kauvery Heart City Hospital, a division of SKMC, the holding company, which is located within the same premises. All the approvals for such procedures are obtained and bills are submitted by the Company. The amount so received from this scheme for such cardiac procedures performed by Heart City is being reimbursed on a monthly basis as per the agreed terms between both the Company and the Holding Company. In the opinion of the management, such outsourcing arrangements are in accordance with the guidelines issued by the Government of Tamil Nadu vide orders in G.O.Ms No. 268 Health and Family Welfare (EAP/1) Department) dated November 17, 2016 (as amended) and in compliance with the Memorandum of Undertaking dated May 2, 2017 entered into with United India Insurance Company Limited. However, at present all these government schemes are empanelled directly by the Kauvery Heart City Hospital, a division of SKMC, the holding company and thus the amount/number of transactions got reduced significantly as compared to the previous years.

b) Commitments

	As at March 31, 2026	As at March 31, 2025
Estimated value of contracts remaining to be executed on capital account and not provided for (net of advances)	14.42	5.78

The Company also receives claims, which arise in the ordinary course of the business. However, the management does not believe that such matters would have a material effect on the financial statements.

40 Segment reporting

Ind AS 108 “Operating Segment” (“Ind AS 108”) establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. Based on the “management approach” as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM).The CODM evaluates the Company’s performance and allocates resources on an overall basis. The Company’s sole operating segment is therefore ‘Medical and Healthcare Services’. The Company’s entire business operations is in India. Accordingly, there are no additional disclosures to be provided under Ind AS 108.

41 Dues to micro and small enterprises

The management has identified the enterprises which have provided goods and services to the Company and which qualify under the definition of micro and small enterprises, as defined under Micro, Small and Medium Enterprises Development Act, 2006. Such determination/ identification has been done on the basis of information received and available with the Company and relied upon by the auditors. Accordingly, the disclosure in respect of the amounts payable to such enterprises as at March 31, 2026 has been made in the financial statements based on information received and available with the Company.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

Particulars	As at March 31, 2026	As at March 31, 2025
(i) The amounts remaining dues to micro and small suppliers as at the end of the year		
• Principal amount	101.67	246.16
• Interest due on the above amount	3.60	-
(ii) Amount of interest paid in terms of section 16 of the Micro, Small and Medium Enterprises Act, 2006 and amounts of payment made to the suppliers beyond the appointed day during the year.	-	-
(iii) Amount of interest due and payable for the period of delay in making payment but without adding the interest specified under this Act.	-	-
(iv) Amount of interest accrued and remaining unpaid at the end of the year.	3.60	-
(v) Amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprises.	-	-

42 Related party disclosures

a) Names of related parties and nature of relationship are as follows:

Nature of relationship	Name of the related party
Holding company	Sri Kauvery Medical Care (India) Limited
Fellow subsidiaries	Curtis Drug Point private limited
	Hamsa Medical Services Private Limited
	Yashomati Hospitals Private Limited
	Healthcare Capital Private Limited
Key management personnel (KMP)	Dr. S. Chandrakumar, Whole-time director
	Dr. S. Manivannan, Managing Director
	Mr. K. Anand Babu - Chief Financial Officer
	Ms. Sushma K - Company Secretary (Upto May 22, 2025)
	Ms. Indumathi P - Company Secretary (From May 28, 2025)
	Mr. Sunil Satyapal Gulati - Director
	Mr. P.Ravichandran - Director
	Mr. S. Mohan - Director
	Mrs. N. Jeyanthei - Director
	Dr. S. Vijayabaskaran - Director
	Dr. T. Senthil Kumar - Director
	Dr. D. Senguttuvan -Executive Director & KMP
Enterprises over which KMP exercises significant influence	Trivitron Health Care Private Limited Neuberg Ehrlich Laboratory Private Limited
	Kauvery Medical Trust Medexpert Software Solutions Private Limited Kauvery Health Enterprises Private Limited
Author of Trust	Kauvery Foundation
Relative of KMP	Dr. N. Suchitra (Relative of Dr. S. Manivannan) Dr. Dhivya (Relative of Dr. T. Senthil Kumar)

Notes:

1. *Related party relationships are as identified by the management and relied upon by the auditors.*
2. *The aforesaid list includes only the list of related parties with transactions during the year except where control exists.*

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

b) Transaction with related parties during the year

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Sri Kauvery Medical Care (India) Limited		
Revenue from hospital services rendered	996.19	430.65
Hospital services availed	336.17	275.75
Doctor fees reimbursed	-	108.79
Sale of goods	3.32	1.34
Purchase of goods	1.37	1.67
Sale of property, plant and equipment	-	4.73
Rental income	34.31	17.12
Rental expenses (Refer note (e) below)	28.34	2.10
Guarantee expenses	76.36	80.00
Guarantee commission income	98.57	82.22
Reimbursement of expenses received	179.72	410.56
Reimbursement of expenses paid	361.78	399.42
Claims made on behalf of the holding company (Refer note 39 a(iii))	52.05	105.45
Reimbursement of claims received on behalf of the holding company (Refer note 39 a(iii))	80.15	120.74
Curtis Drug point private limited		
Purchase of goods	789.94	404.26
Trivitron Health Care Private Limited		
Purchase of goods	1.52	1.35
Neuberg Ehrlich Laboratory Private Limited		
Sub-contracting charges	-	220.81
Purchase of goods/Services	110.40	23.16
Purchase of property, plant and equipment	-	39.23
Kauvery Medical Trust		
Rental expenses	1.89	1.72
Revenue from hospital services rendered	-	1.33
Kauvery Foundation		
Corporate Social Responsibility Expenditure	73.00	-
Payment made against CSR Provision of previous year	74.00	-
Hamsa Medical Services Private Limited		
Hospital services availed	48.09	31.41
Reimbursement of expenses received	14.02	13.78
Medexpert Software Solutions Private Limited		
Software maintenance charges	32.45	32.45
Dr. S. Chandrakumar		
· Remuneration (Refer note (b) & (c) below)	84.00	84.00
Dr. S. Manivannan		
· Remuneration (Refer note (b) & (c) below)	84.00	84.00
Mr. K. Anand Babu		
· Remuneration (Refer note (b) & (c) below)	165.04	119.36
Ms. Sushma K		
· Remuneration (Refer note (b) & (c) below)	3.94	8.73

NOTES TO THE FINANCIAL STATEMENTS
for the year ended March 31, 2026
(All amounts are in Indian Rupees Lakhs except share data or as stated)

Particulars	For the year ended March 31, 2026	For the year ended March 31, 2025
Ms. Indumathi P		
· Remuneration (Refer note (b) & (c) below)	8.61	-
Dr. D. Senguttuvan		
· Professional fees paid to consultants	368.45	353.78
· Remuneration (Refer note (b) & (c) below)	125.05	115.79
· Incentive	81.36	56.99
Dr. N. Suchitra		
· Professional fees	550.56	420.36
Dr. Dhivya		
· Professional fees	30.00	22.32
Mrs. N. Jeyanthei		
· Director sitting fees	5.25	5.25
Mr. Sunil Satyapal Gulati		
· Director sitting fees	7.00	7.50
Mr. P.Ravichandran		
· Director sitting fees	6.75	7.50
Mr. S. Mohan		
· Director sitting fees	4.25	1.25

c) Balances outstanding as at the year end

	As at March 31, 2026	As at March 31, 2025
Sri Kauvery Medical Care (India) Limited		
Other financial assets	-	53.48
Other financial liabilities	165.79	-
Trade receivable	-	9.22
Guarantees and collaterals given (Refer note (d) below)	9,857.21	8,000.00
Guarantees and collaterals taken (Refer note (d) below)	7,135.35	8,230.45
Kauvery Medical Trust		
Trade payable	-	0.16
Neuberg Ehrlich Laboratory Private Limited		
Trade payable	12.42	18.98
Curtis Drug point private limited		
Trade payable	39.90	33.55
Trivitron Health Care Private Limited		
Trade payable	1.04	-
Hamsa Medical Services Private Limited		
Trade payable	-	0.12
Dr. D. Senguttuvan		
· Incentive payable	52.01	37.09
Dr. N Suchitra		
Trade payable	-	22.94

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

(a) The Company accounts for costs incurred by / on behalf of the Related Parties based on the actual invoices / debit notes raised and accruals as confirmed by such related parties. The Related Parties have confirmed to the Management that as at March 31, 2026 and as at March 31, 2025, there are no further amounts payable to / receivable from them, other than as disclosed above. The Company incurs certain costs on behalf of other companies in the group. These costs have been allocated / recovered from the group companies on a basis mutually agreed to with the group companies.

(b) Remuneration and other benefits pertain to short term employee benefits. As the gratuity and compensated absences are determined for all the employees in aggregate, the post-employment benefits and other long-term benefits relating to key management personnel cannot be ascertained individually.

(c) The remuneration payable to key management personnel is determined by the nomination and remuneration committee having regard to the performance of individuals and market trends.

(d) The above guarantees represents financial guarantee provided by the Company for term loans availed by the holding company and financial guarantee provided by the Holding Company for the term loans availed by the company.

(e) The rental expense disclosed above represents the actual amounts payable as per the agreement entered into between the parties (excluding taxes thereon) accounted as payment of lease liabilities in the books.

(f) The amount of transactions disclosed above is without considering goods and services tax (wherever applicable, irrespective of whether input credit has been availed or not) as charged by / to the counter party as part of the invoice/relevant document and is gross of tax deducted at source under the Income-tax Act, 1961 and accounted in the ledger of the concerned expense/transaction head.

(g) The amount of payables / receivables indicated above is after deducting tax (wherever applicable) and after including goods and services tax (wherever applicable) as charged by / to the counter party as part of the invoice/relevant document and accounted in the ledger of the concerned party.

(h) Refer Note 22.2 for guarantees / securities provided by related parties in connection with loans availed by the Company.

43 Additional disclosures - Ratios

The ratios for the year ended March 31, 2026 and March 31, 2025 are as follows:

Particulars	Numerator	Denominator	As at March 31, 2026	As at March 31, 2025	Variance	Notes
Current Ratio	Current assets	Current liabilities	1.90	0.88	116.26 %	a
Debt equity ratio	Total borrowings	Shareholder's equity	0.34	0.50	(32.49)%	b
Debt service coverage ratio	Earnings available for debt services[1]	Debt service[2]	4.07	2.62	55.34 %	c
Return on equity ratio	Net profit after taxes	Average share holder's equity	0.25	0.14	78.15 %	d
Inventory turnover ratio	Cost of goods sold	Average inventory	12.20	12.13	0.58 %	
Trade receivables turnover ratio	Net credit revenue	Average trade receivable	12.47	12.73	(2.04)%	
Trade payables turnover ratio	Net credit purchases	Average trade payables	12.34	11.25	9.72 %	
Net capital turnover ratio	Net revenue	Net working capital (Current assets less current liabilities)	7.93	(49.28)	(116.10)%	e
Net profit ratio	Net profit after tax	Net revenue	15.28%	9.25%	65.24 %	f
Return on capital employed	Earnings before interest and taxes	Capital employed[3]	25.66%	16.88%	52.01 %	g

[1]Earnings available for debt service represents net profit after taxes, non-cash operating expenses like depreciation and other amortizations, interest and other adjustments like loss on sale of property, plant and equipment, etc.

[2]Debt service represents interest, lease payment and principal repayment.

[3]Capital employed represent tangible net worth, total debt and deferred tax liability.

Notes:

a. The company has successfully transitioned from an under-liquidation risk zone (< 1.0) to a highly stable short-term financial position.

b. The company reduced its long-term external borrowings or boosted its equity base via retained earnings, significantly mitigating long-term solvency risk.

c. Driven primarily by surging operational profitability coupled with lower debt obligations. This shows a vastly superior capability to comfortably service interest and principal repayments from existing cash flows.

d. Reflects enhanced wealth generation efficiency for shareholders.

e. It signifies that the company no longer relies on short-term credit lines or trade payables to fund core operations.

f. Indicates robust operational cost management and pricing power. The company managed to expand its bottom-line margin significantly.

g. It proves that the entire pool of deployed capital (both long-term debt and equity) is generating much healthier pre-tax operating returns.

44 Additional regulatory information as required by Schedule III to the Companies Act, 2013 - Others

(a) No proceedings have been initiated during the year or are pending against the company as at March 31, 2026 and March 31, 2025 for holding any benami property under Benami Property Transactions (prohibition) Act, 1988.

(b) Transactions and balances with companies which have been removed from register of Companies [struck off companies] as at the above reporting periods is Nil.

(c) The Company has not traded / invested in Crypto currency or virtual currency.

(d) No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

(e) No funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(f) The Company has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income-tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income-tax Act, 1961).

(g) The Company has not granted any loans or advances in the nature of loans to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013), either severally or jointly with any other person.

(h) The Company does not have any scheme of arrangements which have been approved by the competent authority in terms of sections 230 to 237 of the Act.

(i) The Company has complied with the number of layers prescribed under of Section 2(87) of the Act read with the Companies (Restriction on number of Layers) Rules, 2017.

45 Disclosures required under section 186(4) of the Companies Act, 2013

Name of the entity	Purpose (i.e. proposed utilisation by the recipient)	As at March 31, 2026	As at March 31, 2025
(i) Investment made			
Nazca Energy Private Limited	NA	0.46	0.38
Gardenia Energy Private Limited	NA	0.26	-
(ii) Guarantees given			
Sri Kauvery Medical Care (India) Limited	Term loans	9,857.21	8,000.00

46 Operating leases

As lessor

The Company had entered into an operating lease arrangement in respect of certain office space with a lease term of 29 years, which are subject to renewal at mutual consent thereafter. The cancellable arrangements can be terminated by either party after giving due notice. The lease rent income recognised during the year amounts to Rs. 34.31 Lakhs (Previous year: Rs. 15.89 Lakhs). The schedule for future minimum lease payments in respect of non-cancellable operating lease is set out below:

Particulars	As at March 31, 2026	As at March 31, 2025
Not later than one year	22.19	19.34
Later than one year but not later than five years	69.42	15.22
Later than five years	115.71	16.65
Total	**207.32**	**51.21**

NOTES TO THE FINANCIAL STATEMENTS

for the year ended March 31, 2026

(All amounts are in Indian Rupees Lakhs except share data or as stated)

47 The Indian Parliament has approved the Code on Wages, 2019 and the Code on Social Security, 2020 which could impact the employee compensation expenses including the contributions by the Company towards Provident Fund and Gratuity. The effective date from which the change are applicable is yet to be notified and final rules are yet to be framed. The Company will carry out an evaluation of the impact and record the same in the financial statements in the period in which the Code becomes effective and the related rules are published.

48 In connection with the preparation of the financial statements for the year ended March 31, 2026, the Board of Directors have confirmed the propriety of the contracts / agreements entered into by / on behalf of the Company and the resultant revenue earned / expenses incurred arising out of the same after reviewing the levels of authorisation and the available documentary evidences and the overall control environment. Further, the Board of Directors have also reviewed the realizable value of all the current assets of the Company and have confirmed that the value of such assets in the ordinary course of business will not be less than the value at which these are recognised in the financial statements. In addition, the Board has also confirmed the carrying value of the non-current assets in the financial statements. The Board, duly taking into account all the relevant disclosures made, has approved these financial statements in its meeting held on May 29, 2026 in accordance with the provisions of Companies Act, 2013.

49 Previous year figures have been reclassified to conform to the current year classification / presentation.

for and on behalf of the board of directors of
KMC Speciality Hospitals (India) Limited
CIN: L85110TN1982PLC009781

Dr. S. Manivannan
Managing Director
DIN : 00910804

Dr. S. Chandrakumar
Executive Chairman (Whole-Time)
DIN : 01867847

K. Anand Babu
Chief Financial Officer

Indumathi P
Company Secretary

Place: Chennai
Date: May 29, 2026

KMC Speciality Hospitals (India) Limited

Registered Office

No. 6, Royal Road, Cantonment,
Trichy – 620 001
CIN: L85110TN1982PLC009781

Concept, content and design by YAK REPORT | contact@reportyak.com